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Abstract
Endocytosis is a form of active cellular transport by which cells internalize molecules from
the extracellular environment. This thesis studies proteins involved in endocytosis that
inﬂuence the progression of cancers in humans. Two of the three articles summarized here
employ cell biological experiments to elucidate the role of the proteins N-myc downstream-
regulated gene 1 (NDRG1) and StAR-related lipid transfer protein 3 (StARD3) in the
regulation of endocytic traﬃcking. The third article describes a novel data analysis method
and its application to a large data set of breast cancer patients.
We studied the eﬀects of NDRG1 protein depletion on cellular cholesterol content
and distribution, low-density lipoprotein receptor (LDLR) localization and turn-over,
and the morphology of endosomal organelles. We found that depletion of the NDRG1
protein leads to reduced abundance of LDLR on the plasma membrane (PM) and as
a result, reduced low-density lipoprotein (LDL) uptake. When NDRG1 is depleted,
LDLR accumulates in multi-vesicular bodies (MVBs), and while LDLR ubiquitination
is increased, its degradation is decreased. The PM levels of LDLR and LDL uptake are
rescued upon co-depletion of the inducible degrader of the LDL-receptor (IDOL). Our
ﬁndings identify NDRG1 as regulator of MVB formation and LDLR traﬃcking.
We also found that elevated levels of StARD3 protein alter the cholesterol balance and
adhesiveness of breast cancer cells. We studied the eﬀects of StARD3 overexpression
in cells, as well as the association of StARD3 protein levels with cancer progression
markers in Finnish breast cancer patients. We found that in MCF-7 cells, stable StARD3
overexpression altered the morphological features and the cholesterol balance of the cells.
In the breast cancer tumor samples from patients, high StARD3 protein levels associated
with ErbB2 (receptor tyrosine-protein kinase erbB-2) ampliﬁcation. High protein levels
also associated with proto-oncogene tyrosine-protein kinase Src (Src) activation and
increased 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) transcript levels.
Our ﬁndings suggest that elevated StARD3 levels contribute to breast cancer aggressiveness.
Finally, a systematic approach to data analysis was developed and demonstrated by
applying it to an existing data set of breast cancer patients. High-throughput molecular
level data and clinical data were integrated in the study. This revealed a coampliﬁcation
of NDRG1 and the lysosomal-associated transmembrane protein 4B gene (LAPTM4B),
encoding an endosomal protein that regulates ceramide traﬃcking, and discovered new
genes potentially coregulated with LAPTM4B.
1
1 Introduction
Cells take up and recycle nutrients and signaling molecules by endocytosis. Endocytosis
is an active vesicular transport mechanism. Vesicles are formed at the cell surface as
membrane invaginations that are pinched oﬀ the plasma membrane and internalized.
These early endosomes contain cargo like low-density lipoprotein (LDL). Their membrane
includes proteins like cell surface receptors, for example the LDL receptor. Cell receptors
can be degraded in the lysosome or recycled back to the cell surface, providing a regulating
mechanism.
Cancer cells escape the tight control of the organism over growth, diﬀerentiation, and
cell cycle. Oncogenes cause cancer, either by gene mutation or high gene expression.
HER2, is an oncogene encoding the cell surface receptor protein Her2, overexpressed in a
subtype of cancer. Her2-positive breast patients can be treated with an antibody against
the cell surface receptor, but the mechanism of action is complex and not fully understood,
and relapse is commonly observed.
HER2 is at the core of an ampliﬁed genomic region that contains several other genes. A
commonly co-ampliﬁed gene encodes StARD3, a late endosomal membrane protein, with
a cholesterol-binding transmembrane domain and a cholesterol-binding pocket domain
protruding into the cytosol. Our preliminary experiments showed that the cellular levels of
the StARD3 protein can inﬂuence cell growth. Further studies showed that this eﬀect is
partially due to a deregulation of the endocytic pathway.
This thesis studies how the deregulation of endocytosis can inﬂuence cancer progression.
The focus of the experimental work was on two genes: StAR-related lipid transfer protein
3 (StARD3), and N-myc downstream-regulated gene 1 (NDRG1). Our results suggest
that StARD3 contributes to breast cancer aggressiveness, probably by decoupling de novo
cholesterol synthesis from external growth stimuli. While NDRG1 was shown to regulate
LDL receptor traﬃcking in particular, its role in multi-vesicular body formation suggests a
more general function as a regulator of cell surface receptor degradation.
To provide a systemic view on the regulation of endocytosis in the context of cancer
progression, we analyzed data containing genome wide DNA ampliﬁcation and mRNA
levels, as well as clinical patient data from The Cancer Genome Atlas (TCGA). We
identiﬁed a module of genes that are regulated by the same micro-RNA as LAPTM4B,
a gene encoding a protein involved in lipid transport in the late endosome. In addition,
we demonstrated how to organize and present the data analysis in order to improve its
repeatability and reproducibility.
This book provides an introduction to the topics of cellular cholesterol balance, endocytic
transport, receptor signalling, the role of cholesterol in cancer, and the analysis of biological
data. A review of the most relevant scientiﬁc literature provides a context for the questions
and ﬁndings reported in the original publications. The experimenal methods summarize
the tools used to conduct this research.
2
2 Review of the Literature
2.1 Cellular cholesterol balance
In humans, as in all animals, cholesterol in lipid bilayers of the cell regulates their ﬂuidity.
Cholesterol is also a precursor for the synthesis of steroid hormones. Steroids are molecules
based on a tetracyclic ring system (ﬁg. 1). In humans, most steroids act as hormones: for
example testosterone, androsterone (androgens), estrone and estradiol (estrogens), and
adrenocortical hormones. The two sources of cholesterol are de novo synthesis and dietary
uptake.
Triacylglycerols, cholesterol, and other lipids obtained from the diet are taken up by
the intestine and carried by the blood stream as chylomicrons. Triacylglycerides are
hydrolyzed, and the cholesterol-rich chylomicron remnants are taken up by the liver;
triacylglycerols and cholesterol are released back to the blood stream in the form of
very low-density lipoprotein (VLDL). Again, triacylglycerides are hydrolyzed, and the
remnants, intermediate-density lipoproteins, are either taken up by the liver or converted
to low-density lipoprotein (LDL). The main role of LDL is to transport cholesterol to
peripheral tissues and regulate cholesterol synthesis there. Feedback mechanisms in the
cell sense low cholesterol levels and activate cholesterol synthesis (Ikonen 2008).
2.1.1 Cholesterol synthesis
The ﬁnding by Konrad Bloch that acetate is a precursor of cholesterol provided the ﬁrst
clue to elucidating the pathway for the biological synthesis of cholesterol in animals
(Bloch 1965). In fact, all 27 carbon atoms of cholesterol are derived from acetyl
CoA, and mevalonate and squalene are key intermediates (section 2.1). First, acetyl
HO
H
H
H
Figure 1: Chemical structure of the cholesterol molecule. The molecule is not soluble in water.
The tetracyclic steroid nucleus of cholesterol is planar and rigid. When embedded within the lipid
bilayer, the hydroxyl group interacts with the polar heads of the phospholipids and sphingolipids in
the membrane, while the steroid and the hydrocarbon chain interact with the fatty acid chains of the
other lipids, inﬂuencing membrane ﬂuidity, thickness, and membrane protein aﬃnity.
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Acetyl CoA (Acetate + Coenzime A)
HMG-CoA synthase
3-HMG-CoA
HMGR
Mevalonate
3 ATP
3 ADP + Pi + CO2
Isopentenyl pyrophosphate
Squalene synthase
Squalene
Squalene monooxygenase
Squalene epoxide
Lanosterol synthase
HO
Lanosterol
HCOOH + 2 CO2
HO
H
H
H
Cholesterol
Figure 2: Major steps in cholesterol biosynthesis.
Each arrow represents a chemical reaction that
consists of multiple intermediate steps. The
committed step in cholesterol biosynthesis, the
production of mevalonate, is shown with a thick
arrow. In the last step, lanosterol is converted
to cholesterol in 19 intermediate reactions that
require nine diﬀerent enzymes. Three methyl
groups of lanosterol are oxidized and removed as
formic acid and two carbon dioxide molecules.
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LDL
LDLR
Early endosome
MVB
Lysosome
Recycling endosome
NPC1NPC2
cholesterol
IDOL
Extracellular space
Plasma membrane
Cytosol
Clathrin-coated pit
ESCRT machinery
Figure 3: Overview of LDL uptake, and LDL receptor recycling and degradation. LDL receptor
accumulates in clathrin-coated pits, where it binds LDL. Early endosomes with their cargo mature
to multivesicular bodies. This process is regulated by the ESCRT machinery – endosomal sorting
complexes required for transport. As the acidity increases, LDL dissociates from the LDL receptor.
LDL receptor is recycled back to the plasma membrane via recycling endosomes. IDOL, inducible
degrader of the LDL receptor, is recruited by LDL receptor to the plasma membrane. IDOL provides
an ESCRT-mediated pathway for LDL receptor to the multivesicular bodies and to lysosomes that is
independent of clathrin-coated pits or caveolae. In the lysosome, LDL receptor is degraded, while
LDL particles are broken down, cholesteryl esters are hydrolyzed, and free cholesterol exits the
lysosome in a process regulated by the NPC1 and NPC2 intracellular cholesterol transporter proteins.
CoA, acetoacetyl CoA, and water form 3-hydroxy-3-methylglutaryl CoA (3-HMG-CoA).
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) is the catalyst of the reaction:
3-HMGCoA + 2NADPH + 2H+
HMGR
−−−−−→ mevalonate + 2NADP+ + CoA
This reaction is irreversible. It is the committed step in cholesterol formation, and HMGR
is the rate-determining enzyme.
Mevalonate is converted to isopentenyl pyrophosphate in three consecutive reactions
that require ATP. Squalene is synthesized from six molecules of isopentenyl pyrophosphate.
It is oxidized to squalene epoxide in a reaction that requires molecular oxygen and is
catalyzed by squalene monooxygenase. Squalene epoxide is cyclized to lanosterol by
lanosterol synthase. Lanosterol is then converted to cholesterol.
2.1.2 Cholesterol uptake from LDL
Free cholesterol, with its polar OH group, would be conﬁned to the surface of lipoproteins
like LDL. Instead, the cholesterol in LDL is in the form of cholesteryl esters: the OH
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group is esteriﬁed with a fatty acid, to make the molecule non-polar. LDL is internalized
into cells by clathrin-mediated endocytosis. On the plasma membrane (PM), low-density
lipoprotein receptor (LDLR) associates with clathrin-coated pits and promotes the intake
of LDL and its delivery to early endosomes (ﬁg. 3). From early endosomes, LDL particles
are transported to multi-vesicular bodies (MVBs) and late endosomes (LEs). The low
endosomal pH dissociates the LDLR from the LDL particles and LDL is traﬃcked via
LEs to lysosomes. There, LDL cholesterol esters are hydrolyzed to free cholesterol by
acid lipase (Sugii et al. 2003). Exit of cholesterol from the LEs is regulated by NPC
intracellular cholesterol transporter 1 (NPC1) and NPC intracellular cholesterol transporter
2 (NPC2) (Carstea et al. 1997; Loftus et al. 1997). NPC1 is needed to recruit Rab8a to
LEs, and Rab8a enhances the motility and segregation of recycling endosomes from LEs
and lysosomes (Kanerva et al. 2013).
On the PM, inducible degrader of the LDL-receptor (IDOL) blocks LDL association
with the LDLR in clathrin-coated pits, and regulates LDLR uptake and degradation
(Scotti et al. 2011). IDOL employs the MVB pathway to sort LDLR to the lysosome
for degradation. Endosomal sorting complexes required for transport (ESCRTs) are
evolutionary conserved proteins found even in archaea that control other cellular functions:
receptor signaling, cytokinesis, autophagy, polarity, migration, miRNA activity and mRNA
transport (Zaremba-Niedzwiedzka et al. 2017). More recent ﬁndings suggest that the
endosomal sorting complexes required for transport (ESCRT) pathway is required for
IDOL-mediated LDLR degradation, while LDLR internalized through clathrin-mediated
endocytosis is preferentially recycled to the PM (Scotti et al. 2013).
2.1.3 Regulatory mechanisms
The rate of cholesterol synthesis is highly responsive to the cellular level of cholesterol.
The feedback mechanisms are primarily mediated by changes in the amount and activity
of HMGR (ﬁg. 4). Cholesterol generated from LDL hydrolysis within the lysosome is
responsible for suppressing 3-HMG-CoA activity through the sterol regulatory element-
binding protein (SREBP) pathway. By inhibiting the SREBP pathway, LDL suppresses
the transcription of LDLR, along with other proteins involved in cholesterol uptake and
synthesis (Goldstein and M. S. Brown 2009).
Newly synthesized SREBP is inserted into the ER membrane and is bound to the SREBP
cleavage-activating protein (SCAP). (ﬁg. 4, 1 ). SCAP is a sensor for sterols: when cells
are depleted of cholesterol, SCAP escorts SREBP from the ER to the Golgi, where the
two proteases S1P and S2P sequentially cleave SREBP to release nSREBP (ﬁg. 4, 2 ).
The cleaved nSREBP translocates to the nucleus where it activates SREs. (ﬁg. 4, 3 ).
SRE is regulated by SREBPs SREBP-1a, SREBP-1c, and SREBP-2. In the presence of
sterols, SRE inhibits HMGR mRNA synthesis rate. Of the three SREBPs, SREBP-1a
activates genes mediating the synthesis of cholesterol, fatty acids, and triglycerides, while
SREBP-1c activates genes mediating fatty acid synthesis and glucose metabolism. SREBP-
2 preferentially activates cholesterol synthesis enzymes HMG-CoA synthase, HMGR, and
squalene synthase, as well as LDL receptor (Horton et al. 2002).
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SREBP
SCAP
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Figure 4: Cellular cholesterol balance is regulated through the SREBP pathway. The numbers
designate the site for each consecutive step: 1 – transport of SREBP from the endoplasmic reticulum
(ER) to the Golgi; 2 – cleavage of SREBP to nuclear SREBP (nSREBP) by Site-1 protease (S1P)
and Site-2 protease (S2P); 3 – activation of sterol regulatory element DNA sequences (SREs); and
4 – transcription of the relevant mRNAs. See the text for details.
Feedback mechanisms complementary to the SREBP pathway have also been described.
For example, sterol-responsive nuclear liver X receptor (LXR) maintains cholesterol
homeostasis both through promotion of cholesterol eﬄux and suppression of LDL uptake.
LXR inhibits the LDLR pathway through transcriptional induction of IDOL by triggering
the ubiquitination of LDLR (Zelcer et al. 2009).
The rate of translation of the HMGR mRNA is inhibited by nonsterol mevalonate
products like isoprenoid (Nakanishi et al. 1988). Furthermore, the membrane domain of
HMGR senses high levels of the derivatives of cholesterol and mevalonate in the membrane,
leading to the rapid degradation of HMGR. Oxysterols such as 25-hydroxycholesterol
and 24,25-dihydrolanosterol stimulate ubiquitination of lysine residues in the membrane
domain of HMGR. This triggers extraction of HMGR from the ER membrane and delivery
to proteasomes for degradation (Jo and Debose-Boyd 2010).
2.1.4 Methods for studying cellular cholesterol
Biologically relevant molecules can be studied by using ﬂuorescent or radioactive labels,
or by using molecules that bind them, inﬂuencing their biological activity or allowing the
studied molecule to be visualized. For example, dipyrromethene diﬂuoride-cholesterol is a
ﬂuorescent cholesterol analogue that has been successfully used to visualize the cellular
7
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distribution and accumulation of cholesterol (Hölttä-Vuori et al. 2008, 2016). However,
experimental methods that employ a cholesterol analogue are limited by the fact that the
ﬂuorescent moieties tend to perturb the physical properties of the lipid.
The incorporation of radioactively labeled cholesterol precursors (for example acetate)
into cholesterol can be used to measure the rate of de novo cholesterol synthesis in cells
without changing the physical and chemical properties of cholesterol (Heino et al. 2000).
The isolation of subcellular fractions can be used to study the localization of radioactively
labeled cholesterol. However, the available experimental methods for purifying subcellular
compartments limit the sensitivity of such studies. Pure fractions are exceedingly diﬃcult
to obtain.
Another approach is to use biologically active molecules that target cholesterol in the cell
or the PM. Streptolysin-O (SLO) is a toxin that binds to cholesterol-containing membranes
to assemble to curved rod structures that penetrate the apolar domain of the membrane
bilayer, generating trans-membrane pores (Bhakdi et al. 1985). Treating cells with SLO
can be used as an indirect measure of the free cholesterol content of the PM: for example,
the release of cytosolic lactate dehydrogenase (LDH) upon SLO treatment can be used as
a readout for pore formation (Pimplikar et al. 1994).
Filipin is a ﬂuorescent antibiotic that binds to cholesterol, but not to esteriﬁed sterols:
it can be used for detecting free cholesterol. Filipin binding permeabilizes the cells, so
it cannot be used for live cell imaging, and the molecular basis for ﬁlipin binding is
not completely understood (Maxﬁeld and Wüstner 2012). Still, ﬁlipin staining intensity
correlates well with the amounts of unesteriﬁed cholesterol in cells and can be used as a
tool for quantitative imaging (Linder et al. 2007).
2.2 Endocytic pathway
Endocytosis is the transport of macromolecules, particles, and even other cells from the
PM into the cell. Phagocytosis involves the intake of large particles as microorganisms or
dead cells via phagosomes. It is mainly done by specialized white blood cells, phagocytes:
macrophages, neutrophils, and dendritic cells.
All eucaryotic cells continually ingest some of their PM in the form of small endosomal
vesicles. Conversely, the surface and the volume of the cell are maintained by continually
removing membrane and cargo by exocytosis. Receptor-mediated endocytosis provides a
mechanism for selective concentration and uptake of extracellular ligands. Cholesterol
uptake through LDL by LDLR-mediated endocytosis is the major route for cholesterol
into the cell. The formation of clathrin-coated pits is one mechanism for the formation of
endosomal vesicles. These are specialized regions of the PM, with a diameter in human
epithelial cells typically within a 120 nm to 150 nm range (McMahon and Boucrot 2011).
After cargo selection, clathrin-coated pits invaginate into the cell and pinch oﬀ to form
clathrin-coated vesicles. Clathrin-coated vesicles rapidly shed their clathrin coat and fuse
with early endosomes.
Another pathway for endocytosis is through caveolae, invaginations in the PM of most
cell types. Caveolae are ﬂask-shaped, with a diameter between 70 nm and 120 nm. Based
on their size and lipid content, caveolae are a subset of lipid rafts: specialized membrane
8
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Figure 5: EGF receptor uptake, recycling, and degradation. Unlike LDL receptor, EGF receptor
binds its ligand EGF before localizing to clathrin-coated pits. It is transported through multivesicural
bodies, with the help of the ESCRTmachinery, to the lysosome, where both the receptor and its ligand
are degraded, or it is recycled back to the plasma membrane. There is another, ligand-independent
pathway for EGF receptor uptake regulated by lysosomal-associated transmembrane protein 4B
(LAPTM4B) that does not depend on clathrin-coated pits, and which targets the receptor for
degradation. See the text for details.
microdomains enriched in sphingolipids and cholesterol. Both clathrin-coated pits and
caveolae function in endocytosis, signal transduction, and receptor recycling (Reeves
et al. 2012). Dynamin-2 is a protein located along the neck of the invaginations and
promotes caveolae budding (Yao et al. 2005). Cross-linked GPI-anchored proteins move
into caveolae and become endocytosed. Caveolae are enriched in signaling lipids such
as ceramide, and ceramide is produced in caveolae in response to interleukin-1 beta, an
important mediator of the inﬂammatory response (Simons and Vaz 2004).
2.2.1 Degradative functions
Early endosomes mature to MVBs that are moved along microtubules and become LEs,
either by fusing with each other or with existing LEs. LEs communicate with the trans-
Golgi network via transport vesicles, for example by obtaining the proteins that convert
the LEs into lysosomes (Keller and Simons 1997).
After internalization into early endosomes, cell surface receptors may have diﬀerent fates.
Both LDLR and epidermal growth factor receptor (EGFR) can be either recycled to the
PM through recycling vesicles and tubules, or targeted to lysosomes for degradation (ﬁg. 3
and ﬁg. 5). EGFRs bound to their ligand, epidermal growth factor (EGF), accumulate
in clathrin-coated pits and after uptake are degraded in the lysosomes along with EGF
(Sigismund et al. 2008).
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2.2.2 Endosomal ceramide
The multivesicular endosome membrane can be sorted to the lysosome for degradation, or
secreted in the form of exosomes. Ceramide is required for the segregation of cargo, and for
the transfer of exosome-associated domains into the lumen of the endosome (Trajkovic et al.
2008). In LEs, LAPTM4B interacts with ceramide to remove it from LEs (Blom et al. 2015).
In LAPTM4B-depletedA431 cells, ceramide accumulates in LEs, and stable overexpression
of LAPTM4B in A431 cells lowers cellular ceramide content. Silencing LAPTM4B in
KPL-4 breast cancer cells protects them from chemotherapy-induced caspase-3 activation.
Recruitment of sphingosine kinase 1 (Sphk1) to sphingosine-enriched endocytic vesicles
and the generation of sphingosine-1-phosphate facilitates membrane traﬃcking along the
endosomal pathway. Furthermore, Sphk1 inhibitors induce Sphk1-dependent fusion of
endosomal membranes (Young et al. 2016). This leads to accumulation of enlarged LEs, a
phenotype that could be rescued by activation of ceramide synthase and the restoration of
autophagy.
Interestingly, LAPTM4B is also involved in the traﬃcking and degradation of EGFR
(Tan et al. 2015a,b). LAPTM4B inhibits EGF-stimulated intraluminal sorting of EGFR
and thus its degradation by promoting the ubiquitination of an ESCRT subunit. Thus,
LAPTM4B and ESCRTs regulate EGFR signaling independently of clathrin-mediated
endocytosis (ﬁg. 5).
2.2.3 StARD3 and late endosomes
The StARD3 gene is overexpressed in human breast carcinomas and exhibits a homology
with the steroidogenic acute regulatory protein STAR (Moog-Lutz et al. 1997). It has
a cholesterol-binding trans-membrane domain that targets it to LEs, and a cytosolic
cholesterol binding pocket (Tsujishita and Hurley 2000; Alpy et al. 2005; Alpy and
Tomasetto 2006; van der Kant et al. 2013). The StARD3 protein is transported to
the LE via the PM, and its cholesterol binding pocket is necessary for late endocytic
dynamics and exit of free cholesterol from lysosomes (Zhang et al. 2002). The cholesterol
binding activity of StARD3 is involved in the association of LEs with actin ﬁlaments
and the actin-dependent movement of LEs (Hölttä-Vuori et al. 2005). In NPC1-deﬁcient
chinese hamster ovary cells in which cholesterol transport to the mitochondrial inner
membrane is not aﬀected by the lack of NPC1, StARD3 knockdown results in decreased
cholesterol transport to the inner membrane and reduces mitochondrial cholesterol levels.
Thus, StARD3 might provide a pathway for the egress of cholesterol from endosomes to
mitochondria (Charman et al. 2010). This observation is supported by the ﬁnding that
StARD3 and its close paralogue StARD3NL are involved in the formation of contacts
between LEs and the endoplasmic reticulum: they interact with ER-anchored VAP-A and
VAP-B proteins, allowing ER-endosome contact formation (Wilhelm et al. 2016). The
presence and importance of contact sites between ER and mitochondria are well established
(Rowland and Voeltz 2012); these recent ﬁndings highlight the role of StAR-related lipid
transfer protein 3 (StARD3) in contacts between endosomes, and the ER and mitochondria.
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2.3 EGF receptor signaling
Receptor tyrosine kinases are a class of enzyme-linked cell surface receptors. These
transmembrane proteins have their ligand-binding domain on the outside of the cell. In the
membrane, two or more receptor chains come together to form a dimer or an oligomer that
is activated by ligand binding. Receptor tyrosine kinases then phosphorylate each other at
multiple tyrosines in the cytoplasmic tails, which transmits the activation signal.
2.3.1 ErbB receptor family
EGFR belongs to the ErbB family of receptor tyrosine kinases implicated in cancers; its
ligand is EGF. The main responsibility of the EGF signal is to stimulate proliferation. Of
the four family members, ErbB2 is the most potent oncoprotein. It is the only protein in the
ErbB family for which a high-aﬃnity ligand has not been identiﬁed (Yarden and Sliwkowski
2001). ErbB2 forms dimers with the other family member receptors, creating docking sites
for adapter proteins or enzymes that stimulate downstream pathways (ﬁg. 6). Through
induction of downstream signaling pathways, ErbB receptors enhance cancer cell survival
and proliferation, migration and adhesion, tumorigenesis, as well as apoptosis inhibition
(Karamouzis et al. 2007; Yarden and Sliwkowski 2001). For example, the PI3K/Akt/mTOR
pathway regulates the cell cycle; the cSrc/FAK pathway regulates cell migration, adhesion,
and angiogenesis; and the cSrc/STAT pathway regulates tumorigenesis.
Interestingly, cross-talk between EGF receptor signaling and cholesterol balance has
been reported. For example, a family member, ERBB4, can undergo ligand-induced
proteolytic cleavage to release a soluble intracellular domain that enters the nucleus to
modify transcription and activate SREBP-2 (Haskins et al. 2015).
2.4 Cholesterol and cancer
The role of dietary cholesterol and plasma cholesterol levels in cancer progression has
been extensively studied. For instance, in a Finnish nation-wide study, pre-diagnostic
statin use was found to be associated with lowered risk of breast cancer death in a dose-
and time-dependent manner (Murtola et al. 2014). In a Danish nationwide study, statin use
in patients with cancer was associated with reduced cancer-related mortality in 13 types
of cancer including breast cancer (Nielsen et al. 2012). In a mouse model of mammary
tumor formation, dietary cholesterol accelerated and enhanced tumor formation. Moreover,
plasma cholesterol levels were reduced during tumor development but not prior to its
initiation (Llaverias et al. 2011).
The cellular homeostasis of cholesterol is also involved in cancer progression. For exam-
ple, overexpression of PPP1R1B-STARD3 fusion transcript in MKN-28 cells signiﬁcantly
increased cell proliferation and colony formation by increasing activation of PI3-kinase
and AKT signaling (Yun et al. 2014).
Mutations in the tumor suppressor protein p53 have been shown to inﬂuence cancer
progression by directly regulating de novo cholesterol synthesis. Mutant p53 can upregulate
mevalonate pathway genes via SREBP transcription factors. In cell lines derived from
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Figure 6: A simpliﬁed diagram of selected ErbB receptor family signaling pathways. Some of the
most important ligands for the ErbB receptor family dimers are shown in green; there many other
known ligands (the light green empty box). The known receptor dimers are shown in blue; if an
EGF receptor is known to form dimers with multiple other receptor family members, the second box
is left empty. The most important downstream signal transducers are shown in red, and the cellular
processes that they regulate are shown in yellow.
metastatic breast tumors and grown in 3D culture, HMGR inhibitors mimicked the
phenotypic eﬀects of mutant p53 depletion. The p53 mutation correlated with the elevation
of mevalonate pathway genes in human tumors (Freed-Pastor et al. 2012).
The SQLE gene encodes squalene monooxygenase. In a study of a panel of breast cancer
cell lines, SQLE inhibition resulted in a decrease in cell viability, and in a noticeable
increase in replication time. The eﬀects depended both on gene copy number and on
inhibitor dosage. These eﬀects were observed only in the cell lines with detectable SQLE
transcript, suggesting that SQLE can act as an oncogene in breast cancer (D. N. Brown
et al. 2016).
Oxidosqualene cyclase is a lanosterol synthase, a post-squalenic enzyme of cholesterol
biosynthesis. In a study employing a selective inhibitor of oxydosqualene cyclase, Ro
48-8071, enzyme inhibition had a strong anti-angiogenic eﬀect by impairing endothelial
cell adhesion and migration, and by blocking vessel formation in angiogenesis assays by
speciﬁcally inhibiting AKT phosphorylation (Maione et al. 2015).
2.4.1 NDRG1 in cancer
The N-myc downstream-regulated gene 1 (NDRG1) protein is widely expressed in human
tissues, mostly in epithelial cells, and is strongly upregulated under hypoxia (Lachat
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et al. 2002). In vitro overexpression of NDRG1 in metastatic colon cancer cells reduced
invasion; in mice, overexpression suppressed colon cancer metastasis (Guan et al. 2000).
The expression of the NDRG1 protein in prostate cancer patient tumors was inversely
correlated with overall survival, while in mice, it inhibited lung colonization of metastatic
prostate cancer cells (Bandyopadhyay et al. 2003).
The levels of the NDRG1 protein were signiﬁcantly reduced in patient breast tumors
and metastases, while in vitro overexpression suppressed the invasiveness of breast cancer
cells (Bandyopadhyay et al. 2004). In pancreatic cancer cells, NDRG1 overexpression lead
to decrease in tumor growth and a reduction in tumor-induced angiogenesis (Maruyama
et al. 2006). In colorectal cancer tissue, patients with lower NDRG1 mRNA had a lower
survival rate (Strzelczyk et al. 2009). In prostate cancer cell lines, NDRG1 recruited onto
recycling endosomes, interacted with membrane bound Rab4aGTPase, and colocalized
with transferrin (Kachhap et al. 2007).
The NDRG1 protein has also been speciﬁcally implicated in cellular cholesterol
homeostasis. In a genome-wide expression analysis of Niemann-Pick disease, Type C
(NPC) ﬁbroblasts, NDRG1 mRNA was elevated (Reddy et al. 2006). 1,1′-dioctadecyl-
3,3,3′,3′-tetramethyl-indocarbocyanine-perchlorate – labeled LDL (DiI-LDL) uptake in
HeLa was stimulated by knockdown of NDRG1 (Bartz et al. 2009).
2.4.2 StARD3 in cancer
STARD3 is one of several genes coampliﬁed with ERBB2 and found in the same genomic
region (17q12-q21). StARD3 knockdown results in decreased cell proliferation of
overexpressing cancer cell lines (Kauraniemi and Kallioniemi 2006; Kao and Pollack 2006;
Staaf et al. 2010). Its overexpression in ErbB2 overexpressing cell lines was required
for the growth and survival of breast cancer cell lines (Sahlberg et al. 2013). Until very
recently, however, very little was known about the function of the StARD3 protein, or the
mechanism by which its co-ampliﬁcation in ErbB2-positive breast cancers contributed to
cancer progression.
2.5 Generation of knowledge from existing data
Applying high-throughput screening to experiments has generated a wealth of data
such as nucleotide and protein sequences, protein crystal structures, gene-expression
measurements, protein and genetic interactions and phenotype studies (Howe et al. 2008).
This accumulation of publicly available data has created an opportunity and a need:
generating biologically interesting results from existing “raw” data.
2.5.1 Studies of the TCGA database
The Cancer Genome Atlas (TCGA) is a collaboration between the National Cancer Institute
and the National Human Genome Research Institute. TCGA has generated comprehensive,
multi-dimensional maps of the key genomic changes in 33 types of cancer, including breast
cancer. The data is publicly available.
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TCGA has provided a comprehensive molecular portrait of human breast tumors by
analyzing genomic DNA copy number arrays, DNA methylation, exome sequencing,
messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays (Koboldt
et al. 2012). These data has been used by many bioinformatics studies. The study by Grieb
et al. (2014) is just one example of utilizing the TCGA database. Evaluation of mRNA
expression and copy number variation data revealed that the MDM2 Binding Protein is
commonly overexpressed in breast cancer and increased transcript of gene ampliﬁcation
signiﬁcantly correlated with reduced breast cancer patient survival.
2.5.2 Sharing and reproducing computational research
Automatic computers have enabled us to conduct research in a radically novel way (Dijkstra
1989). In computational research, performing an experiment amounts to instructing a
machine to carry out arithmetic and logical operations automatically. A high level free
text description of the instructions carried out by the machine is usually enough to explain
the rationale and the logic of the experiment to other researchers. To instruct the computer
to carry out the experiment, a computational scientists must provide the “program”: a
deﬁnition of the experiment in a formal language. Computer architectures vary, and the
instructions that deﬁne the same experiment on two diﬀerent machines will be diﬀerent.
Until the last ten years of last century, computers were rare and very diﬀerent from each
other. It was usual that a computer program had to be rewritten for every machine it ran on.
However, the situation has been changing. There are fewer computer architectures still
developed and sold, and existing architectures have converged to some degree. General-
purpose computers have become aﬀordable and ubiquitous. At the same time, the idea
that computer programs can and should be freely available is slowly gaining acceptance.
It is increasingly easy to do computational research using only free∗software, which has
further encouraged the development and standardization of free tools for computational
research. As a result, it is easier than ever to write a computer program, share it, and have
others run it with minimal eﬀort.
Currently, sharing and reproducing computational research can be achieved by following
simple guiding principles and adhering to straightforward rules and best practices (ﬁg. 7).
For example, the computational analysis should be understandable to someone unfamiliar
with the project, and everything that was done once should be easy to repeat, either exactly
as is, or after improving or correcting it (Noble 2009). This can be done by keeping track
of how every result was produced, avoiding manual data manipulations, providing full
access to the original data and the analyzes, as well as explaining the design and purpose
of the experiments (Sandve et al. 2013; Wilson et al. 2014).
Many of the rules, best practices, and guiding principles in computational research are
well known in the ﬁeld of software engineering: version control, self-documenting code,
automated documentation generation, automated tests, scripting, open source. However,
in software engineering, the ﬁnal product is usually the software itself. In computational
research, the software is just a means to obtaining a scientiﬁcally relevant result. The
∗“Free” as in “free speech”, not as in “free beer”.
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Figure 7: Summary of the best practices and rules for reproducible computing. For example, to
improve Reproducibility, document all intermediate results, and present, to the human reader, the
purpose and the design of the data analysis.
electronic notebook is the alternative to an experimental notebook – it contains the software
and the results obtained, and can be shared with others to inspect, reproduce, or modify
(Shen 2014). Existing electronic notebook implementations include Sweave and Knitr for
R (Leisch 2002), IPython for Python (Pérez and Granger 2007), and Jupyter for almost any
widely used programming language. A diﬀerent approach is to embed all software within
the PDF ﬁles published by scientiﬁc journals: it is invisible in a conventional PDF reader,
but a special tool can extract the source code from the PDF ﬁle (Kitchin 2015).
For larger, more complex computational analysis projects, a lab notebook might not be
well-suited. Frameworks for large-scale data acquisition and integration aim to facilitate
projects involving many people and data sources by providing better tools for collaboration
and documentation, along with libraries for acquiring data. These frameworks incur some
unavoidable overhead to install and use (Ovaska et al. 2010; Börnigen et al. 2015).
The work by Donald Knuth on literate programming (Knuth 1983, 1984) has inﬂuenced
the concept of the lab notebook. The literate programming tool Noweb (Ramsey 1994,
2008) is a generalization and simpliﬁcation of the original work by Knuth. Sweave, the
ﬁrst widely used lab notebook software tool, is build upon Noweb.
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The overall aim of this study was to gain insights into the functions of the endocytic lipid
traﬃcking regulators NDRG1, StARD3, and LAPTM4B, and how they may contribute to
cancer progression. The following three main questions were addressed in the course of
the study:
• What is the role of NDRG1 in cellular lipid homeostasis and LDLR endocytic
traﬃcking, and how is it relevant in cells expressing the protein abundantly?
• Does the cholesterol-binding protein StARD3 contribute to the progression of
Her2-positive breast cancer and if so, what mechanisms are involved?
• What further clues to the role of these proteins in breast cancer progression can be
extracted from an existing genome-wide breast cancer patient dataset?
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Methods from diﬀerent ﬁelds were employed: cell biology, biochemistry, statistics, and
computational data analysis. For each method, the original publications in which it was
used, as numbered in “Original Publications” on page vi, is given in parenthesis. The
methods that were used in previously unpublished results presented in this thesis are
marked with ‘U’.
Importantly, only the materials and methods for the experiments performed by the author
of this thesis summary are listed here; for full details on all materials and methods, see the
original publications.
4.1 Cell biology
4.1.1 Cell culture (I, II, U)
All cell lines were cultured at 37 ◦C in a CO2-conditioned, humidiﬁed incubator. A431 cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (D-MEM) supplemented with 10%
fetal bovine serum (FBS), 0.5mM l-glutamine and 100 IU/mL penicillin, 100 µg/mL
streptomycin.
Oli-neu cells were cultured in D-MEM with B27 supplement on 50 µg/mL poly-D-
lysine-coated plastic.
MCF-7 cells were cultured in Eagle’s minimum essential medium (E-MEM) supple-
mented with 10% FBS, 0.5mmol/L l-glutamine, 0.01mg/mL insulin, non-essential
amino acids, and 100 IU/mL penicillin and 100 µg/mL streptomycin.
KPL-4 cells were cultured in D-MEM supplemented with 5% FBS.
BT-474 cells were cultured in D-MEM supplemented with 10% FBS, 1mM sodium
pyruvate, 4mM l-glutamine, 0.01mg/mL insulin, as well as 100 IU/mL penicillin and
100 µg/mL streptomycin.
4.1.2 Plasmid and siRNA transfections (I, II)
Plasmid DNA was introduced to cells either using Lipofectamine-LTX or Eﬀectene as a
transfection reagent, following the manufacturer’s protocol. To inhibit gene expression,
siRNAs were introduced to cells using the HiPerfect transfection reagent, following the
manufacturer’s protocol.
4.1.3 Lentiviral particle transduction (U)
Cells were plated on 48-well plates 24 h before transduction. At the time of transduction
cells were 50% conﬂuent. Equal amounts of lentiviral particles (functional viral titer was
determined using the p24 viral capsid protein) were added to a 1:1 mixture of polybrene
and full medium, added to the cells, and incubated for 5 h before replacing with fresh full
medium. After 24 h of incubation the selection antibiotic, 1 µg/µL puromycin, was added
to the culture medium. The cells were cultured at 37 ◦C in a CO2-conditioned, humidiﬁed
incubator.
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4.1.4 DiI-LDL binding and uptake (I)
Cells were incubated with DiI-LDL for 30min at 4 ◦C for plasma membrane (PM) receptor
binding and 20–30min at 37 ◦C for internalization in serum-free medium prior to ﬁxation
with 4% PFA and nuclear staining with DAPI.
4.1.5 Immunofluorescent staining (I, II, U)
For imaging of focal adhesions, cells were ﬁxed and permeabilized with methanol for
5min at −20 ◦C. For ﬁlipin staining, the cells were ﬁxed, stained, and permeabilized with
0.05% ﬁlipin in 10% FBS in phosphate-buﬀered saline for 30min at 37 ◦C.
Otherwise, cells were ﬁxed with 4% paraformaldehyde for 20min at room temperature,
and autoﬂuorescence was quenched in 50mmol/L ammonium chloride for 15min at room
temperature. Cells were permeabilized with 0.1% Triton X-100 in phosphate-buﬀered
saline (PBS) for 5min and blocked with 10% FBS for 30min at room temperature. Primary
and secondary antibody incubations were done in separate steps.
4.1.6 Cell imaging (I, II, U)
Red/green ﬂuorescent images were acquired with an Olympus AX70 microscope using
10×, 20×, and 40× air objectives.
Filipin ultraviolet light images were acquired with the same microscope and with an
inverted Olympus microscope with a Polychrome IV monochromator using a 10× air
objective.
Confocal images were acquired with a Leica TCS SP2 AOBS confocal microscope with
a 40× and 63× oil immersion objective.
Total internal reﬂection ﬂuorescence (TIRF) images were acquired with a Nikon
Eclipse Ti-E inverted microscope equipped with an argon laser and a 100× oil immersion
objective with 1.49 numerical aperture. The corresponding wide-ﬁeld images of ﬁlipin
and StARD3-GFP were taken at a focal plane 1 µm above the TIRF plane.
Phase-contrast and green ﬂuorescent images of live cells and ﬁxed cells were acquired
with a Zeiss AxioVert 200 microscope equipped with a Zeiss AxioCam HRc camera using
a 10× air objective.
Diﬀerential interference contrast (DIC) images of live cells on plastic were taken with
an inverted Olympus microscope with a 10× air objective.
4.2 Biochemistry
4.2.1 Immunoblotting (I, II, U)
Cell lysates were collected in a stringent denaturing lysis buﬀer (1% SDS, 5mM EDTA)
containing phosphatase inhibitors (1mMactivated ortho-vanadate, 25mMsodiumﬂuoride)
and protease inhibitors chymostatin, leupeptin, antipain and pepstatin A (CLAP), boiled
for 5min and passed through a needle to decrease viscosity. Total protein concentration in
each sample was determined by a BioRad colorimetric protein assay. All samples were
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adjusted to the same protein concentration before loading to a sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gel. After separation, the proteins were
transferred to a nitrocellulose membrane and immunoblotted. Secondary antibodies were
detected either with an Odyssey infrared scanner, or with enhanced chemiluminescence
reagents and ﬁlms by Amersham.
4.2.2 Lipid extraction and thin layer chromatography (I, II)
Lipids were extracted from cells using the Bligh and Dyer method (Bligh and Dyer 1959).
Free cholesterol and cholesterol esters were resolved on high-performance thin layer
chromatography plates using hexane, diethyl ether, and acetic acid in 80:20:1 ratio as the
mobile phase. Total amounts were quantiﬁed by charring and comparing to a standard
lipid mix separated on the same plate. Cholesterol synthesis and cholesterol eﬄux in
cells fed with radioactively labeled lipid precursors was measured by separating the total
lipids, then scraping the plate according to the migration of non-radioactive standards and
detecting the scintillation counts.
4.2.3 Cell membrane permeabilization (II)
Cells were permeabilized in a cell membrane cholesterol-dependent manner using the
Streptolysin O (SLO) toxin from Streptococcus pyogenes. After 30min of cell membrane
permeabilization at 37 ◦C the medium was collected and the cells were lyzed. The decrease
in absorbance at 340 nm, resulting from the oxidation of NADH by LDH on addition of
pyruvate to each sample was measured over 1min. The slope of the absorbance curve,
δM for the medium and δL for the lysate, provides a measure for the amount of LDH in
a sample. For each medium-lysate pair, the permeability ρ of the membrane after SLO
treatment was calculated as:
ρ =
δM
δM + δL
and is indicative of the amount of cholesterol in the cell membrane.
4.2.4 Cell surface biotinylation (I)
The complete assay was performed at 4 ◦C in a cold room. Cells were washed in PBS
containing 0.02mM CaCl2 and 0.15mM MgCl2 (PBS+), cell surface proteins were
biotinylated for 20min on ice with 0.5mg/mL biotin in PBS+, and unbound biotin was
quenched by two incubations of 5min in 0.1M glycine and 0.3% BSA in PBS+. Cells
were then rinsed twice in PBS+ and lyzed in PBS containing 0.2% SDS, 2% NP-40, and
protease inhibitors (CLAP). Lysates were collected and cleared by centrifugation, and an
aliquot taken for the total protein amount. Biotinylated proteins from the rest of the lysate
were precipitated with 50 µL streptavidin-agarose beads by rotation overnight. The beads
were then washed before eluting the protein from the beads by boiling in 2× sample buﬀer;
at this point the samples are analyzed by immunoblotting. To quantify the degradation of
a cell-surface protein, cells were chased for 0 h, 2 h and 5 h in complete medium at 37 ◦C
before cell surface biotinylation.
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4.2.5 Quantitative Real-Time RT-PCR (II)
Samples were homogenized in RLT buﬀer from Qiagen, and total RNA was isolated with
the RNeasy Mini Kit from Qiagen, according to the manufacturer’s protocols. 1 µg of
the isolated total RNA was reverse transcribed and quantiﬁed using a LightCycler 480.
TATAA box protein was used as an internal control for normalization. Each sample was
run in triplicate. Normalized gene expression values were obtained using LightCycler 480
software version 1.5.1, using the basic relative quantiﬁcation method.
4.3 Statistics
All statistical analyses consisted of testing the statistical signiﬁcance of a result and
visualizing a summary of the results. Plots for the data analyzed with the Student’s t-test
were made with Microsoft Excel. Plots for all other data were made with the facilities
provided by the R environment for statistical computing.
4.3.1 Student’s t-test (I, II)
To test the statistical signiﬁcance of normally distributed values in exactly two groups, a
non-paired two-tailed Student’s t-test was performed. The data was visualized using bar
charts, with the height of the bar representing the mean and the error bars representing the
standard error of the means.
4.3.2 Mann-Whitney-Wilcoxon rank sum test (II)
Continuous distributions of values in two groups that could not be assumed to be normally
distributed were tested for statistical signiﬁcance using the Mann-Whitney-Wilcoxon rank
sum test. The data was visualized in box-and-whiskers plots, with the bottom and the top
of the box representing the ﬁrst and third quartiles and the band inside the box representing
the median. The lower and upper whisker represent the lowest datum within 1.5× the
interquartile range of the lower quartile, and the highest datum within 1.5× the interquartile
range of the upper quartile. Data points outside of those ranges were not visualized.
4.3.3 Chi-square test (II, III)
Correlation between categorical data was tested for statistical signiﬁcance with the χ2-test.
In the case of two variables with two possible values each, the 2 × 2 contingency table was
visualized as a bar plot, where the height for each bar represents the number of observations
in each table cell.
4.3.4 Log-rank test (III)
Censured survival data was tested for statistical signiﬁcance using the log-rank test. All p
values are two-sided. Survival curves were plotted using the R survival package.
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4.3.5 Pearson’s correlation (III)
To estimate the correlation between two continuous variables without assuming any
distribution, the Pearson’s product-moment correlation coeﬃcient was used. Such data
was visualized as a scatter plot.
4.4 Computational methods
4.4.1 Image quantification (I, II)
All manual image quantiﬁcations – microscopy images, immunoblots, thin layer chro-
matography plates – were performed using the standard distribution of ImageJ, version
1.48 or later, without using any additional plugins (Schneider et al. 2012).
4.4.2 Data analysis (I, II, III)
For the Student’s t-test, either Microsoft Excel or R was used. For all other statistical tests,
the built-in R facilities were used. All data visualizations in Original Publications I and
II were done with Microsoft Excel. All data visualizations in Original Publication III
were done with R. High-throughput data was pre-processed with standard command line
utilities. The data base engine used was SQLite.
4.4.3 Reproducible computation (III)
The tool for reproducible computation Lir was implemented in Bash using the command
line tools available in the distribution of Noweb, as well as the standard command line
programs GNU-Sed and GNU-Awk. SWI-Prolog was used for parsing the pipeline
representation emitted by Noweb and generating HTML. Pandoc was used for generating
the ﬁnal human-readable document.
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5 Results and Discussion
In each subsection of “Results and Discussion”, the original publications containing all
data are referred to with I, II, and III, as numbered in “Original Publications” on page vi.
All following ﬁgures are unpublished data related to publication II.
5.1 NDRG1 regulates LDLR trafficking (I)
The protein N-myc downstream-regulated gene 1 (NDRG1) is widely expressed, particularly
in the nervous system. Subcellularly, it is mostly localized in the cytoplasm and the
endosomes. NDRG1 was ﬁrst identiﬁed as a potential regulator of cellular cholesterol
levels in studies of the neurodegenerative disease Niemann-Pick Type C. Reddy et al.
(2006) found that in ﬁbroblasts from patients suﬀering from this lysosomal storage disease
NDRG1 mRNA was elevated. Furthermore, in an Aﬃmetrix gene expression proﬁling of
NPC1-deﬁcient murine macrophages by Hölttä-Vuori et al. (2012), NDRG1 was identiﬁed
as a gene highly induced by cholesterol loading (Elina Ikonen, unpublished observation).
Finally, an RNAi screen by Bartz et al. (2009) studying cellular lipid phenotypes showed that
1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine-perchlorate – labeled LDL (DiI-
LDL) uptake by HeLa cells was stimulated by the knockdown of NDRG1. Together, these
ﬁndings suggested a connection between NDRG1 and cellular cholesterol homeostasis.
We studied the role of NDRG1 in lipid homeostasis by testing the eﬀects of altering
NDRG1 protein levels on cellular cholesterol, low-density lipoprotein (LDL) uptake, and
low-density lipoprotein receptor (LDLR) traﬃcking and degradation.
5.1.1 NDRG1 alters cellular cholesterol balance
First, we tested whether NDRG1 protein levels are inﬂuenced by cellular cholesterol levels.
In A431 cells, drug-induced lysosomal cholesterol accumulation resulted in a three-fold
increase of total NDRG1 protein amounts. Loading the cells with cholesterol from LDL
resulted in a two-fold increase of total NDRG1 protein amounts.
As NDRG1 protein levels were upregulated by an increase in lysosomal cholesterol
content or total cellular cholesterol, we next tested whether the protein is needed for
cholesterol homeostasis. Eﬃcient knockdown of NDRG1 protein levels in A431 cells led
to a redistribution of cholesterol from the plasma membrane (PM) to perinuclear, punctate
structures. The total level of free cholesterol in the cells was largely unchanged. However,
cholesterol ester levels were reduced dramatically. Since there were no major diﬀerences
in cholesterol biosynthesis or eﬄux, we studied whether this imbalance upon NDRG1
knockdown is mediated by cholesterol uptake.
5.1.2 Diminished LDL uptake in NDRG1-depleted cells
Knockdown of NDRG1 in A431 cells resulted in an increase of total LDL receptor protein
levels. Still, there was a decrease in the binding and internalization of DiI-LDL. A
biotinylation of the PM LDLR showed a clear decrease of the fraction of LDLR on the
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PM upon NDRG1 knockdown. Biotinylation followed by the uptake and degradation of
the biotinylated LDLR showed that in NDRG1 depleted cells, LDLR is internalized and
degraded at a lower rate. These results demonstrated that NDRG1 is required for the
localization of LDLR to the PM and the rate at which LDL is internalized and degraded.
5.1.3 In NDRG1-depleted cells LDLR accumulates in the early endosomes
As the total levels of LDLR were increased, we tested whether LDLR is redistributed
within the cell upon NDRG1 silencing. In control A431 cells LDLR is found mostly
in small, punctate early endosomes and to some extent in late endosomes (LEs) and
lysosomes. In NDRG1-silenced cells enlarged endosomes and lysosomes were scattered in
the cytoplasm; LDLR was sequestered in the abnormal early endosomes with a high free
cholesterol content. Silencing prenylated Rab acceptor protein 1 (PRA1), an interaction
partner for NDRG1, showed a similar phenotype. In NDRG1-depleted cells, PRA1 protein
levels were also down; overexpressing PRA1 in NDRG1-depleted cells could partially
rescue the LDLR phenotype.
These ﬁndings showed the abnormal sequestration of LDLR upon NDRG1 knockdown
or knockdown of its interaction partner PRA1. LDLR accumulated in abnormal early
endosome antigen 1 (EEA1)-positive endosomal vesicles.
5.1.4 NDRG1 is required for endosomal maturation
NDRG1-silenced cells contained enlarged multivesicular bodies with more intraluminal
vesicles, as observed by electron microscopy. In parallel, total ceramide levels in these cells
were increased. Fluorescently-labeled ceramide incorporation showed that in NDRG1-
depleted cells, ceramide was enriched in enlarged multi-vesicular bodies (MVBs), and
was retained there longer. Feeding A431 cells with radioactively labeled sphingomyelin
revealed increased levels of sphyngomyelin-derived ceramide in NDRG1-depleted cells.
These results suggested that NDRG1 function is required for proper endosomal matu-
ration. Despite the reduction of ESCRT components, NDRG1 deﬁciency increases the
number of intraluminal vesicles in MVBs. These vesicles are ceramide enriched: this
suggests that this endosomal ceramide accumulation triggers the formation of intraluminal
vesicles.
5.1.5 LDLR recycling and degradation depends on NDRG1
NDRG1 silencing in A431 cells enhanced the colocalization of LDLR with ubiquitin
in enlarged endosomes. In HEK293T cells, co-transfection with NDRG1 siRNA and
HA-tagged LDLR plasmid showed that NDRG1 depletion increased the amounts of
ubiquitynated LDLR. In A431 cells, preventing LDLR ubiquitination by silencing inducible
degrader of the LDL-receptor (IDOL) increased both PMand total LDLR levels, as expected.
In NDRG1-depleted A431 cells, IDOL depletion reversed the decrease in LDLR on the
PM and alleviated the endosomal sequestration of LDLR; it also rescued, to some degree,
the levels of cholesterol esters.
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These results demonstrate that LDLR is ubiquitynated in NDRG1-depleted cells and
accumulates in enlarged endosomes and MVBs. When LDLR ubiquitination is prevented,
the receptor is not abnormally sequestered and can recycle to the PM and cholesterol
uptake is rescued.
As epidermal growth factor receptor (EGFR) has to be transported to the lysosomes
to be degraded, defects in the pathway to the lysosome could inﬂuence its degradation.
A recent ﬁnding by Kovacevic et al. (2016) suggests one example of a possible action
of NDRG1 through this mechanism. In pancreatic cancer cells and colon cancer cells,
overexpression of NDRG1 decreased the expression and activation of EGFR, HER2,
and HER3 in response to EGF. Furthermore, it inhibited the formation of EGFR/HER2
and HER2/HER3 heterodimers, and decreased the activation of downstream MAPKK in
response to EGF. Anti-tumor agents that up-regulate NDRG1 inhibited EGFR, HER2, and
HER3 in cancer cells.
5.1.6 Reduced LDL uptake and Olig2 amounts in NDRG1-depleted
oligodendrocytes
Because of the abundant expression of NDRG1 in the nervous system, we depleted
NDRG1 in oligodendrocytic cells. Silencing of NDRG1 in murine Oli-neu cells reduced
DiI-LDL binding and uptake. Conversely, silencing IDOL resulted in increase of DiI-LDL
binding and uptake. Moreover, depletion of IDOL restored DiI-LDL binding and uptake in
NDRG1-silenced cells. The number of outgrowths characteristic of oligodendrocytes were
diminished in NDRG1-depleted Oli-neu cells. The levels of Olig2, important regulator of
oligodendrocyte diﬀerentiation and myelination, were signiﬁcantly reduced. This eﬀect
was reversed upon IDOL depletion in NDRG1-depleted Oli-neu cells.
These ﬁndings suggest that NDRG1 is important for oligodendrocyte cholesterol balance
and diﬀerentiation. This eﬀect could be mediated through IDOL-sensitive LDLR family
members VLDLR and ApoE receptor 2, both sharing a strong homology with the LDLR
(Herz and Bock 2002). Hong et al. (2010) have reported that IDOL is involved in the
ubiquitination and degradation of both receptors.
5.2 StARD3 and cholesterol in breast cancer (II)
The STARD3 gene is located in the genomic region of ERBB2 in chromosome 17 (17q12-
q21) and is frequently ampliﬁed in ErbB2-positive cancers (Kauraniemi and Kallioniemi
2006; Staaf et al. 2010). The RNAi studies by Kao and Pollack (2006) and Sahlberg
et al. (2013) suggested that StARD3 contributes to the proliferation of ErbB2-positive
cancer cells. We found that ErbB2-positive breast cancer cell lines KPL-4 and BT-474
co-overexpress StARD3 (ﬁg. 8). To study the mechanisms by which StARD3 in particular
contributes to cancer progression, we needed a system in which we can decouple it from
ErbB2. This was done either by knocking down StARD3 in an overexpressing cell line, or
overexpressing it in a ErbB2-negative cell line.
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Figure 8: Comparison of StARD3 and ErbB2 protein levels in cervical cancer cell line HeLa and
ErbB2-positive breast cancer cell lines KPL-4 and BT-474. A: Samples from cells grown in normal
culture conditions from each of the cell lines were collected and the same amount of protein was
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The ﬁlter was
stained with Ponceau dye after transfer. The ﬁlter was cut horizontally and the pieces immunoblotted
against StARD3 and ErbB2 antibodies, respectively. B: The quantiﬁcation shows the StARD3 and
ErbB2 cellular protein levels.
5.2.1 ErbB2-positive breast cancer cell lines require StARD3 overexpression for
survival
Transient knockdown of StARD3 and ErbB2 in BT-474 cells had a cumulative negative
eﬀect on cell proliferation. In BT-474 cells, 3 d of siRNA knockdown of either StARD3 or
ErbB2 decreased cell amounts. (ﬁg. 9, A and B). To create a cell line with stable knockdown
of either StARD3 or ErbB2, we transduced KPL-4 cells with shRNA lentiviral vectors.
Lentiviral transduction of KPL-4 cells with shRNA resulted in eﬃcient knockdown of
StARD3 and ErbB2 protein levels. The knockdown of StARD3 and ErbB2 levels had a
strong negative eﬀect on cell growth (ﬁg. 9, C and D). This eﬃcient knockdown inhibited
cell proliferation so strongly that the generation of a stable cell line was not possible.
Within 8 d to 12 d of transfection all cells died.
In comparison, the results by Kishida et al. (2004) show that StARD3 was largely
dispensable in healthy tissue. In mice homozygous for a StARD3 mutant allele, there
was no clear phenotype, only non-lethal defects in sterol traﬃcking. However, our result
strongly suggested that the overexpression of StARD3 is required by ErbB2-overexpressing
breast cancer cells.
5.2.2 Stable overexpression of StARD3 alters cell morphology
The Her2-negative breast cancer cell line, MCF-7, was used to generate a stable clone
overexpressing StARD3-GFP. As a control, a cell line overexpressing GFP was generated.
The StARD3-GFP exhibited a punctate distribution and partly colocalized with the late-
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Figure 9: Knockdown of StARD3 and ErbB2 protein levels in Erb2-positive breast cancer cell lines
BT-474 and KPL-4. A: Diﬀerential interference contrast (DIC) images of live BT-474 cells on
plastic after 3 d of siRNA knockdown of either StARD3, ErbB2, or both. B: BT-474 cells treated as
in (A) and grown on 12-well plates were lyzed in equal amounts of lysis buﬀer. Total protein amount
in each sample was used as measure of cell amounts. n = 5 for all samples but StARD3, where n = 3.
For all conditions compared to control, p < 0.05. C: Samples of KPL-4 cells after 6 d of lentiviral
transduction with shRNAs were separated by SDS-PAGE and immunoblotted using StARD3 and
ErbB2 antibodies. “C” stands for control shRNA, “S1” and “S2” are two diﬀerent shRNAs targeting
StARD3, and “E1” and “E2” are two diﬀerent shRNAs targeting ErbB2. D: Relative proliferation of
KPL-4 cells after shRNA knockdown of StARD3 and ErbB2. Cells were collected in lysis buﬀer 6,
8 and 11 d after lentiviral transduction and total protein was measured.
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Figure 10: Eﬀects of StARD3 overexpression on focal adhesions in HeLa cells. A: Immunoblots of
activated Src (Y416) and FAK (Y397) in HeLa cells after 3 d of GFP or StARD3-GFP transient
overexpression. Cells were trypsinized and allowed to readhere for 50min on ﬁbronectin-coated
plastic. B: Quantiﬁcation of the size of focal adhesions in HeLa cells. Cells were treated as in (A) and
plated on ﬁbronectin-coated coverslips. Representative images in section 5.2.2. C: Quantiﬁcation of
the number of focal adhesions per cell in HeLa cells as in (B). For (B) and (C), n = 33 cells for GFP
and n = 38 cells for StARD3-GFP.
endosomal marker Lamp-1. Some of the StARD3-GFP localized to the PM, and confocal
microscopy revealed a punctate pattern that could indicate PM domains and small vesicles
immediately below the PM. Phase-contrast and green ﬂuorescence images showed that
the StARD3-GFP expressing cells had a strikingly diﬀerent morphology compared to the
parental MCF-7 cell line or the GFP overexpressing controls. They grew in clusters of
rounded-up cells that did not spread on the substratum and lacked contact inhibition: a
malignant cell growth pattern.
The altered adhesion of MCF-7 cells was in line with the eﬀects of transient StARD3
overexpression on cell morphology and focal adhesions in HeLa cells. In HeLa cells,
transient StARD3 overexpression activated both proto-oncogene tyrosine-protein kinase Src
(Src) and focal adhesion kinase (FAK), as indicated by the increased the phosphorylation
of Src on tyrosine 416 and FAK on tyrosine 397. (ﬁg. 10). The StAR-related lipid transfer
protein 3 (StARD3) overexpressing cells were also less spread out, with fewer, but larger
irregularly shaped focal adhesions (ﬁg. 10 and section 5.2.2).
5.2.3 StARD3 overexpression alters cholesterol balance
The StARD3-GFP overexpressing MCF-7 cell clusters showed increased ﬁlipin staining
intensity, especially on the PM. However, the total amount of cellular free cholesterol was
similar to that of control cells, suggesting that the cholesterol distribution was altered. In
StARD3-GFP overexpressing cells, the levels of the rate-limiting enzyme of cholesterol
synthesis HMGR was increased. In addition, both the precursor and the mature form of
SREBP2, the key transcriptional regulator of cholesterol metabolism, were increased. Both
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expressing StARD3-GFP are
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ﬁndings suggest that the endoplasmic reticulum (ER) was cholesterol depleted as a result
of StARD3 overexpression. Moreover, streptolysin O (SLO) resistance of StARD3-GFP
overexpressing cells was decreased, suggesting an increase of cholesterol in the PM.
5.2.4 Signaling in StARD3 overexpressing cells does not depend on growth
stimuli
Within 5 h of removal of serum and insulin from the cell culture medium, StARD3-GFP
overexpressing cells were found to revert to a ﬂat, adherent morphology reminiscent of
that of the control cells. The GFP-overexpressing control cells did not show a change
in morphology within this time frame. In complete medium, the rounded StARD3-GFP
overexpressing cells had fewer, larger focal adhesions. StARD3-GFP overexpressing cells
under serum and insulin deprivation conditions ﬂattened and adhered to the substratum,
developing larger, more prominent, irregularly shaped focal adhesions, as observed by
confocal microscopy. In full serum conditions, there was no marked diﬀerence between
the total levels or the phosphorylation status of focal adhesion kinase. Under serum and
insulin deprivation, StARD3 overexpressing cells had signiﬁcantly higher focal adhesion
kinase total protein levels and phosphorylation than control cells.
5.2.5 StARD3-overxpressing cells maintain increased cellular and PM
cholesterol in the absence of serum and insulin
Upon removal of serum and insulin from the medium for 5 h and 24 h, cells with high levels
of StARD3-GFP showed a robust increase in ﬁlipin intensity compared to control GFP
cells or cells with low levels of StARD3-GFP expression. The ﬁlipin intensity of control
cells decreased from 5 h to 24 h. The ﬁlipin intensity of StARD3-GFP cells however did
not decrease. Under these conditions, StARD3-GFP cells had higher levels of cholesterol
than control cells, as determined by a biochemical lipid determination and SLO resistance.
This diﬀerence was abolished when lovastatin, an inhibitor of HMGR, was added to the
cells, indicating that StARD3-overexpressing cells exhibit increased de novo cholesterol
synthesis in the absence of growth factors.
5.2.6 High StARD3 protein levels in breast tumor samples
We generated a StARD3 polyclonal antibody, and cell culture experiments showed that it
is speciﬁc. It was also tested in patient tissue samples. In a cohort of 1325 Finnish breast
cancer patients (Joensuu et al. 2003), high StARD3 immunoreactivity in tumor samples
associated with ErbB2 immunoreactivity and HER2 ampliﬁcation, as well as positive Src
phosphorylation. High StARD3 immunoreactivity also associated with factors related
to poor disease outcome: high proliferation rate, bigger tumor size, nodal metastases
at the time of diagnosis, estrogen and progesterone receptor negativity and p53 protein
expression. In an independent breast cancer cohort of 895 patients (Joensuu et al. 2006),
these results were reproduced. For a subset of these samples, RNA was available. A qPCR
analysis of HMGR mRNA levels showed that the highest transcript levels were found in
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the highly StARD3-positive tumors. High StARD3 protein level was strongly associated
with decreased cumulative patient survival in both cohorts. Thus, our ﬁndings in MCF-7
cells were strengthened by the ﬁndings in patient breast cancer tumor samples from two
independent patient cohorts.
5.3 TCGA breast cancer database analysis (III)
The results so far suggested a role for NDRG1 in cancer progression, possibly through the
eﬀects that abnormal lysosomal formation have on ErbB-family receptor recycling (Tan et al.
2015a,b). Our results also demonstrated that StARD3 overexpression in ErbB2-positive
breast cancer plays a role in breast cancer progression. Since the TCGA database contains
comprehensive molecular portraits of breast cancer tumors and clinical patient data, we
analyzed the available data searching for further clues to the role of these proteins in
cancer progression. We also included in the computational analysis lysosomal-associated
transmembrane protein 4B (LAPTM4B), because it regulates ceramide-dependent cell
death pathways in cancer cells (Blom et al. 2015; Trajkovic et al. 2008).
5.3.1 STARD3, NDRG1, and LAPTM4B in cancer progression
The strong correlation between STARD3 and ERBB2 ampliﬁcation and expression was
reproduced in the TCGA breast cancer dataset. This ﬁnding provided us with a validation
of the analysis methods that we aimed to use in the study. We found that NDRG1 and
LAPTM4B were co-ampliﬁed, and there was a positive correlation between the mRNA
levels of the two genes. LAPTM4B ampliﬁcation and high NDRG1 mRNA levels both had
a statistically signiﬁcant negative eﬀect on breast cancer patient survival. This correlation
between the two genes is not too surprising: they are on the same chromosome arm and it
is likely that they are coampliﬁed in some cancer patients.
Given the role of LAPTM4B in ceramide export from LEs reported by Blom et al. (2015),
this ﬁnding reinforces the hypothesis that altered ceramide traﬃcking is the common
denominator upon deregulation of NDRG1 or LAPTM4B expression. However, in this
dataset, co-overexpression of NDRG1 and LAPTM4B did not exhibit an additive negative
eﬀect on patient survival.
5.3.2 Reproducible computational data analysis
In the course of this data mining study, our attempts to document all computational analyses
and ensure their reproducibility were hampered. This was caused by a lack of software for
documenting and automating a computational analysis that combines diﬀerent tools. We
therefore proposed a method and provided Lir, a software tool for reproducible computing.
We demonstrated that a computational data analysis can be documented, shared, and
reproduced without increasing the work load. Instead, by allowing a combination of
computational data analysis tools to be used in the same coherent workﬂow, we were able
to minimize the total amount of work to obtain biologically relevant results.
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The positive eﬀect of documenting and automating a heterogeneous workﬂow in a literate
programming style is synergistic. By automating the workﬂow, we have already deﬁned
it formally and thus provided the most basic documentation. An automated workﬂow
requires no manual eﬀort to run, encouraging an iterative, exploratory approach. An
automated workﬂow also requires no manual eﬀort to re-run, increasing its reproducibility.
Since it is easy to share the workﬂow in full, other scientists can validate and reproduce the
results, or adapt the analysis for their data. Finally, a workﬂow documented in a literate
programming style can follow the established structure of an experimental protocol: Aims;
Experimental design; Methods; Results; Discussion. The clear structure and its familiarity
help communicate the goals and results of the analysis to other scientists.
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In this work we studied the role of proteins that have been implicated in cancer progression
and in endocytic lipid traﬃcking, and how these two processes may be functionally
connected. Two possible mechanisms emerged. On the one hand, through regulation of
multi-vesicular body (MVB) formation, N-myc downstream-regulated gene 1 (NDRG1)
functions as a regulator of cell surface receptor recycling and degradation. On the
other hand, StAR-related lipid transfer protein 3 (StARD3) overexpression promotes cell
proliferation by deregulating the cholesterol content of the late endocytic membrane.
While the two mechanisms do not seem to be tightly coupled, they both further the
understanding of endocytic traﬃcking. An analysis of genome wide breast cancer patient
data provided clues to other understudied proteins involved in cancer progression and
endocytic traﬃcking. The data analysis was presented, published, and made publicly
available: it can serve as a starting point to further analysis of the same dataset, or as a
template for analysing another dataset with the same methods.
In particular, we identiﬁed NDRG1 as a regulator of MVB formation and endosomal
low-density lipoprotein receptor (LDLR) traﬃcking. Its function in endosomal dynamics
suggested that it could be involved in tumorigenesis. Indeed, the results by Kovacevic
et al. (2016) showed that NDRG1 overexpression decreases the expression and activation
of ErbB-family receptors in response to EGF stimulation, inhibits the formation of
ErbB-family receptor heterodimers, and decreases the activation of downstream MAPK
kinase in response to EGF. These eﬀects might be partly explained with the positive
correlation between NDRG1 and the endosomal ceramide regulator lysosomal-associated
transmembrane protein 4B (LAPTM4B) that we found in the TCGA breast cancer tumor
dataset. It is possible that the LAPTM4B-mediated inhibition of EGFR degradation oﬀsets
the negative eﬀects of NDRG1 upregulation on EGF signaling.
We established that elevated levels of StARD3 protein even in the absence of ErbB2
overexpression alter the cholesterol balance of breast cancer cells, enhance oncogenic
signaling, and cause a phenotype characteristic of malignant cells. Importantly, the
enhanced oncogenic signaling we observed upon StARD3 overexpression was independent
of external growth stimuli, further reinforcing the conclusion that StARD3 overexpression
in tumors is a necessary component of ErbB2-positive cancer progression. The recent
results by Wilhelm et al. (2016) and Wilhelm et al. (2017) showing that StARD3 tethers
ER to late endosomes provide a possible mechanistic explanation for the uncoupling of
external growth stimuli and ER functions such as cholesterol synthesis that we observed
in StARD3-overexpressing cells. If these ER-endosome contacts help deplete the ER
membrane of cholesterol, this would activate the sterol regulatory element-binding protein
(SREBP) feedback mechanism and enhance de novo cholesterol synthesis. There is in
fact recent evidence for another cholesterol binding protein, ORP1L, in facilitating such
cholesterol transfer (Eden et al. 2016).
Finally, we demonstrated that automating, documenting, and presenting a data analysis
not only can improve reproducibility, but also can minimize work, eﬀort, and room for
potential errors. Of course, the positive eﬀects we claim would have to be empirically
measured; however, reliable methods for empirical studies of the process of writing
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computer programs are still to be developed and applied systematically. An interesting
question is whether traditional, “wet lab” experimental methods and protocols would
beneﬁt from a formal description language that can be automatically parsed by machines.
The goal would not be to automate the carrying out of experiments. It would be already
very advantageous if the protocols and the results of all experiments within a lab can be
searched and summarized, maybe even shared with collaborators and the wider scientiﬁc
community.
33
6 Conclusions
Acknowledgements
All work for this dissertation was conducted at the Intracellular Cholesterol Traﬃcking
lab of prof. Elina Ikonen. The lab has a double aﬃliation with the University of Helsinki,
Faculty of Medicine, Department of Anatomy, and with the Minerva Foundation Institute
for Medical Research, both located at Biomedicum Helsinki.
The work was in part ﬁnanced by the Doctoral Programme in Biomedicine, formerly
the Helsinki Biomedical Graduate School; as well as grants from the Ida Montinin Säätiö,
K. Albin Johanssons stiftelse, Paulon Säätiö, Biomedicum Helsinki Foundation, and
The Finnish Society of Sciences and Letters. The preparation of this dissertation was
ﬁnanced by a grant by the Doctoral Programme in Biomedicine, and a grant by the Minerva
Foundation Institute for Medical Research.
I would like to thank all collaborators that have made this work possible, in particular
prof. Heikki Joensuu, Harri Sihto, and prof. Sampsa Hautaniemi.
I would like to thank the thesis pre-examiners, Petri Auvinen and Simon Anders, for
taking the time and the eﬀort to read the thesis and provide invaluable comments.
I would like to thank my thesis supervisor, prof. Elina Ikonen, who has contributed
to this work in every possible way: from agreeing to supervise the thesis, to providing
the environment necessary for academic research, to providing education, guidance, and
support.
I would like to thank Anna Uro and Pipsa Kaipainen for all the experiments they have
performed, and Anna Uro in particular for teaching me so many things about our lab in
particular and experimental work in general.
I would like to thank all current and former members of the lab for the help, the
patience, and the good times. In particular, Maurice Jansen, my hands-on mentor; Maarit
Hölttä-Vuori for her invaluable advice; and Tomas Blom for sacriﬁcing a considerable
amount of his time to talk and listen. The list goes on.
I would like to thank my family for putting up with me and helping me during this time:
Lotta, Alli, Aatos, Maja, and Toma. I would like to thank my parents, Bojko and Boyana,
for never pushing and always believing; and my grandparents, Anna, Boris, Liljana, and
Pavel, for the important role they have had in my upbringing and my education.
34
References
Alpy, F. and Tomasetto, C. (2006). “MLN64 and MENTHO, two mediators of endosomal cholesterol
transport.” Biochemical Society Transactions 34.Pt 3, pp. 343–345.
Alpy, F., Latchumanan, V. K., Kedinger, V., Janoshazi, A., Thiele, C., Wendling, C., Rio, M.-C.,
and Tomasetto, C. (2005). “Functional characterization of the MENTAL domain.” Journal of
Biological Chemistry 280.18, pp. 17945–17952.
Bandyopadhyay, S., Pai, S. K., Gross, S. C., Hirota, S., Hosobe, S., Miura, K., Saito, K., Commes, T.,
Hayashi, S., Watabe, M., and Watabe, K. (2003). “The Drg-1 gene suppresses tumor metastasis in
prostate cancer.” Cancer Research 63.8, pp. 1731–1736.
Bandyopadhyay, S., Pai, S. K., Hirota, S., Hosobe, S., Takano, Y., Saito, K., Piquemal, D., Commes,
T., Watabe, M., Gross, S. C., Wang, Y., Ran, S., andWatabe, K. (2004). “Role of the putative tumor
metastasis suppressor gene Drg-1 in breast cancer progression.” Oncogene 23.33, pp. 5675–5681.
Bartz, F., Kern, L., Erz, D., Zhu, M., Gilbert, D., Meinhof, T., Wirkner, U., Erﬂe, H., Muckenthaler,
M., Pepperkok, R., and Runz, H. (2009). “Identiﬁcation of cholesterol-regulating genes by targeted
RNAi screening.” Cell Metabolism 10.1, pp. 63–75.
Bhakdi, S., Tranum-Jensen, J., and Sziegoleit, A. (1985). “Mechanism of Membrane Damage by
Streptolysin-O”. Infection and Immunity 47.1, pp. 52–60.
Bligh, E. G. and Dyer, W. J. (1959). “A Rapid Method of Total Lipid Extraction and Puriﬁcation”.
Canadian Journal of Biochemistry and Physiology 37.8. PMID: 13671378, pp. 911–917.
Bloch, K. (1965). “The biological synthesis of cholesterol”. Science 150.3692, pp. 19–28.
Blom, T., Li, S., Dichlberger, A., Bäck, N., Kim, Y. A., Loizides-Mangold, U., Riezman, H., Bittman,
R., and Ikonen, E. (2015). “LAPTM4B facilitates late endosomal ceramide export to control cell
death pathways.” Nature Chemical Biology 11.10, pp. 799–806.
Börnigen, D., Moon, Y. S., Rahnavard, G., Waldron, L., McIver, L., Shafquat, A., Franzosa, E. A.,
Miropolsky, L., Sweeney, C., Morgan, X. C., Garrett, W. S., and Huttenhower, C. (2015). “A
reproducible approach to high-throughput biological data acquisition and integration.” PeerJ 3,
e791.
Brown, D. N., Caﬀa, I., Cirmena, G., Piras, D., Garuti, A., Gallo, M., Alberti, S., Nencioni,
A., Ballestrero, A., and Zoppoli, G. (2016). “Squalene epoxidase is a bona ﬁde oncogene by
ampliﬁcation with clinical relevance in breast cancer.” Scientific Reports 6, p. 19435.
Carstea, E. D., Morris, J. A., Coleman, K. G., Loftus, S. K., Zhang, D., Cummings, C., Gu, J.,
Rosenfeld, M. A., Pavan, W. J., Krizman, D. B., Nagle, J., Polymeropoulos, M. H., Sturley,
S. L., Ioannou, Y. A., Higgins, M. E., Comly, M., Cooney, A., Brown, A., Kaneski, C. R.,
Blanchette-Mackie, E. J., Dwyer, N. K., Neufeld, E. B., Chang, T. Y., Liscum, L., Strauss 3rd, J.,
Ohno, K., Zeigler, M., Carmi, R., Sokol, J., Markie, D., O’Neill, R. R., van Diggelen, O. P.,
Elleder, M., Patterson, M. C., Brady, R. O., Vanier, M. T., Pentchev, P. G., and Tagle, D. A. (1997).
“Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis.” Science
277.5323, pp. 228–231.
Charman, M., Kennedy, B. E., Osborne, N., and Karten, B. (2010). “MLN64 mediates egress of
cholesterol from endosomes to mitochondria in the absence of functional Niemann-Pick Type C1
protein.” Journal of Lipid Research 51.5, pp. 1023–1034.
Dijkstra, E. W. (1989). “On the cruelty of really teaching computing science”. Communications of
the ACM 32.12, pp. 1398–1404.
Eden, E. R., Sanchez-Heras, E., Tsapara, A., Sobota, A., Levine, T. P., and Futter, C. E. (2016).
“Annexin A1 Tethers Membrane Contact Sites that Mediate ER to Endosome Cholesterol
Transport”. Developmental Cell 37.5, pp. 473–483.
35
References
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R.,
Barsotti, A., Chicas, A., Li, W., Polotskaia, A., Bissell, M. J., Osborne, T. F., Tian, B., Lowe, S. W.,
Silva, J. M., Børresen-Dale, A.-L., Levine, A. J., Bargonetti, J., and Prives, C. (2012). “Mutant p53
disrupts mammary tissue architecture via the mevalonate pathway.” Cell 148.1-2, pp. 244–258.
Goldstein, J. L. and Brown, M. S. (2009). “The LDL receptor.” Arteriosclerosis, Thrombosis, and
Vascular Biology 29.4, pp. 431–438.
Grieb, B. C., Chen, X., and Eischen, C. M. (2014). “MTBP Is Overexpressed in Triple-Negative
Breast Cancer and Contributes to Its Growth and Survival”.Molecular Cancer Research 12.9,
pp. 1216–1224.
Guan, R. J., Ford, H. L., Fu, Y., Li, Y., Shaw, L. M., and Pardee, A. B. (2000). “Drg-1 as a
diﬀerentiation-related, putative metastatic suppressor gene in human colon cancer.” Cancer
Research 60.3, pp. 749–755.
Haskins, J. W., Zhang, S., Means, R. E., Kelleher, J. K., Cline, G. W., Canfrán-Duque, A., Suárez,
Y., and Stern, D. F. (2015). “Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol
biosynthetic pathway and increases low-density lipoprotein uptake.” Science Signaling 8.401,
ra111.
Heino, S., Lusa, S., Somerharju, P., Ehnholm, C., Olkkonen, V.M., and Ikonen, E. (2000). “Dissecting
the role of the golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell
surface.” Proceedings of the National academy of Sciences of the United States of America 97.15,
pp. 8375–8380.
Herz, J. and Bock, H. H. (2002). “Lipoprotein Receptors in the Nervous System”. Annual Review of
Biochemistry 71.1, pp. 405–434.
Hölttä-Vuori,M., Vainio, S., Kauppi,M., VanEck,M., Jokitalo, E., and Ikonen, E. (2012). “Endosomal
Actin Remodeling by Coronin-1A Controls Lipoprotein Uptake and Degradation in Macrophages”.
Circulation Research 110.3, pp. 450–455.
Hölttä-Vuori, M., Alpy, F., Tanhuanpää, K., Jokitalo, E., Mutka, A.-L., and Ikonen, E. (2005).
“MLN64 is involved in actin-mediated dynamics of late endocytic organelles.”Molecular Biology
of the Cell 16.8, pp. 3873–3886.
Hölttä-Vuori, M., Sezgin, E., Eggeling, C., and Ikonen, E. (2016). “Use of BODIPY-Cholesterol
(TF-Chol) for Visualizing Lysosomal Cholesterol Accumulation”. Traffic 17.9, pp. 1054–1057.
Hölttä-Vuori, M., Uronen, R.-L., Repakova, J., Salonen, E., Vattulainen, I., Panula, P., Li, Z., Bittman,
R., and Ikonen, E. (2008). “BODIPY-Cholesterol: A New Tool to Visualize Sterol Traﬃcking in
Living Cells and Organisms”. Traffic 9.11, pp. 1839–1849.
Hong, C., Duit, S., Jalonen, P., Out, R., Scheer, L., Sorrentino, V., Boyadjian, R., Rodenburg,
K. W., Foley, E., Korhonen, L., and al., et (2010). “The E3 Ubiquitin Ligase IDOL Induces the
Degradation of the Low Density Lipoprotein Receptor Family Members VLDLR and ApoER2”.
Journal of Biological Chemistry 285.26, pp. 19720–19726.
Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002). “SREBPs: activators of the complete
program of cholesterol and fatty acid synthesis in the liver.” Journal of Clinical Investigation
109.9, pp. 1125–1131.
Howe, D., Costanzo, M., Fey, P., Gojobori, T., Hannick, L., Hide, W., Hill, D. P., Kania, R., Schaeﬀer,
M., St Pierre, S., and al., et (2008). “Big data: The future of biocuration”. Nature 455.7209,
pp. 47–50.
Ikonen, E. (2008). “Cellular cholesterol traﬃcking and compartmentalization”. Nature Reviews
Molecular Cell Biology 9.2, pp. 125–138.
36
References
Jo, Y. and Debose-Boyd, R. A. (2010). “Control of cholesterol synthesis through regulated ER-
associated degradation of HMG CoA reductase.” Critical Reviews in Biochemistry and Molecular
Biology 45.3, pp. 185–198.
Joensuu, H., Isola, J., Lundin, M., Salminen, T., Holli, K., Kataja, V., Pylkkänen, L., Turpeenniemi-
Hujanen, T., Smitten, K. von, and Lundin, J. (2003). “Ampliﬁcation of erbB2 and erbB2 Expression
Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT1N0M0
Breast Cancer: A Nationwide Population-based Study”. Clinical Cancer Research 9.3, pp. 923–
930.
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T.,
Kokko, R., Hemminki, A., Tarkkanen, M., and al., et (2006). “Adjuvant Docetaxel or Vinorelbine
with or without Trastuzumab for Breast Cancer”. New England Journal of Medicine 354.8,
pp. 809–820.
Kachhap, S. K., Faith, D., Qian, D. Z., Shabbeer, S., Galloway, N. L., Pili, R., Denmeade, S. R.,
DeMarzo, A. M., and Carducci, M. A. (2007). “The N-Myc down regulated Gene1 (NDRG1) Is a
Rab4a eﬀector involved in vesicular recycling of E-cadherin.” PLOS ONE 2.9, e844.
Kanerva, K., Uronen, R.-L., Blom, T., Li, S., Bittman, R., Lappalainen, P., Peränen, J., Raposo, G.,
and Ikonen, E. (2013). “LDL cholesterol recycles to the plasma membrane via a Rab8a-Myosin5b-
actin-dependent membrane transport route.” Developmental Cell 27.3, pp. 249–262.
Kao, J. and Pollack, J. R. (2006). “RNA interference-based functional dissection of the 17q12
amplicon in breast cancer reveals contribution of coampliﬁed genes.” Genes, Chromosomes and
Cancer 45.8, pp. 761–769.
Karamouzis, M. V., Grandis, J. R., and Argiris, A. (2007). “Therapies Directed Against Epidermal
Growth Factor Receptor in Aerodigestive Carcinomas”. JAMA 298.1, p. 70.
Kauraniemi, P. and Kallioniemi, A. (2006). “Activation of multiple cancer-associated genes at the
ERBB2 amplicon in breast cancer.” Endocr Relat Cancer 13.1, pp. 39–49.
Keller, P. and Simons, K. (1997). “Post-Golgi biosynthetic traﬃcking.” Journal of cell science 110 (
Pt 24), pp. 3001–3009.
Kishida, T., Kostetskii, I., Zhang, Z., Martinez, F., Liu, P., Walkley, S. U., Dwyer, N. K., Blanchette-
Mackie, E. J., Radice, G. L., and Strauss, J. F. (2004). “Targeted Mutation of the MLN64 START
Domain Causes Only Modest Alterations in Cellular Sterol Metabolism”. Journal of Biological
Chemistry 279.18, pp. 19276–19285.
Kitchin, J. R. (2015). “Examples of Eﬀective Data Sharing in Scientiﬁc Publishing”. ACS Catalysis
5.6, pp. 3894–3899.
Knuth, D. E. (1983). The WEB system of structured documentation. Department of Computer Science,
Stanford University.
– (1984). “Literate programming”. The Computer Journal 27.2, pp. 97–111.
Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F.,
Fulton, L. L., Dooling, D. J., Ding, L., Mardis, E. R., and al., et (2012). “Comprehensive molecular
portraits of human breast tumours”. Nature 490.7418, pp. 61–70.
Kovacevic, Z., Menezes, S. V., Sahni, S., Kalinowski, D. S., Bae, D.-H., Lane, D. J. R., and
Richardson, D. R. (2016). “The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1
(NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic
Signaling Pathways.” Journal of Biological Chemistry 291.3, pp. 1029–1052.
Lachat, P., Shaw, P., Gebhard, S., van Belzen, N., Chaubert, P., and Bosman, F. T. (2002). “Expression
of NDRG1, a diﬀerentiation-related gene, in human tissues.” Histochemistry and Cell Biology
118.5, pp. 399–408.
37
References
Leisch, F. (2002). “Sweave: Dynamic generation of statistical reports using literate data analysis”. In:
Compstat. Springer, pp. 575–580.
Linder, M. D., Uronen, R.-L., Hölttä-Vuori, M., van der Sluijs, P., Peränen, J., and Ikonen, E.
(2007). “Rab8-dependent recycling promotes endosomal cholesterol removal in normal and
sphingolipidosis cells.” Molecular Biology of the Cell 18.1, pp. 47–56.
Llaverias, G., Danilo, C., Mercier, I., Daumer, K., Capozza, F., Williams, T. M., Sotgia, F., Lisanti,
M. P., and Frank, P. G. (2011). “Role of cholesterol in the development and progression of breast
cancer.” American Journal of Pathology 178.1, pp. 402–412.
Loftus, S. K., Morris, J. A., Carstea, E. D., Gu, J. Z., Cummings, C., Brown, A., Ellison, J., Ohno,
K., Rosenfeld, M. A., Tagle, D. A., Pentchev, P. G., and Pavan, W. J. (1997). “Murine model
of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene.” Science 277.5323,
pp. 232–235.
Maione, F., Oliaro-Bosso, S., Meda, C., Di Nicolantonio, F., Bussolino, F., Balliano, G., Viola, F.,
and Giraudo, E. (2015). “The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new
target to impair tumour angiogenesis and metastasis dissemination.” Scientific Reports 5, p. 9054.
Maruyama, Y., Ono, M., Kawahara, A., Yokoyama, T., Basaki, Y., Kage, M., Aoyagi, S., Kinoshita, H.,
and Kuwano, M. (2006). “Tumor growth suppression in pancreatic cancer by a putative metastasis
suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis.” Cancer Research
66.12, pp. 6233–6242.
Maxﬁeld, F. R. and Wüstner, D. (2012). “Analysis of cholesterol traﬃcking with ﬂuorescent probes.”
Methods in Cell Biology 108, pp. 367–393.
McMahon, H. T. and Boucrot, E. (2011). “Molecular mechanism and physiological functions of
clathrin-mediated endocytosis”. Nature Reviews Molecular Cell Biology 12.8, pp. 517–533.
Moog-Lutz, C., Tomasetto, C., Régnier, C. H., Wendling, C., Lutz, Y., Muller, D., Chenard, M. P.,
Basset, P., and Rio, M. C. (1997). “MLN64 exhibits homology with the steroidogenic acute
regulatory protein (STAR) and is over-expressed in human breast carcinomas.” International
Journal of Cancer 71.2, pp. 183–191.
Murtola, T. J., Visvanathan, K., Artama, M., Vainio, H., and Pukkala, E. (2014). “Statin use and
breast cancer survival: a nationwide cohort study from Finland.” PLOS ONE 9.10, e110231.
Nakanishi, M., Goldstein, J. L., and Brown, M. S. (1988). “Multivalent control of 3-hydroxy-3-
methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA
and accelerates degradation of enzyme.” Journal of Biological Chemistry 263.18, pp. 8929–8937.
Nielsen, S. F., Nordestgaard, B. G., and Bojesen, S. E. (2012). “Statin use and reduced cancer-related
mortality.” New England Journal of Medicine 367.19, pp. 1792–1802.
Noble, W. S. (2009). “A quick guide to organizing computational biology projects.” PLoS Computa-
tional Biology 5.7, e1000424.
Ovaska, K., Laakso, M., Haapa-Paananen, S., Louhimo, R., Chen, P., Aittomäki, V., Valo, E.,
Núñez-Fontarnau, J., Rantanen, V., Karinen, S., et al. (2010). “Large-scale data integration
framework provides a comprehensive view on glioblastoma multiforme”. Genome Medicine 2.9,
p. 65.
Pérez, F. and Granger, B. E. (2007). “IPython: a System for Interactive Scientiﬁc Computing”.
Computing in Science and Engineering 9.3, pp. 21–29.
Pimplikar, S. W., Ikonen, E., and Simons, K. (1994). “Basolateral protein transport in streptolysin
O-permeabilized MDCK cells”. The Journal of Cell Biology 125.5, pp. 1025–1035.
Ramsey, N. (1994). “Literate programming simpliﬁed”. IEEE Software 11.5, pp. 97–105.
– (2008). Noweb—a simple, extensible tool for literate programming. url: http://www.cs.tufts.
edu/~nr/noweb.
38
References
Reddy, J. V., Ganley, I. G., and Pfeﬀer, S. R. (2006). “Clues to neuro-degeneration in Niemann-Pick
type C disease from global gene expression proﬁling.” PLOS ONE 1, e19.
Reeves, V. L., Thomas, C. M., and Smart, E. J. (2012). “Lipid rafts, caveolae and GPI-linked
proteins”. In: Caveolins and Caveolae. Springer, pp. 3–13.
Rowland, A. A. and Voeltz, G. K. (2012). “Endoplasmic reticulum–mitochondria contacts: function
of the junction”. Nature Reviews Molecular Cell Biology 13.10, pp. 607–625.
Sahlberg, K. K., Hongisto, V., Edgren, H., Mäkelä, R., Hellström, K., Due, E. U., Moen Vollan, H. K.,
Sahlberg, N., Wolf, M., Børresen-Dale, A.-L., Perälä, M., and Kallioniemi, O. (2013). “The HER2
amplicon includes several genes required for the growth and survival of HER2 positive breast
cancer cells.” Mol Oncol 7.3, pp. 392–401.
Sandve, G. K., Nekrutenko, A., Taylor, J., and Hovig, E. (2013). “Ten simple rules for reproducible
computational research.” PLoS Computational Biology 9.10, e1003285.
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). “NIH Image to ImageJ: 25 years of
image analysis.” Nature methods 9 (7), pp. 671–675.
Scotti, E., Hong, C., Yoshinaga, Y., Tu, Y., Hu, Y., Zelcer, N., Boyadjian, R., Jong, P. J. de, Young,
S. G., Fong, L. G., and al., et (2011). “Targeted Disruption of the Idol Gene Alters Cellular
Regulation of the Low-Density Lipoprotein Receptor by Sterols and Liver X Receptor Agonists”.
Molecular and Cellular Biology 31.9, pp. 1885–1893.
Scotti, E., Calamai, M., Goulbourne, C. N., Zhang, L., Hong, C., Lin, R. R., Choi, J., Pilch, P. F., Fong,
L. G., Zou, P., Ting, A. Y., Pavone, F. S., Young, S. G., and Tontonoz, P. (2013). “IDOL stimulates
clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the
low-density lipoprotein receptor.” Molecular and Cellular Biology 33.8, pp. 1503–1514.
Shen, H. (2014). “Interactive notebooks: Sharing the code.” Nature 515.7525, pp. 151–152.
Sigismund, S., Argenzio, E., Tosoni, D., Cavallaro, E., Polo, S., and Di Fiore, P. P. (2008).
“Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for
Degradation”. Developmental Cell 15.2, pp. 209–219.
Simons, K. and Vaz, W. L. (2004). “Model Systems, Lipid Rafts, and Cell Membranes1”. Annual
Review of Biophysics and Biomolecular Structure 33.1, pp. 269–295.
Staaf, J., Jönsson, G., Ringnér, M., Vallon-Christersson, J., Grabau, D., Arason, A., Gunnarsson, H.,
Agnarsson, B. A., Malmström, P.-O., Johannsson, O. T., Loman, N., Barkardottir, R. B., and
Borg, A. (2010). “High-resolution genomic and expression analyses of copy number alterations in
HER2-ampliﬁed breast cancer.” Breast Cancer Research 12.3, R25.
Strzelczyk, B., Szulc, A., Rzepko, R., Kitowska, A., Skokowski, J., Szutowicz, A., and Pawelczyk,
T. (2009). “Identiﬁcation of high-risk stage II colorectal tumors by combined analysis of the
NDRG1 gene expression and the depth of tumor invasion.” Annals of Surgical Oncology 16.5,
pp. 1287–1294.
Sugii, S., Reid, P. C., Ohgami, N., Du, H., andChang, T.-Y. (2003). “Distinct endosomal compartments
in early traﬃcking of low density lipoprotein-derived cholesterol.” Journal of Biological Chemistry
278.29, pp. 27180–27189.
Tan, X., Sun, Y., Thapa, N., Liao, Y., Hedman, A. C., and Anderson, R. A. (2015a). “LAPTM4B is a
PtdIns(4,5)P2 eﬀector that regulates EGFR signaling, lysosomal sorting, and degradation”. The
EMBO Journal 34.4, pp. 475–490.
Tan, X., Thapa, N., Sun, Y., and Anderson, R. (2015b). “A Kinase-Independent Role for EGF
Receptor in Autophagy Initiation”. Cell 160.1-2, pp. 145–160.
Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B.,
and Simons, M. (2008). “Ceramide triggers budding of exosome vesicles into multivesicular
endosomes.” Science 319.5867, pp. 1244–1247.
39
References
Tsujishita, Y. and Hurley, J. H. (2000). “Structure and lipid transport mechanism of a StAR-related
domain.” Nature Structural Biology 7.5, pp. 408–414.
van der Kant, R., Zondervan, I., Janssen, L., and Neefjes, J. (2013). “Cholesterol-binding molecules
MLN64 and ORP1L mark distinct late endosomes with transporters ABCA3 and NPC1.” Journal
of Lipid Research 54.8, pp. 2153–2165.
Wilhelm, L. P., Tomasetto, C., and Alpy, F. (2016). “Touché! STARD3 and STARD3NL tether the
ER to endosomes.” Biochemical Society Transactions 44.2, pp. 493–498.
Wilhelm, L. P., Wendling, C., Védie, B., Kobayashi, T., Chenard, M.-P., Tomasetto, C., Drin, G., and
Alpy, F. (2017). “STARD3 mediates endoplasmic reticulum-to-endosome cholesterol transport at
membrane contact sites.” The EMBO journal.
Wilson, G., Aruliah, D. A., Brown, C. T., Chue Hong, N. P., Davis, M., Guy, R. T., Haddock, S. H. D.,
Huﬀ, K. D., Mitchell, I. M., Plumbley, M. D., Waugh, B., White, E. P., and Wilson, P. (2014).
“Best practices for scientiﬁc computing.” PLoS Biology 12.1, e1001745.
Yao, Q., Chen, J., Cao, H., Orth, J. D., Michael McCaﬀery, J., Stan, R.-V., and McNiven, M. A.
(2005). “Caveolin-1 Interacts Directly with Dynamin-2”. Journal of Molecular Biology 348.2,
pp. 491–501.
Yarden, Y. and Sliwkowski, M. X. (2001). Nature Reviews Molecular Cell Biology 2.2, pp. 127–137.
Young,M.M., Takahashi, Y., Fox, T. E., Yun, J. K., Kester, M., andWang, H.-G. (2016). “Sphingosine
Kinase 1 Cooperates with Autophagy to Maintain Endocytic Membrane Traﬃcking.” Cell Rep
17.6, pp. 1532–1545.
Yun, S. M., Yoon, K., Lee, S., Kim, E., Kong, S.-H., Choe, J., Kang, J. M., Han, T.-S., Kim, P.,
Choi, Y., Jho, S., Yoo, H., Bhak, J., Yang, H.-K., and Kim, S.-J. (2014). “PPP1R1B-STARD3
chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of
PI3K/AKT signaling.” Oncogene 33.46, pp. 5341–5347.
Zaremba-Niedzwiedzka, K., Caceres, E. F., Saw, J. H., Bäckström, D., Juzokaite, L., Vancaester, E.,
Seitz, K. W., Anantharaman, K., Starnawski, P., Kjeldsen, K. U., Stott, M. B., Nunoura, T.,
Banﬁeld, J. F., Schramm, A., Baker, B. J., Spang, A., and Ettema, T. J. G. (2017). “Asgard archaea
illuminate the origin of eukaryotic cellular complexity.” Nature 541 (7637), pp. 353–358.
Zelcer, N., Hong, C., Boyadjian, R., and Tontonoz, P. (2009). “LXR regulates cholesterol uptake
through Idol-dependent ubiquitination of the LDL receptor.” Science 325.5936, pp. 100–104.
Zhang, M., Liu, P., Dwyer, N. K., Christenson, L. K., Fujimoto, T., Martinez, F., Comly, M., Hanover,
J. A., Blanchette-Mackie, E. J., and Strauss 3rd, J. F. (2002). “MLN64 mediates mobilization of
lysosomal cholesterol to steroidogenic mitochondria.” Journal of Biological Chemistry 277.36,
pp. 33300–33310.
40
A Original publication reprints
Original publications I and II are reused with the permission of the publisher. Original
publication III is an open access article distributed under the terms of the Creative
Commons Attribution License.
41
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
NDRG1 functions in LDL receptor trafficking by
regulating endosomal recycling and degradation
Vilja Pietia¨inen1,2,*, Boris Vassilev1,3, Tomas Blom1,3, Wei Wang1,3, Jessica Nelson4, Robert Bittman5,
Nils Ba¨ck1, Noam Zelcer4 and Elina Ikonen1,3
1Institute of Biomedicine, Anatomy, University of Helsinki, Helsinki, Finland
2Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
3Minerva Foundation Institute for Medical Research, Helsinki, Finland
4Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5Department of Chemistry and Biochemistry, Queens College of The City University of New York, Flushing, NY, USA
*Author for correspondence (vilja.pietiainen@helsinki.fi)
Accepted 17 May 2013
Journal of Cell Science 126, 3961–3971
 2013. Published by The Company of Biologists Ltd
doi: 10.1242/jcs.128132
Summary
N-myc downstream-regulated gene 1 (NDRG1) mutations cause Charcot–Marie–Tooth disease type 4D (CMT4D). However, the
cellular function of NDRG1 and how it causes CMT4D are poorly understood. We report that NDRG1 silencing in epithelial cells results
in decreased uptake of low-density lipoprotein (LDL) due to reduced LDL receptor (LDLR) abundance at the plasma membrane. This is
accompanied by the accumulation of LDLR in enlarged EEA1-positive endosomes that contain numerous intraluminal vesicles and
sequester ceramide. Concomitantly, LDLR ubiquitylation is increased but its degradation is reduced and ESCRT (endosomal sorting
complex required for transport) proteins are downregulated. Co-depletion of IDOL (inducible degrader of the LDLR), which
ubiquitylates the LDLR and promotes its degradation, rescues plasma membrane LDLR levels and LDL uptake. In murine
oligodendrocytes, Ndrg1 silencing not only results in reduced LDL uptake but also in downregulation of the oligodendrocyte
differentiation factor Olig2. Both phenotypes are rescued by co-silencing of Idol, suggesting that ligand uptake through LDLR family
members controls oligodendrocyte differentiation. These findings identify NDRG1 as a novel regulator of multivesicular body formation
and endosomal LDLR trafficking. The deficiency of functional NDRG1 in CMT4D might impair lipid processing and differentiation of
myelinating cells.
Key words: Endocytosis, Cholesterol, IDOL, Multivesicular body, NDRG1
Introduction
Low-density lipoprotein (LDL)-cholesterol is internalized into cells
by clathrin-mediated endosytosis of the LDL receptor (LDLR) to
meet cellular cholesterol needs (Goldstein and Brown, 2009;
Ikonen, 2008). In endosomes, LDLR disassociates from LDL
particles because of the acidic pH and returns to the plasma
membrane (PM). Alternatively, recycling of the LDLR to the PM
can be prevented by proprotein convertase subtilisin/kexin type 9
(PCSK9) or by the E3 ubiquitin ligase, inducible degrader of the
LDLR (IDOL), which promotes ubiquitylation of the LDLR under
conditions of excess cellular sterols (Zelcer et al., 2009). The ability
of PCSK9 to alter LDLR levels is independent of, and additive with,
the IDOL pathway and does not require LDLR ubiquitylation
(Wang et al., 2012; Zhang et al., 2012). Ubiquitylation is an
established signal for controlling endocytosis and sorting of
membrane receptors, such as the LDLR, to multivesicular bodies
(MVBs) and further to lysosomes for degradation (Mukhopadhyay
and Riezman, 2007; Piper and Katzmann, 2007; Zelcer et al., 2009).
From early endosomes, LDL particles are transported to MVBs/late
endosomes (Goldstein and Brown, 2009) for the hydrolysis of LDL-
cholesterol esters to free cholesterol (FC) by acid lipase (Sugii et al.,
2003) and exit of cholesterol from the late endosomes by Niemann–
Pick type C1 and 2 (NPC1 and NPC2) proteins (Carstea et al., 1997;
Loftus et al., 1997).
Our interest in the possibility that N-myc downstream
regulated gene 1 (NDRG1) might be involved in cellular
cholesterol metabolism was initiated by Affymetrix gene
expression profiling of cholesterol loaded, NPC1-deficient
murine macrophages (Ho¨ltta¨-Vuori et al., 2012). In this
experiment, we identified NDRG1 as one of the highly induced
genes in response to cholesterol loading (E. I., unpublished
observations). Interestingly, a genome-wide expression analysis
of NPC disease fibroblasts found that NDRG1 mRNA is also
elevated in these patient-derived cells (Reddy et al., 2006).
Moreover, in an RNAi screen focused on cellular lipid
phenotypes, NDRG1 was identified as a gene potentially
affecting cellular cholesterol levels (Bartz et al., 2009). Yet,
how NDRG1 affects cholesterol homeostasis remains unknown.
NDRG1 is widely expressed, with particularly high levels in
the nervous system (Lachat et al., 2002). It participates in diverse
cellular functions, such as differentiation (van Belzen et al.,
1997) and proliferation (Piquemal et al., 1999). NDRG1
expression is often altered in neoplasms, where it can act either
as a tumor promoter or suppressor (Bandyopadhyay et al., 2003;
Guan et al., 2000). In the demyelinating neuropathy Charcot-
Marie–Tooth disease 4D (CMT4D), the deficiency of functional
NDRG1 leads to autonomous dysfunction of Schwann cells, the
glial cells of the peripheral nervous system (PNS) (Kalaydjieva
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et al., 2000; Kalaydjieva et al., 1996). CMT4D can also be
accompanied by abnormalities of the central nervous system
(CNS) white matter (Echaniz-Laguna et al., 2007) and functional
CNS disturbances (Kalaydjieva et al., 1998).
Subcellularly, NDRG1 is mostly found in the cytoplasm
(Lachat et al., 2002) and in endosomes (Kachhap et al., 2007).
NDRG1 can interact with proteins involved in vesicular
trafficking, and was reported to regulate the recycling of E-
cadherin by acting as an effector protein for Rab4a (Kachhap
et al., 2007). NDRG1 also binds to prenylated Rab acceptor-1
(PRA1; also known as YIP3, RABAC1) (Hunter et al., 2005; Kim
et al., 2012; King et al., 2011), which can act as a GDI
displacement factor for endosomal Rab proteins, such as Rab4,
Rab5, Rab7 and Rab9 (Bucci et al., 1999; Sivars et al., 2003).
How these interactions contribute to the physiological function of
NDRG1 or to the consequences of NDRG1 deficiency are poorly
understood.
In this study, we describe a role for NDRG1 in cellular lipid
homeostasis and endocytic trafficking of the LDLR. Our data
further implicate NDRG1 as an important regulator of endosomal
maturation that is required for efficient uptake of LDL receptor
family members in both epithelial and glial cells.
Results
NDRG1 affects cellular cholesterol distribution and content
To assess whether the endosomal cholesterol content affects the
abundance of the NDRG1 protein, we treated epithelial A431
cells with the hydrophobic amine U18666A. This compound
induces lysosomal cholesterol accumulation, mimicking the loss
of NPC1 function (Ko et al., 2001). Treatment of A431 cells with
U18666A resulted in an approximately threefold increase in the
endogenous NDRG1 protein content, in line with the
upregulation of NDRG1 mRNA in NPC fibroblasts (Reddy
et al., 2006). Moreover, loading of cells with LDL-cholesterol led
to an approximately twofold increase in the NDRG1 protein
levels (Fig. 1A). These findings suggest a role for NDRG1 in
LDL-cholesterol trafficking.
To study whether NDRG1 affects cellular cholesterol
homeostasis, we silenced NDRG1 using small interfering
RNAs (siRNA) in A431 cells. NDRG1 knockdown (k/d) was
assessed by immunoblotting, showing consistently a ,90%
reduction (8967% s.e.m.) in NDRG1 protein amount
(supplementary material Fig. S1A,B). To examine cholesterol
distribution in NDRG1 k/d cells, the cells were stained with
filipin, a widely used fluorescent sterol-binding polyene
antibiotic. NDRG1 silencing resulted in the redistribution of
free cholesterol (FC) from the PM to perinuclear, punctate
structures (Fig. 1B). Biochemical lipid analysis revealed that
NDRG1 silencing was associated with a decreased cellular
cholesterol content. Specifically, while FC remained essentially
unchanged upon NDRG1 k/d, an approximately fourfold
reduction was observed in cholesterol esters (CE; Fig. 1C). No
major changes in cholesterol biosynthesis or efflux to
apolipoprotein A-I (apoA-I) were observed in NDRG1 k/d cells
(the ratio of values in NDRG1-silenced cells to control cells was
1.2660.11 and 1.2260.06, respectively). These data indicate that
NDRG1 depletion leads to an abnormal endosomal distribution of
FC. Furthermore, as cholesterol biosynthesis and efflux were not
substantially affected by NDRG1 k/d, the reduction in the CE
content could result from decreased cellular cholesterol uptake.
Decreased LDLR plasma membrane localization and
degradation leads to diminished LDL uptake in NDRG1 -
depleted cells
To test whether NDRG1 depletion affects LDL uptake, we
monitored the binding and internalization of 1,19-dioctadecyl-
3,3,39,39-tetramethyl-indocarbocyanine-perchlorate-labeled LDL
(DiI–LDL) in NDRG1 siRNA-transfected A431 cells. LDL
uptake was visualized by fluorescence microscopy and
quantified by measuring the fluorescence intensity in cell
lysates. These assays revealed that both the binding and
internalization of DiI–LDL were severely (up to ,50%)
diminished upon NDRG1 k/d (Fig. 2A; see also supplementary
material Fig. S1C). This phenotype could, in principle, result
from decreased LDLR levels. Unexpectedly, the total LDLR
protein content was found to be increased upon NDRG1 silencing
(Fig. 2B; see also supplementary material Fig. S1B).
Biotinylation of the PM pool of LDLR, revealed, however, a
clear decrease in the fraction of LDLR in the PM of NDRG1 k/d
cells (Fig. 2B). To follow the intracellular degradation of PM
LDLR, the biotinylated receptors were internalized for 0–
5 hours, pulled down by streptavidin beads, and detected with
an anti-LDLR antibody by immunoblotting. In control-siRNA-
treated cells, ,80% of the biotinylated LDLR was degraded in
5 hours. However, in NDRG1 k/d cells, degradation of the LDLR
Fig. 1. NDRG1 is regulated by endosomal cholesterol loading and its
depletion affects cholesterol distribution and amount. (A) U18666A or
LDL loading increases cellular NDRG1 protein content. A431 cells were
treated with U18666A (1 mg/ml) in 10% FBS for 48 hours or with LDL
(50 mg/ml) in serum-free medium for 18 hours, followed by western blotting
of NDRG1 and b-tubulin as a loading control. n54–6 samples; values are
means 6 s.e.m., *P,0.05 (Student’s t-test). (B) Cholesterol distribution is
affected by NDRG1 silencing in A431 cells. Cells were transfected with
control (CTRL) or NDRG1 siRNAs for 72 hours, fixed, and stained with
filipin. (C) Cholesterol ester (CE) content is decreased upon NDRG1 k/d.
After siRNA treatment of A431 cells, the lipids were extracted and analyzed
by TLC. Free cholesterol (FC) and CEs were quantified by densitometry.
Results of a representative (means 6 s.d.) of three independent experiments
with comparable results are shown. **P,0.001 (Student’s t-test).
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was severely attenuated with less than 40% of the receptor lost in
5 hours (Fig. 2C). Together, these results demonstrate that
NDRG1 is required for the proper PM localization of the
LDLR. The reduction of LDLR at the PM results in diminished
LDL-cholesterol uptake and is accompanied by retarded
degradation of the LDLR.
Silencing of NDRG1 or its interaction partner PRA1 leads
to endosomal LDLR sequestration
To define the intracellular localization of excess LDLRs in
NDRG1-silenced cells, LDLR was co-immunostained with
markers for early endosomes (endosomal antigen 1; EEA1) and
late endosomes/lysosomes (Lysosome-associated membrane
glycoprotein 1; LAMP1) and imaged by confocal microscopy.
In control cells, LDLR typically localized to small, punctate
EEA1-positive endosomes in the perinuclear region and to some
extent to LAMP1-positive late endosomes/lysosomes (Fig. 3A).
In NDRG1-silenced cells, enlarged endosomes and lysosomes
were more irregularly scattered in the cytoplasm. Strikingly, the
LDLR was largely sequestered in the abnormal EEA1-positive
endosomal vesicles (Fig. 3A). These structures also accumulated
FC, as detected by filipin staining (supplementary material Fig.
S2).
To investigate how NDRG1 deficiency results in the strikingly
altered endosome morphology, we considered the involvement of
the previously described NDRG1 interaction partners Rab4a and
PRA1 (Hunter et al., 2005; Kachhap et al., 2007; Kim et al.,
2012; King et al., 2011). Therefore, we tested the consequences
of Rab4a or PRA1 silencing on LDLR distribution by
immunostaining of A431 cells. We observed that the LDLR
phenotype of Rab4a depletion was not identical to that of
NDRG1 depletion, with the latter leading to larger intracellular
LDLR-positive accumulations (Fig. 3B). However, depletion of
PRA1 led to the appearance of enlarged early endosomes and late
endosomes (Fig. 3C) as well as to the accumulation of the LDLR
in these enlarged EEA1-positive endosomes, closely resembling
the LDLR phenotype of NDRG1 k/d cells. We then analyzed
whether NDRG1 silencing affects the levels of endogenous
PRA1 or endosomal Rab proteins in A431 cells. Remarkably, we
observed a significant decrease in the amount of endogenous
PRA1 protein, both by immunostaining and immunoblotting of
NDRG1 k/d cells (Fig. 4A; see also supplementary material Fig.
S3). In contrast, the levels of Rab4, 5 and 7 were not substantially
altered (supplementary material Fig. S4).
To address whether the reduced levels of PRA1 contribute to the
LDLR trafficking defect observed upon NDRG1 depletion, we
overexpressed PRA1 in NDRG1-depleted cells. After fixation, the
cells were immunostained for PRA1 and LDLR and assessed for
the degree of LDLR endosomal sequestration. pEGFP was
expressed as a control to evaluate the possible effect of
transfection on LDLR localization. In control cells
overexpressing GFP, LDLR showed a punctate staining
throughout the cytoplasm, whereas in NDRG1 k/d cells
overexpressing GFP, LDLR was abnormally sequestered as
expected (Fig. 4B). Importantly, overexpression of PRA1
partially rescued the LDLR phenotype in NDRG1-siRNA-treated
Fig. 2. NDRG1 depletion results in diminished LDL uptake, and
decreased PM localization and degradation of LDLR. (A) NDRG1
depletion decreases the binding and uptake of DiI–LDL. siRNA-
transfected A431 cells were incubated with 5 mg/ml DiI–LDL for
30 minutes at 4 C˚ (binding) or 20 minutes at 37 C˚ (uptake), and
imaged with a wide-field microscope immediately post-fixation.
Cellular fluorescence intensity was quantified from cell lysates, and
normalized to the protein amounts (right panel). Values are means 6
s.e.m, *P,0.05 (Student’s t-test). (B) Total LDLR is increased but the
PM fraction of LDLR is decreased in NDRG1 k/d cells. siRNA-
transfected A431 cells were subjected to cell-surface biotinylation and
streptavidin pull-down. LDLR amounts were analyzed by western
blotting and quantified by densitometry; Total, input protein; PM, pull-
down of biotinylated PM protein. Values are means6 s.e.m. of three to
five experiments, *P,0.05 (Student’s t-test). (C) LDLR degradation is
slowed down in NDRG1-silenced cells. After surface biotinylation,
cells were incubated for the indicated times at 37 C˚ to allow
internalization and degradation of biotinylated LDLR, before analysis
as in B. Please note that PM LDLR levels at 0 hours were set as 1; in
CTRL-siRNA-treated samples there was an approximate twofold more
LDLR at the PM than in NDRG1-siRNA-treated samples. Values are
means 6 s.e.m. of three samples/condition from two independent
experiments.
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cells (Fig. 4B). These results demonstrate that NDRG1 deficiency
leads to an abnormal endosomal sequestration of the LDLR. They
also suggest that the reduced levels of PRA1 accompanying
NDRG1 deficiency might contribute to the aberrant endosomal
morphology and LDLR sequestration.
NDRG1 affects the morphology and function of
multivesicular bodies
The effect of NDRG1 silencing on the ultrastructure of
endosomal organelles was studied by electron microscopy
(EM). To this end, siRNA-transfected A431 cells were allowed
to internalize BSA-gold for 40 min to label the endosomes and
subsequently processed for EM. Both in the control- and
NDRG1-silenced cells, BSA-gold accumulated in vesicles with
MVB-like morphology (Fig. 5A). For quantification, we
measured the diameter of 60 MVBs from unlabeled siRNA-
treated EM samples and counted the number of intraluminal
vesicles in each. Compared with control cells, MVBs in NDRG1-
silenced cells were enlarged and contained approximately
threefold more intraluminal vesicles (Fig. 5A).
Because the formation of intraluminal vesicles destined for
lysosomal degradation requires endosomal sorting complex
required for transport (ESCRT) proteins (Raiborg and
Stenmark, 2009), we assessed the levels of the ESCRT
components in NDRG1-silenced cells by western blotting. The
immunoblots revealed a significant reduction in the amounts of
the tested ESCRT proteins, i.e. Hrs (ESCRT-0), TSG101
(ESCRT-I), Vps22 (ESCRT-II), Vps24 (ESCRT-III) and Vps32
(ESCRT-III) (Fig. 5B). In addition to ESCRTs, lipids might play
an important role in the membrane invagination step of MVB
formation. MVBs are abundant in sphingolipids, such as
sphingomyelin (SM) and ceramide, and the latter can induce
the formation of internal vesicles in liposomes and trigger
budding of exosome vesicles into multivesicular endosomes in
cells (Trajkovic et al., 2008). Interestingly, we found a significant
increase in the total ceramide levels of NDRG1 k/d cells
(Fig. 5C).
To test whether the increase in ceramide is due to its
accumulation in the enlarged MVBs, we incorporated a
fluorescent derivative of ceramide (BODIPY-labeled ceramide)
into LDL particles, and applied them to NDRG1-silenced cells.
The cells had been prelabeled overnight with the fluorescent
fluid-phase tracer dextran to visualize lysosomes. (Please note
that dextran distribution is altered upon NDRG1 depletion due to
the redistribution of late endocytic organelles; see supplementary
material Fig. S5.) As shown in Fig. 6A, after 1 hour of LDL
labeling BODIPY-labeled ceramide was already partially
colocalized with dextran in control cells. The extent of
colocalization increased until a 2-hour chase, after which it
decreased (Fig. 6A). However, in NDRG1 k/d cells, BODIPY-
labeled ceramide localized to a lesser extent with dextran after
1 hour of labeling and remained for a prolonged time in enlarged
dextran negative vesicular structures (Fig. 6A). This suggests that
the transport of ceramide through the endosomal pathway is
slower in NDRG1-depleted cells. To address the source of
increased endosomal ceramide, we internalized LDL particles
labeled with [3H]SM into cells. This revealed increased levels of
[3H]SM-derived [3H]ceramide in NDRG1-silenced cells,
providing evidence that at least part of the ceramide derives
from endosomal SM hydrolysis (Fig. 6B). Together, these
findings imply that NDRG1 function is required for proper
endosomal maturation. In NDRG1 deficiency, MVBs accumulate
increased numbers of intraluminal vesicles despite a marked
reduction of ESCRT components. Furthermore, the endosomal
retention of both fluorescent ceramide and increased LDL/
[3H]SM-derived [3H]ceramide suggests that the intraluminal
vesicles in NDRG1-depleted cells are ceramide enriched.
Prevention of IDOL-induced LDLR ubiquitylation rescues
LDLR distribution and cholesterol levels in NDRG1-
silenced cells
Ubiquitylation of membrane proteins can negatively regulate
their cell surface expression by targeting them to the MVBs and
for degradation (Staub and Rotin, 2006). Interestingly, silencing
Fig. 3. LDLR accumulates in modified enlarged endosomes upon
knockdown of NDRG1 or PRA1. (A) LDLR localizes in enlarged
endosomes in NDRG1-depleted cells. Confocal images of siRNA-transfected
A431 cells, immunostained for LDLR (red), EEA1 (green) and LAMP-1
(green). Scale bars:10 mm (Merge), 5 mm (Zoom). (B) Silencing of Rab4a
interferes with LDLR distribution in A431 cells but the phenotype differs
from that of NDRG1 silencing. Cells were permeabilized with filipin and
immunostained with LDLR antibody. Scale bars: 20 mm. (C) PRA1 silencing
leads to accumulation of LDLR in enlarged EEA1-positive endosomes.
Confocal images of PRA1 siRNA-transfected A431 cells, immunostained for
LDLR (red) and EEA1 (green) or LAMP1 (green). Scale bars: 10 mm.
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of NDRG1 enhanced the colocalization of the LDLR with
ubiquitin in enlarged endosomes (Fig. 7A). This suggests that the
abnormal endosomes in NDRG1-silenced cells can accumulate
ubiquitin and possibly also ubiquitylated LDLR despite reduced
ESCRT levels. To directly analyze whether NDRG1 silencing
affects the ubiquitylation status of the LDLR, we used HEK293T
cells. The cells were co-transfected with control or NDRG1
siRNAs and an expression plasmid encoding HA-tagged LDLR.
The cell lysates were immunoprecipitated with anti-HA beads,
followed by immunoblotting with an anti-ubiquitin antibody to
detect the ubiquitylated LDLR. As shown in Fig. 7B, depletion of
NDRG1 results in increased amounts of ubiquitylated LDLR.
Recently, the E3 ubiquitin ligase IDOL was identified as a
novel post-translational regulator of LDLR ubiquitylation (Hong
et al., 2010; Sorrentino and Zelcer, 2012; Zelcer et al., 2009). We
examined whether prevention of LDLR ubiquitylation by IDOL
Fig. 4. PRA1 is reduced in NDRG1-silenced cells and its
overexpression rescues LDLR distribution in these cells.
(A) NDRG1 silencing is accompanied by reduced amounts of
PRA1. Immunostaining (confocal images) and western blotting of
endogenous PRA1 in siRNA-transfected A431 cells. Values are
means 6 s.e.m. of two to three experiments with parallel samples;
*P,0.05 (Student’s t-test). Scale bars: 20 mm. (B) PRA1
overexpression (OE) rescues the LDLR accumulation phenotype
of NDRG1-silenced cells. PRA1 was overexpressed in NDRG1-
silenced A431 cells. Cells overexpressing PRA1 were detected
with anti-PRA1 antibody (green), and endogenous LDLR was
detected with anti-LDLR antibody (red). pEGFP was used as a
transfection control. The number of intracellular LDLR-positive
accumulations was quantified from confocal images, n570 cells/
sample; values are means 6 s.e.m., *P,0.05; **P,0.001
(Student’s t-test). Scale bars: 10 mm.
Fig. 5. NDRG1 affects MVB morphology and ESCRT levels.
(A) NDRG1 silencing results in enlarged MVBs with increased
number of intraluminal vesicles. Left: EM images of siRNA-
transfected A431 cells, labeled with BSA-gold for 40 minutes.
MVBs with ILVs are marked by an asterisk. MVB diameter and
the number of intraluminal vesicles (ILVs) were quantified from
60 MVBs of unlabeled EM samples. Values are means 6 s.e.m.,
**P,0.001 (Student’s t-test). Scale bars: 200 nm. (B) NDRG1
silencing results in the downregulation of ESCRTs. ESCRT
protein amounts relative to CTRL were analyzed by western
blotting of siRNA-transfected A431 cells. The representative
immunoblots are shown for each ESCRT protein. Values are
means 6 s.e.m. from two to five independent experiments,
*P,0.05, **P,0.001 (Student’s t-test). (C) Total ceramide
content is increased upon NDRG1 depletion in A431 cells. Total
cellular ceramide amounts were determined in siRNA-treated
A431 cells by HPTLC and densitometry. Values are means 6
s.e.m. of five samples/condition from two independent
experiments, *P,0.05 (Student’s t-test).
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the endosomal LDLR accumulation in NDRG1-depleted cells.
As expected, silencing of IDOL led to an increase in both
total and PM LDLR abundance (Fig. 7C). Remarkably,
depletion of IDOL in NDRG1 k/d cells was able to reverse
the decrease in LDLR PM levels (Fig. 7C). Furthermore,
under these conditions, depletion of IDOL alleviated the
endosomal sequestration of LDLR (Fig. 7D). We also
assessed the consequence of IDOL silencing on cellular
cholesterol stores. Silencing of IDOL resulted in increased
CES, whereas silencing of NDRG1 led to the opposite
outcome (Fig. 7E). Strikingly, when IDOL and NDRG1
were silenced simultaneously, the level of CEs was rescued
(Fig. 7E).
Fig. 6. Ceramide is enriched in enlarged MVBs in NDRG1
knockdown cells. (A) Altered BODIPY-labeled ceramide
(BPY-Cer) transport in NDRG1-silenced cells. Cells pre-
labeled with dextran were pulse-labeled with BPY-Cer/LDL for
1 hour and chased for 0–4 hours (images from 1 hour chase).
Colocalization of BPY-Cer (green) and dextran (red) was
analyzed using Pearson’s correlation coefficient at 0–4 hours of
chase. n53 confocal sections and .30 cells per time point;
values are means 6 s.e.m. (B) [3H]Ceramide accumulation
derives from endosomal SM hydrolysis in NDRG1-silenced
cells. [3H]SM incorporated into LDL particles was internalized
into A431 cells for 2 hours and the amounts of [3H]SM and
derived [3H]ceramide were analyzed by TLC. Values are means
6 s.e.m. of six samples/condition from two independent
experiments, *P,0.05 (Student’s t-test).
Fig. 7. LDLR ubiquitylation is increased in NDRG1-
silenced cells, and its prevention by IDOL depletion rescues
LDLR distribution and CE content. (A) LDLR colocalizes
with HA–Ub in NDRG1-depleted cells. A431 cells were
transfected with siRNAs and a plasmid encoding HA–Ub. HA–
Ub was immunostained with anti-HA antibodies (green) and
LDLR with anti-LDLR antibodies (red). Confocal microscopy
images are shown. Scale bars: 10 mm. (B) LDLR is heavily
ubiquitylated upon NDRG1 k/d. HEK293T cells were co-
transfected with LDLR-HA and siRNAs and immunoblotted as
indicated. LDLR–HA was immunoprecipitated from total cell
lysates using HA-beads and the ubiquitylated LDLR–HA was
detected with an anti-Ub antibody; a-tubulin was used as a
loading control. A representative immunoblot of three
independent experiments with comparable results is shown.
(C) IDOL k/d rescues the PM localization of LDLR in
NDRG1-silenced cells. siRNA-transfected A431 cells were
analyzed by surface biotinylation as in Fig. 2B. Values are
means 6 s.e.m. of two independent experiments; a
representative immunoblot is shown. (D) Depletion of IDOL in
NDRG1-silenced cells complements the endosomal LDLR
accumulation. siRNA-transfected A431 cells were
permeabilized with filipin, immunostained with anti-LDLR
antibody and imaged by confocal microscopy, using a 406
objective. Scale bars: 20 mm. (E) Depletion of IDOL in
NDRG1-silenced cells rescues cellular CE content. To
determine the CEs in siRNA-treated cells, lipids were
extracted, separated by TLC, and quantified by densitometry.
Values are means 6 s.e.m., *P,0.05 (Student’s t-test).
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Taken together, these results demonstrate that LDLR is
ubiquitylated in NDRG1-depleted cells and accumulates in
abnormal enlarged endosomes/MVBs. If LDLR ubiquitylation
in these cells is prevented, the receptor is not similarly
sequestered in endosomes but can apparently recycle to the PM
to rescue LDLR PM levels and LDL uptake. Accordingly, the
cholesterol content of NDRG1-depleted cells is rescued.
NDRG1-depletion reduces glial cell LDL uptake and
decreases the amount of Olig2 in an Idol-dependent
manner
NDRG1 is highly expressed in myelinating glial cells (Okuda et al.,
2008) and NDRG1 mutations cause CMT4D. The major CMT4D-
causing founder mutation of NDRG1 contains a premature
termination signal at residue 148 (R148X) (Kalaydjieva et al.,
2000). The Ndrg12/2 mice display a progressive demyelinating
disorder, providing evidence that NDRG1 deficiency accounts for
the disease (Okuda et al., 2004). Accordingly, we observed that
although the overexpression of WT NDRG1 rescued the LDLR
accumulation in NDRG1 k/d cells (supplementary material Fig.
S6), a construct of NDRG1 truncated at R148 was unstable and
was unable to rescue the phenotype (V. P. and E. I., unpublished
observations). These data suggest that the effects of NDRG1
silencing might mimic the effects of functional NDRG1 deficiency
in CMT4D.
We therefore studied the role of Ndrg1 in regulating LDL
uptake in murine Oli-neu cells, a widely used oligodendroglial
cell line generated by immortalization of mitotic oligodendrocyte
precursor cells by retroviral t-neu oncogene expression (Jung
et al., 1995). Silencing of Ndrg1 in Oli-neu cells (see
supplementary material Fig. S1D) reduced DiI–LDL binding
and uptake (Fig. 8A), analogously to our observations in A431
cells. In line with the effect of IDOL in other cell types, silencing
of Idol in Oli-neu cells resulted in an increase in both DiI–LDL
binding and uptake (Fig. 8A). Furthermore, depletion of Idol in
Ndrg1-silenced cells re-established DiI–LDL binding and uptake
to the level of control-siRNA-treated cells (Fig. 8A). These
results suggest that Ndrg1 and Idol are involved in LDL uptake in
oligodendrocytes and that these processes are interconnected.
Light microscopy revealed that control-siRNA-treated Oli-neu
cells exhibited outgrowths characteristic of oligodendrocytes,
whereas the Ndrg1-depleted cells had a distinct, spindle-shaped
morphology. To quantify the number of outgrowths, control and
Ndrg1-siRNA-treated cells were transfected with an expression
plasmid encoding a constitutively farnesylated GFP construct
(GFP-F). This construct localizes to the PM and enables
visualization of neurite outgrowths (Lalli and Hall, 2005). The
Ndrg1-depleted cells had fewer outgrowths per cell than control
cells (Fig. 8B). A possible explanation is that the silencing of
Ndrg1 affects the differentiation of Oli-neu cells. To test this
idea, we immunoblotted and immunostained siRNA-transfected
Oli-neu cells with an antibody against oligodendrocyte lineage
transcription factor 2 (Olig2). Olig2 is necessary for the genesis
of oligodendrocytes and is an important regulator of
oligodendrocyte differentiation and myelination (Ligon et al.,
2006). In Ndrg1-depleted cells Olig2 immunoreactivity was
significantly reduced (,50%, based on immunoblotting; Fig. 8C)
and the remaining Olig2 protein was largely cytoplasmic, in
contrast to control cells that showed a strong nuclear Olig2
localization (V.P. and E.I., unpublished observations).
Finally, we examined the potential connection of
oligodendrocyte differentiation and LDLR regulation by
analyzing Olig2 levels after Idol k/d. Depletion of Idol slightly
increased Olig2 protein levels. Importantly, Idol co-depletion in
Ndrg1-silenced cells was able to rescue the reduced Olig2 levels
(Fig. 8C). Cumulatively, these findings suggest that NDRG1 is
Fig. 8. Ndrg1 knockdown in murine oligodendrocytes results in
reduced LDL uptake and decreases the amount of Olig2. (A) DiI–
LDL binding and uptake are reduced in Ndrg1-silenced Oli-neu cells.
Cells were incubated with 2 mg/ml DiI–LDL for 20 minutes at 4 C˚
(binding) or for 30 minutes at 37 C˚ (uptake). Cells were imaged and
the fluorescence intensity per cell was quantified. Values are means6
s.e.m. of two to four independent experiments (at least 900 cells
analyzed/condition); **P,0.001, *P,0.05 (Student’s t-test).
(B) Number of Oli-neu cell outgrowths is diminished upon Ndrg1 k/d.
A plasmid encoding GFP-F was transfected to siRNA-treated Oli-neu
cells to visualize and quantify outgrowths. Values are mean 6 s.e.m.,
50 cells/condition, **P,0.001 (Student’s t-test). (C) Ndrg1 silencing
leads to a reduction in the amount of Olig2 but co-depletion of Idol
complements the phenotype. Oli-neu cells were collected after
72 hours of siRNA transfection and Olig2 protein amounts were
analyzed by western blotting and quantified by densitometry. Values
are means 6 s.e.m. of four experiments, **P,0.001 (Student’s
t-test).
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important for oligodendrocyte cholesterol balance and
differentiation and that these actions might be mediated through
IDOL-sensitive LDLR family members (Hong et al., 2010).
Discussion
NDRG1 as a regulator of LDLR trafficking
When cells are in need of cholesterol, the endocytosed LDLR
normally recycles rapidly to the PM (Goldstein and Brown,
2009). We found that in NDRG1-depleted cells, the receptor was
reduced at the cell surface and accumulated in modified early
endosomes and MVBs. In parallel, the degradation of LDLR was
slowed down, contributing to an increase in the total cellular
LDLR. The decreased LDLR degradation is in agreement with
the fact that a functional MVB pathway is needed for lysosome
biogenesis and is essential for cargo degradation (Mukhopadhyay
and Riezman, 2007).
LDLR ubiquitylation by IDOL is known to act as a sorting
signal that directs the receptor for lysosomal degradation (Hong
et al., 2010; Zelcer et al., 2009). Our findings indicate that the
LDLR in NDRG1-depleted cells is heavily ubiquitylated,
suggesting that it is targeted for lysosomal degradation. We
propose that the LDLR must be ubiquitylated by IDOL in order
to be sequestered into the abnormal endosomal compartment
observed in NDRG1-deficient cells. In line with this, LDLR is
able to recycle to the PM in the simultaneous absence of IDOL
and NDRG1. This recycling LDLR is likely to utilize distinct
endosomal subpopulations or subdomains from those involved in
MVB formation and eventual cargo degradation. Indeed,
endosomes are known to exist in cargo-specific populations
(Lakadamyali et al., 2006) and cargo-specific signals can modify
the endosomal pathway (Miaczynska et al., 2004; van der Goot
and Gruenberg, 2006).
NDRG1 as a regulator of endosomal morphology and
function
The enlarged MVBs in NDRG1 k/d cells contained more
intraluminal vesicles, suggesting that the mechanism(s) of
intraluminal vesicle formation and/or turnover were altered
upon NDRG1 depletion. These atypical MVBs sequestered
recycling membrane proteins, such as the LDLR. Of note, they
also accumulate the transferrin receptor, E-cadherin (Kachhap
et al., 2007), and b1-integrin (V. P. and E. I., unpublished
observations). In addition, they accumulated lipids (free
cholesterol and ceramide) and ubiquitin, and were positive for
EEA1. The mechanisms by which the enlarged MVBs and
increased number of intraluminal vesicles are generated upon
NDRG1 k/d might involve several mechanisms. Based on earlier
studies and our observations these mechanisms could include:
(1) altered activity of endosomal Rab GTPases (Huotari and
Helenius, 2011); (2) downregulation of ESCRT complex
components (Stuffers et al., 2009); (3) increased cholesterol/
ceramide content in MVBs (Kobuna et al., 2010; Trajkovic et al.,
2008); (4) increased ubiquitylation of cargo (MacDonald et al.,
2012); and (5) decreased degradation of cargo (Huotari and
Helenius, 2011).
The biogenesis of the atypical MVBs in NDRG1 k/d cells was
accompanied by diminished amounts of PRA1 and ESCRT
complex components. Of PRA1, about two-thirds was depleted
upon NDRG1 silencing. PRA1 has been shown to interact with
NDRG1 and regulate several endosomal Rab GTPases, including
Rabs 4, 5, 7 and 9 (Bucci et al., 1999; Sivars et al., 2003), and to
affect the endosomal cholesterol content (Liu et al., 2011).
Moreover, we found that PRA1 overexpression alleviates the
LDLR redistribution in NDRG1-silenced cells. Therefore, the
shortage of PRA1 in NDRG1-silenced cells might alter the
delivery of Rab GTPases to endosomal membranes (Sivars et al.,
2003), thereby contributing to the disturbed endosomal
morphology and membrane transport.
Interestingly, our data indicate that MVB biogenesis and
endosomal concentration of ubiquitylated cargo can proceed in
NDRG1-depleted cells despite downregulation of ESCRT
proteins. Although ESCRT-independent mechanisms for MVB
formation have been proposed (Stuffers et al., 2009; Trajkovic
et al., 2008), the physiological regulators of this process remain
largely unknown. We suggest that in NDRG1-silenced cells, the
endosomal accumulation of ceramide (presumably deriving from
SM hydrolysis) triggers the formation of intraluminal vesicles.
As such, NDRG1 appears as the first protein to negatively
regulate the formation of ceramide-rich intraluminal vesicles. In
future studies, it will be important to elucidate in more detail how
NDRG1 could control this process.
NDRG1 and CMT4D
To extend our findings to a pathophysiologically relevant cell
model, we studied glial cells. We show that in rodent
oligodendrocytes, which normally exhibit strong Ndrg1
expression in the cytoplasm and processes (Berger et al., 2004;
Okuda et al., 2008), Ndrg1 deficiency results in reduced LDL
uptake. Importantly, this implies that the NDRG1 effect on LDL
uptake is not specific for a certain cell type or species. High
cholesterol availability is known to be required for myelin
membrane growth (Saher et al., 2005). In addition, studies in
other CMT neuropathies have emphasized the importance of
endocytic pathways in the formation of myelin (Lee et al., 2012;
Roberts et al., 2010; Sidiropoulos et al., 2012; Stendel et al.,
2010; Verhoeven et al., 2003), reinforcing a link between
NDRG1 function in endocytic trafficking and myelin formation/
maintenance.
NDRG1 might also affect oligodendrocyte differentiation, as
suggested by the lack of outgrowths and downregulation of Olig2
in Ndrg1-silenced oligodendrocytes. This agrees with the notion
that the NDRG1 transcript is strongly upregulated during
oligodendrocyte differentiation (Cahoy et al., 2008). We
describe for the first time that Idol is involved in the regulation
of lipid uptake in oligodendroglial cells. This finding is consistent
with a recent report showing that liver X receptors (LXRs) that
are transcriptional regulators of Idol expression control lipid
metabolism in this cell type (Nelissen et al., 2012).
Intriguingly, IDOL not only promotes the ubiquitylation of the
LDLR (Zelcer et al., 2009) but also two related receptors, the
ApoE receptor 2 (ApoER2) and very-low-density lipoprotein
receptor (VLDLR) (Hong et al., 2010), known to be expressed in
oligodendrocytes (Zhao et al., 2007). Indeed, a potential
explanation for the rescue of Olig2 levels by Idol depletion in
Ndrg1 k/d cells is that uptake of LDL, or other ligands of IDOL-
regulated receptors, is required to maintain Olig2 expression and
oligodendrocyte differentiation. Notably, both ApoER2 and
VLDLR have been shown to mediate Idol-sensitive Reelin
signaling (Hong et al., 2010), a pathway crucial for the proper
development of the nervous system. Moreover, Olig2-expressing
oligodendroglial precursor cells are absent in mice lacking
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megalin, another LDLR family member involved in the
endocytosis of multiple ligands (Wicher and Aldskogius, 2008).
In summary, this study identifies NDRG1 as a novel regulator
of MVB integrity and LDLR endosomal recycling. In the absence
of this protein, ubiquitylated LDLR accumulates in modified
early endosomes/MVBs that harbor increased amounts of
ceramide-rich intraluminal vesicles. Thus, NDRG1 emerges as
a critical protein that stimulates receptor recycling and limits the
number of intraluminal vesicles in MVBs. Exactly how NDRG1
co-operates with known regulators of this process, such as
ESCRT components and Rab GTPases, and how broadly NDRG1
regulates recycling membrane proteins, remain to be addressed.
Importantly, the regulatory function of NDRG1 in endosomal
dynamics appears to hold for several cell systems; therefore, it is
likely to be relevant for understanding the contribution of
NDRG1 both in neuropathy and in tumorigenesis.
Materials and Methods
Antibodies and other reagents
The following antibodies were used: NDRG1 (rabbit pAb; T. Commes, Universite
Montpellier, France), NDRG1 (rabbit pAb; Atlas Antibodies AB, Stockholm,
Sweden), LDLR (mAb C7, mouse hybridoma supernatant; Beisiegel et al., 1981;
immunostainings), LDLR (rabbit pAb, 20R-LR002, Fitzgerald Industries
International, Acton, Massachusetts, USA; immunostainings and western
blotting), LDLR (rabbit mAb, clone EP1553Y, Epitomics, Burlingame, CA,
USA; western blotting), LAMP1 (mAb H4A3, Developmental Studies Hybridoma
Bank, Iowa, Maryland, USA), EEA1 (mAb, BD Biosciences, San Jose, CA, USA),
PRA1 (mAb 2A4, Novus Biologicals, Littleton, Colorado, USA), TSG101 (mAb
4A10, GeneTex Inc., Irvine, CA, USA), ubiquitin (mAb FK2, BML-PW8810,
Enzo Life Sciences, Farmingdale, New York, USA), hemagglutinin (HA) (mAb,
Sigma-Aldrich, St. Louis, MO, USA), b-tubulin (mAb, T4026, Sigma-Aldrich), a-
tubulin (mAb, T9026/clone DM1A, Sigma) and Hrs, Vps22, Vps24 and Vps32
rabbit pAbs (H. Stenmark). U81666A [3b-(2-diethylaminoethoxy)androst-5-en-17-
one], HPLC-grade solvents, lovastatin, and silica gel 60 TLC plates were from
Merck (Darmstadt, Germany), [1,2-3H]cholesterol from Perkin Elmer (Waltham,
MA), [3H]acetic acid from GE Healthcare (Chalfont St. Giles, UK), dextran–
Alexa-Fluor-568 (10000MW) and DiI–LDL from Invitrogen-Life Technologies
(Carlsbad, California, USA), Effectene and Hiperfect from Qiagen (Germantown,
Maryland, USA), protease inhibitors (chymostatin, leupeptin, antipain and
pepstatin A), Triton X-100, filipin and mevalonic acid lactone (mevalonate)
from Sigma-Aldrich and diethyl ether and petroleum ether from J. T. Baker
(Avantor Performance Materials, Center Valley, Pennsylvania, USA). For electron
microscopy, glutaraldehyde and osmium tetroxide were purchased from Electron
Microscopical Sciences (Hatfield, Pennsylvania, USA) and sodium cacodylate and
potassium ferrocyanide were from Sigma-Aldrich. D-erythro-N-palmitoyl-
BODIPY-sphingosine (Ceramide-BDY) was prepared by N-acylation of
BODIPY–sphingosine, as described by Blom et al. (Blom et al., 2012). All cell
culture reagents, except poly-D-lysine (Sigma-Aldrich), were obtained from Gibco
Life Technologies (Invitrogen). Lipoprotein-deficient serum (LPDS) was prepared
as described previously (Jansen et al., 2008).
Plasmid and siRNA transfections
Human PRA1 cDNA (NM_006423.1) in pCMV6-XL5 was purchased from
Origene (Rockville, Maryland, USA). The LDLR-HA and HA-ubiquitin plasmids
have been previously described (Hong et al., 2010; Zelcer et al., 2009).
The following siRNAs were used: CTRL (Sigma-Aldrich; 59-CGUAC-
GCGGAAUACUUCGA-39), human NDRG1 (Stealth-modified, Invitrogen; 59-
CAUCGAGACUUUACAUGGCUCUGUU-39), mouse Ndrg1 (Qiagen FlexiTube,
target sequence 59-AACTCATTCCTGGAAACAAA-39), human IDOL (s26522,
Ambion Silencer Select, Invitrogen; 59-GACUUUAGCCCAAUUAAUATT-39),
mouse Idol-6 (Ambion Silencer Select, Invitrogen; target sequence 59-AA-
CATTAACCTTGGTAAGAAA-39), mouse Idol-9 (Ambion Silencer Select,
Invitrogen; target sequence 59-AGGGATCATCGAGGTTGATTA-39), Rab4a
(Qiagen validated, 59-AAUGCAGGAACUGGCAAAUCT-39) and PRA1 (Kim
et al., 2006) (Stealth-modified, Invitrogen, 59-GCGCCUGUUACAUUC-
UCUAUCUGCG-39). TSG101 and Hrs siRNAs have been previously described
(Bache et al., 2003; Garrus et al., 2001). cDNA transfections were performed with
Effectene and siRNA transfections in 10 nM final concentration with HiPerfect
according to the manufacturer’s instructions. To silence mouse Idol, two different
siRNAs (Idol-6 and 29) were used (total 10 nM final concentration). In co-
silencing experiments of two different genes, each siRNA was used at 10 nM. The
siRNA transfection time was 72 hours unless otherwise stated.
Cell culture and western blot analysis
A431 cells (epidermoid carcinoma cell line, American Type Culture Collection;
ATCC) and HEK293T cells (human embryonic kidney cells, ATCC) were cultured
in Dulbecco’s modified Eagle’s medium (D-MEM) supplemented with 10% fetal
bovine serum, 0.5 mM L-glutamine and 100 IU/ml penicillin, 100 mg/ml
streptomycin at 37 C˚ in a CO2-conditioned, humidified incubator. Oli-neu, an
immortalized oligodendrocyte precursor cell line (Jung et al., 1995) was cultured
in 1:1 D-MEM/HAM’s F12 with B27 supplement on poly-D-lysine (50 mg/ml)-
coated plastic. Cells were treated with U18666A (48 hours) in 10% FBS or loaded
with LDL (18 hours) in 5% LPDS. Cells were collected for western blotting by
adding 1% NP-40 including a protease inhibitor mixture (chymostatin, leupeptin,
antipain and pepstatin A; 25 mg/ml each; CLAP) in PBS. The protein amount was
determined by using a BioRad kit. Proteins were subjected to SDS-PAGE and
western blotting as described (Jansen et al., 2008). In some experiments, the
IRDye-conjugated secondary antibodies (IRDye 800CW-conjugated donkey anti-
rabbit and 680LT donkey anti-mouse, LI-COR, Superior St. Lincoln, Nebraska,
USA) were used prior to image capture with Odyssey Imager (LI-COR).
Immunoreactive bands were quantified using ImageJ software (National
Institutes of Health, Bethesda, Maryland, USA; NIH, http://rsbweb.nih.gov/ij/).
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature,
and permeabilized with 0.1% or 0.3% Triton X-100 for 5 minutes. For
visualization of free cholesterol, cells were stained with 0.05% filipin in 10%
FBS–PBS blocking solution for 30 minutes at 37 C˚. The immunostainings were
performed sequentially as described by Jansen et al. (Jansen et al., 2008). Images
were acquired with an Olympus AX70 epifluorescence microscope (Olympus,
Center Valley, Pennsylvania, USA) equipped with an Olympus DP71 CCD
camera, using 206or 406objectives. Confocal images were acquired with a Leica
TCS SP2 AOBS confocal microscope (Leica Microsystems, Wetzlar, Germany),
with 406 (NA51.25) or 606 (NA51.4) oil objectives.
Biochemical lipid analyses
siRNA-transfected A431 cells were collected in 0.2 N NaOH and lipids were
extracted as described previously (Bligh and Dyer, 1959). FC and CE were
resolved on TLC plates using hexane/diethyl ether/acetic acid (80:20:1) as the
mobile phase. Lipids were visualized by charring and quantified by ImageJ after
scanning. To measure cholesterol synthesis, cells were pulse-labeled in serum-free
medium with 20 mCi/ml [3H]acetic acid in six-well plates for 2 hours at 37 C˚,
chased for 2 hours in serum-free medium with 10 mM lovastatin and 2.5 mM
mevalonate, and analyzed as described previously (Heino et al., 2000). For
analysis of cholesterol efflux, [3H]cholesterol (2 mCi/ml) was added to A431 cells
24 hours after siRNA transfection, the cells were incubated for an additional
8 hours, and then for 16 hours in serum-free medium in the presence of ApoA-I
(10 mg/ml). The medium was collected, cells were scraped into ice-cold PBS,
harvested by centrifugation and resuspended in 0.2 N NaOH. The radioactivity in
medium and cells was measured by scintillation counting.
DiI–LDL binding and uptake
siRNA-transfected A431 and Oli-neu cells on coverslips were incubated with 5 mg/
ml (A431 cells) or 2 mg/ml (Oli-neu cells) of DiI–LDL for 30 minutes at 4 C˚
(binding) or 20–30 minutes at 37 C˚ (uptake) in serum-free medium prior to
fixation with 4% PFA and staining with DAPI for detection of the nuclei. The
samples were imaged with an Olympus AX70 microscope to quantify DiI–LDL
intensity. The total intensity obtained from background-substracted DiI–LDL
images was divided by the number of nuclei in the image to obtain an intensity-
per-cell value. Alternatively, cells were plated onto 48-well plates, transfected with
siRNAs and incubated with DiI–LDL as above. Cells were washed three times
with PBS prior to lysis into 200 ml of PBS–1% NP-40. The lysates were incubated
on ice for 10 minutes, and 150 ml aliquots were measured in a PheraStar
microplate reader (BMG Labtech, Ortenberg, Germany) with an ex540/em590
filter set. Fluorescence counts were normalized to total protein (determined from
10 ml aliquots).
Cell surface biotinylation and LDLR degradation
Cell surface biotinylation protocol was modified from Scotti et al. (Scotti et al.,
2011). Cells on 60 mm plates were rinsed twice with ice-cold PBS containing
0.02 mM CaCl2 and 0.15 mM MgCl2 (PBS+). Cell surface proteins were
biotinylated for 20 minutes with 0.5 mg/ml biotin (Sulfo-NHS-LC-Biotin;
Pierce/Thermo Fisher Scientific, Rockford, Illinois, USA) diluted in PBS+.
Unbound biotin was quenched by two incubations (5 minutes at 4 C˚) with PBS+
containing 0.1 M glycine and 0.3% BSA. The cells were washed with PBS+ and
lysed (10 minutes at 4 C˚) in 300 ml lysis buffer (0.2% SDS, 2% NP-40 in PBS,
supplemented with protease inhibitors). Lysates were collected and cleared by
centrifugation, and an aliquot (20 ml) was taken for immunoblotting with the LDL
receptor antibody (‘total’). Biotinylated proteins from the rest of the lysate
(250 ml) were precipitated with 50 ml streptavidin–agarose beads (Sigma-Aldrich)
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by rotation overnight at 4 C˚. The beads were washed three times in cold lysis
buffer and twice in PBS+. Biotinylated proteins were eluted from the beads by
boiling in 26 sample buffer, separated by SDS-PAGE, and transferred to
nitrocellulose for western blotting. Blots were quantified by densitometry using
ImageJ. To quantify LDLR degradation, the cell surface was biotinylated and
quenched as above. The cells were washed in PBS+ and chased for 0, 2, or 5 hours
in complete culture medium at 37 C˚, lysed, and the biotinylated proteins were
precipitated and LDLR amounts detected as described above.
Quantification of LDLR accumulation
Cells were transfected with control or NDRG1 siRNAs as described above and
with PRA1 or pEGFP cDNA 48 hours later. At day 3, cells were fixed with 4%
PFA and stained with anti-PRA1 and anti-LDLR antibodies. The number of
intracellular LDLR-positive accumulations was quantified from Leica confocal
images in ImageJ by counting the local maxima of the region of interest (ROI),
using the ‘Find maxima’ plugin filter of ImageJ (http://rsbweb.nih.gov/ij/
docs/menus/process.html). Cells expressing the transfected constructs (PRA1 or
GFP) were defined as ROIs, and maxima were scored as ‘LDLR-positive
accumulations’.
Electron microscopy
Cells were cultured on glass coverslips, fixed with 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer, post-fixed with 1% osmium tetroxide and 1.5%
potassium ferrocyanide and dehydrated. A plastic capsule filled with embedding
resin was inverted over the coverslip. After polymerization the coverslip was
removed and the cells were sectioned horizontally. MVBs were systematically
sampled to give a total of 60 MVBs from two individual experiments in each
group, and the diameter of MVBs and number of intraluminal vesicles in the plane
of sectioning were assessed in prints with a final magnification of 1450006. BSA–
16 nm colloidal gold complexes were prepared according to the method of
Griffiths (Griffiths, 1993). Cells were incubated with BSA–gold (OD52051) in
Hepes-buffered D-MEM for 40 minutes at 37 C˚, fixed and processed as described
above.
Ceramide quantification
Cells were washed with PBS and scraped into 800 ml of ice cold 2% NaCl.
Aliquots (5 ml) were removed for protein determination. Then, 3 ml CHCl3/
methanol (2:1) was added, the suspension was vortexed, 1 ml of CHCl3 and 1 ml
of H2O were added for phase separation, and the lower phase was collected. Lipid
extracts were dried under a stream of nitrogen, lipids were re-dissolved in CHCl3/
methanol (2:1), and resolved with known standards on HPTLC plates with
CHCl3:acetic acid (9:1) as the mobile phase. HPTLC plates were dried, dipped in
3% CuSO4/8% H3PO4, and the ceramide bands were visualized by charring with
H2SO4 in ethanol at 180 C˚.
Metabolism of LDL-derived [3H]SM cells was measured as previously
described (Blom et al., 2012). In brief, cells were serum-starved overnight and
then incubated with 50 mg/ml [3H]SM/LDL for 2 hours. Cellular lipids were
extracted and separated on HPTLC. Bands corresponding to lipid standards were
scraped and measured by scintillation counting.
BODIPY-Cer trafficking
LDL particles were labeled with BODIPY-Cer according to (Blom et al., 2012).
Cells were labeled overnight with Alexa-Fluor-568–dextran in medium containing
5% LPDS, incubated for an additional 2 hours in the absence of dextran (to chase
dextran to lysosomes) and then labeled with 50 mg/ml BODIPY–Cer/LDL for
1 hours. The cells were washed and imaged by confocal microscopy at 37 C˚ for
4 hours. Colocalization of BODIPY-labeled ceramide and dextran was quantified
using Pearson’s correlation coefficient.
Immunoprecipitation of ubiquitylated proteins
Immunoprecipitation of HA-tagged proteins was performed as previously
described (Zelcer et al., 2009). Briefly, equal amounts of protein in the cleared
lysates were incubated with EZviewTM red anti-HA affinity beads (Sigma-Aldrich)
for 16 hours. Subsequently, beads were washed 46 with RIPA buffer. All
incubations and washes were performed at 4 C˚ with rotation. Proteins were eluted
from the beads by boiling in 16 protein sample buffer for 5 minutes prior to
western blotting and quantification.
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The STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a
cholesterol-binding membrane protein. To study how elevated StAR-related lipid transfer protein
3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing
StARD3egreen ﬂuorescent protein. We found that StARD3-overexpressing cells exhibited non-
adherent morphological features, had increased Src levels, and had altered cholesterol balance, as
evidenced by elevated mRNA levels of the cholesterol biosynthesis rate-limiting enzyme 3-
hydroxy-3-methylglutaryl-coenzyme A reductase, and increased plasma membrane cholesterol
content. On removal of serum and insulin from the culture medium, the morphological charac-
teristics of the StARD3-overexpressing cells changed, the cells became adherent, and they
developed enlarged focal adhesions. Under these conditions, the StARD3-overexpressing cells
maintained elevated Src and plasma membrane cholesterol content and showed increased phos-
phorylation of focal adhesion kinase. In two Finnish nationwide patient cohorts, approximately
10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly asso-
ciated with HER2 ampliﬁcation; several factors related to poor disease outcome and poor breast
cancerespeciﬁc survival. In addition, high StARD3 levels in breast cancers were associated with
elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and antieSrc-Tyr416
immunoreactivity. These results provide evidence that StARD3 overexpression results in increased
cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated
StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane
cholesterol and enhancing oncogenic signaling. (Am J Pathol 2015, 185: 987e1000; http://
dx.doi.org/10.1016/j.ajpath.2014.12.018)
The genomic region in chromosome 17 containing the HER2
(ERBB2) oncogene (17q12-q21) is frequently ampliﬁed in
cancers. This region contains multiple genes coampliﬁed with
HER2.1,2Several of these genes, including STARD3, have been
suggested to functionally contribute to the proliferation of
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HER2-positive cells, on the basis of RNA interference
studies.3,4The receptor tyrosine-protein kinase erbB-2 (ErbB2)
protein is a cell surface transmembrane tyrosine kinase that
forms long-lived, potent heterodimers with other receptors of
the epidermal growth factor receptor family, and acts as a
networking receptor that mediates growth, survival, migration,
and proliferation signals to cancer cells.5,6 A monoclonal
antibody directed against the extracellular domain of ErbB2,
trastuzumab, forms the basis for the treatment of HER2-posi-
tive breast cancers. However, more than half ofHER2-positive
cancers either are or become resistant to the drug, implying
that other genes, such as those coampliﬁed with HER2, may
contribute to the aggressive behavior of these tumors.3,4,7
The StAR-related lipid transfer protein 3 (StARD3; alias
MLN64 for metastatic lymph node 64) transcript was origi-
nally identiﬁed as being highly expressed in 14 of 93 invasive
breast carcinomas that also expressed high HER2 mRNA
levels.8 The STARD3 transcript encodes a ubiquitously
expressed protein that localizes to the late endosomal organ-
elles (LEs)9 and binds cholesterol.10 Its N-terminal domain
with four transmembrane spans targets the protein to the LE
membrane,9,11 and its C-terminal START domain harbors a
hydrophobic cholesterol-binding pocket that projects toward
the cytoplasm.10 The N-terminal domain is also capable of
interacting with cholesterol.12 Despite considerable interest in
the StARD3 protein, its precise function is not well under-
stood. Targeted disruption of the START domain causes only
modest alterations in whole body cholesterol metabolism in
mice.13However, there are several indications that cholesterol
binding or transfer by StARD3 affects cellular functions. The
cholesterol-binding activity of StARD3 is involved in con-
trolling the association of LEs with the actin cytoskeleton and
the actin-dependent movement of LEs.14 The protein can also
facilitate the transfer of cholesterol between LEs and other
membrane compartments, such as mitochondria15 and the
plasma membrane.11 The nascent StARD3 protein is trans-
ported to the LEs via the plasma membrane.16
Recent work suggests that the coampliﬁcation of STARD3
with ERBB2 might play a role in breast cancer progression.
First, StARD3 overexpression, as measured by quantitative
real-time PCR, increased the prognostic power of ErbB2
overexpression for disease-free survival of breast cancer
patients.17 Second, knockdown of StARD3 by siRNA in
HER2-positive breast cancer cell lines (both trastuzumab-
responding cell lines BT474 and SKBR3 and non-
responding lines JIMT1 and KPL4) led to induction of
apoptosis, suggesting that StARD3 is required for the growth
and survival of these cells.4 However, the mechanisms by
which StARD3 may mediate these effects are not known.
To learn whether increased StARD3 protein amounts can
alter the characteristics of cancer cells independently ofHER2
ampliﬁcation, we investigated the effects of StARD3 over-
expression in a well-studied model of HER2-negative human
breast cancer MCF-7 cells. We provide evidence that the
elevated expression of StARD3 protein is accompanied by
signiﬁcant morphological and biochemical alterations in these
cells, including altered membrane cholesterol content and
enhanced signaling related to cell adhesion. We also raised a
polyclonal StARD3-speciﬁc antibody and demonstrate high
StARD3 immunoreactivity, coinciding with HER2 ampliﬁ-
cation, in 1 of 10humanbreast tumors in two cohorts of>2000
patients. High StARD3 levels also associate with indicators of
altered cholesterol metabolism and signaling in these tumors.
Together, our data suggest that, in highly StARD3-expressing
breast cancer cells, the cholesterol-mobilizing andmembrane-
altering properties of the protein might exaggerate oncogenic
signaling via membrane-associated kinases and thereby
contribute to breast cancer aggressiveness.
Materials and Methods
Antibodies
To raise anti-StARD3 antibodies, the START domain of the
StARD3 protein (corresponding to amino acids 230 to 445)
was expressed as a His6eglutathione S-transferase fusion
protein in Escherichia coli JM109(DE3) and puriﬁed from
cell debris on preparative SDS-polyacrylamide gels. New
Zealand white rabbits were immunized with the puriﬁed
protein. The polyclonal antiserum was afﬁnity puriﬁed using
the glutathione S-transferaseefusion protein and used at
1:10 dilution for immunoﬂuorescence staining and at 1:50 to
1:200 dilution for immunoblotting. Anti-ErbB2 mouse
monoclonal antibody (3B5; ab16901) was purchased from
Abcam (Cambridge, UK), Lamp-1 H43A-c mouse mono-
clonal antibody was from the Developmental Studies Hy-
bridoma Bank (University of Iowa, Iowa City), sterol
regulatory element-binding protein 2 mouse monoclonal
antibody (557037) was from BDBiosciences (San Jose, CA),
phospho-Src (Tyr416) rabbit polyclonal antibody (number
2101) was from Cell Signaling Technology (Danvers, MA),
anti-focal adhesion kinase (pp125FAK) rabbit antibody
(F2918) was from Sigma-Aldrich (St. Louis, MO), and FAK
(pY397) puriﬁed mouse antibody (611807) was from BD
Transduction Laboratories (San Jose, CA).
Cell Culture
MCF-7 cells were cultured in Eagle’s minimum essential
medium from Lonza (Verviers, Belgium), supplemented with
10% fetal bovine serum (10270-106) from Life Technologies
(Grand Island, NY), 0.5 mmol/L L-glutamine (25030-024)
from Life Technologies, 0.01 mg/mL insulin (human, rDNA)
from Novo Nordisk (Bagsværd, Denmark), MEM nonessential
amino acids (M7145) from Sigma-Aldrich, and 100 IU/mL
penicillin and 100 mg/mL streptomycin (DE17-602E) from
Lonza. Flasks and dishes were purchased from Nunc (Ros-
kilde, Denmark), and 12- and 6-well dishes were from Falcon
(Becton-Dickinson Labware, Franklin Lakes, NJ).
For the control cell line, a pEGFP-C1emptyplasmid fromBD
Biosciences Clontech (Palo Alto, CA) was used. The plasmid
encoding green ﬂuorescent protein (GFP)efused full-length
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StARD3 has been described.14 To establish a StARD3-
overexpressing cell line, cells were seeded at 1.25  105 cells
perwell on24-well plates and transfectedwith1mgplasmidwith
Lipofectamine-LTX (Life Technologies) at 1:3 ratio, according
to the manufacturer’s protocol. After 48 hours, cells were
passaged into medium containing 0.4 or 0.75 mg/mL
geneticin G-418 sulfate (Life Technologies) and selected for
3 weeks before single-cell cloning. Expression efﬁciency of
single clones was screened by ﬂuorescence microscopy. For
the StARD3-GFPeoverexpressing cell line, single-cell
cloning was performed a second time to obtain higher
StARD3-GFP expression. Both stable cell lines were
maintained with 0.2 mg/mL geneticin G-418 sulfate. The
GFP control cell line was split twice a week at 1:3 and 1:6
ratios. The StARD3-GFP cell line was split once a week at
1:3 and 1:6 ratios, and medium was changed once between
splitting. To inhibit cholesterol synthesis, cells were treated
for 24 hours with 10 mmol/L lovastatin (Merck & Co, White
House Station, NJ) dissolved in dimethyl sulfoxide (Sigma-
Aldrich). Control samples were treated with dimethyl sulf-
oxide only.
Immunoblotting
Cell lysates for Western blot analysis were collected in dena-
turing lysis buffer containing 5 mmol/L EDTA and 1%SDS in
phosphate-buffered saline, with added protease inhibitors
[chymostatin, leupeptin, antipain, and pepstatin A (all from
Sigma-Aldrich) at a ﬁnal concentration of 25 mg/mL each]
and phosphatase inhibitors [activated Na-ortho-vanadate
(Sigma-Aldrich) at 2 mmol/L ﬁnal concentration and NaF
(Sigma-Aldrich) at 25 mmol/L ﬁnal concentration]. For
Western blot analysis, comparable amounts of cells were
collected in denaturing lysis buffer containing protease in-
hibitors and chymostatin, leupeptin, antipain, and pepstatin A.
Protein concentration was determined with the DC Protein
Assay from Bio-Rad Laboratories (Hercules, CA). Proteins
(20 mg of protein per lane) were separated by SDS-PAGE,
transferred to a nitrocellulose membrane, immunoblotted and
detected with an Odyssey infrared scanner from LI-COR
(Lincoln, NE) or, alternatively, with Amersham ECLWestern
Blotting Detection Reagents (RPN2106) on Amersham
Hyperﬁlm ECL (28-9068-36) from GE Healthcare Limited
(Buckinghamshire, UK). The resulting images were quantiﬁed
with ImageJ software version 1.48 (NIH, Bethesda, MD).18
Fluorescence Staining and Imaging of Cells
For imaging focal adhesions (FAs), cells were ﬁxed and per-
meabilized with methanol for 5 minutes at20C. Otherwise,
cells on coverslips were ﬁxed with 4% paraformaldehyde for
20 minutes at room temperature, and autoﬂuorescence was
quenched in 50 mmol/L ammonium chloride for 15 minutes at
room temperature. Forﬁlipin staining and permeabilization, the
cells were ﬁxed and stained with 0.05% ﬁlipin (F9765) from
Sigma-Aldrich in 10% fetal bovine serum in phosphate-
buffered saline for 30 minutes at 37C. Otherwise, cells were
permeabilized with 0.1% Triton X-100 (T8787) from Sigma-
Aldrich in phosphate-buffered saline for 5 minutes at room
temperature and blocked with 10% fetal bovine serum for 30
minutes at 37C. Primary and secondary antibody incubation
was performed sequentially. Red/green ﬂuorescence images
Figure 1 StAR-related lipid transfer protein 3e
green ﬂuorescent protein (StARD3-GFP) over-
expression in breast cancer MCF-7 cells results in
clustered growth of rounded-up cells without
increasing ErbB2 levels. A: Immunoblots of cell ly-
sates from control GFP and StARD3-GFPeexpressing
MCF-7 cell lines. Equal amounts of total protein were
separated by SDS-PAGE, transferred by Western blot
analysis, and detected by immunostaining with the
indicated antibodies (Abs). The anti-GFP antibody
detects a cross-reactive band (asterisk) close to the
StARD3 band (arrow). B: Fluorescence micrographs of
GFP and StARD3-GFP cells. Cells were ﬁxed with
paraformaldehyde, immunostainedwith antieLamp-1
antibodies, and imaged with a confocal microscope at
the focal plane withmost prominent Lamp-1 staining.
C: Micrographs of live cells. Phase-contrast and wide-
ﬁeld ﬂuorescence images. Arrowheads indicate a
strongly StARD3-GFPeexpressing, poorly adherent
cell cluster. D: Wide-ﬁeld ﬂuorescence and total in-
ternal reﬂection ﬂuorescence (TIRF) micrograph of a
StARD3-GFPeexpressing cell. Cells were ﬁxed with
PFA, stained with ﬁlipin, and imaged with a TIRF mi-
croscope for plasma membrane visualization. Scale
bars: 5 mm (B); 20 mm (C); 10 mm (D).
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were acquired with an Olympus AX70 microscope from
Olympus Corporation (Hamburg, Germany) equipped with an
Olympus DP71 charge-coupled device camera using 10 or
20 air objectives. Filipin (UV) images were acquired with the
same microscope and with an inverted Olympus microscope
with a Polychrome IV monochromator by TILL Photonics
(Gräfelﬁng, Germany) equipped with a TILL IMAGO-QE
camera using a 10 air objective. Confocal images were ac-
quiredwith a Leica TCS SP2AOBS confocal microscope from
Leica Microsystems (Mannheim, Germany) with a 63 oil
immersion objective. Total internal reﬂection ﬂuorescence
microscopy images were acquired with a Nikon Eclipse Ti-E
inverted microscope (Nikon Corporation, Kanagawa, Japan)
equipped with an argon laser and a 100 oil immersion
objective (numerical aperture, 1.49). The corresponding wide-
ﬁeld images of ﬁlipin and StARD3-GFP ﬂuorescence were
taken at a focal plane 1 mm above the total internal reﬂection
ﬂuorescence. Phase-contrast and green ﬂuorescent images of
live cells and ﬁxed cells were acquired with a Zeiss AxioVert
200 microscope from Carl Zeiss Jena (Jena, Germany)
equipped with a Zeiss AxioCam HRc color camera using
10 air objective. All quantiﬁcations were done with ImageJ
software version 1.48.18
Lipid Extraction and Quantiﬁcation
Lipids were extracted using the Bligh and Dyer method.19
Free cholesterol was resolved on a high performance thin
layer chromatography plate using hexane/diethyl ether/ace-
tic acid (80:20:1) as the mobile phase, visualized by char-
ring, and quantiﬁed as described previously.20
SLO Permeabilization
Streptolysin O (SLO) from Streptococcus pyogenes
(S0149), b-nicotinamide adenine dinucleotide, reduced
dipotassium salt (N4505), and sodium pyruvate (P2256)
were purchased from Sigma-Aldrich. SLO was dissolved in
deionized water to 50 U/mL, and stored at 70C. SLO
activation and membrane permeabilization were performed
Figure 2 StAR-related lipid transfer protein 3egreen ﬂuorescent protein (StARD3-GFP) overexpression results in increased plasma membrane cholesterol and 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) transcript levels. A: Filipin staining. Cells grown in full medium were ﬁxed with paraformaldehye, stained
with ﬁlipin, and imaged with a wide-ﬁeld ﬂuorescence microscope. B: Determination of cholesterol levels. Lipids were extracted, and the amount of free cholesterol
was analyzed biochemically. C: Analysis of HMGR transcript levels. Total RNA extracted from cells was reverse transcribed, and HMGR cDNAwas quantiﬁed by real-time
RT-PCR. D: Immunoblots of cell lysates. Equal protein amounts were separated by SDS-PAGE, transferred by Western blot analysis, and detected by immunostaining
with sterol regulatory element-binding protein 2 (SREBP-2) antibody. The approximately 130-kDa precursor and the approximately 66-kDamature form are indicated.
E: Quantiﬁcation of SREBP-2 precursor and mature form levels by densitometry. PZ 0.007 versus GFP control cell line for SREBP-2 mature form. F: Sensitivity of cells
to streptolysin O (SLO). Resistance of the plasmamembrane to SLO was measured as the fraction of total cellular lactate dehydrogenase (LDH) released to themedium
after 30minutes of treatment at 37C. Themeasurements at 0 U per well SLO were lower than the sensitivity of the assay and set to 0. Data represent means SEM for
content of cholesterol (ng) per protein (mg) (B); HMGR transcript levels normalized to control (MCF-7eGFP cells) (C); seven replicates per condition from two
independent experiments normalized to control GFP cells (E); two independent experiments (F). nZ 6 from two independent experiments (B); nZ 7 from three
independent experiments (C). *P < 0.05 versus GFP control cell line (Student’s t-test). Scale barZ 20 mm (A).
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as previously described.21 Brieﬂy, nonconﬂuent cells in 12-
well plates were washed and incubated in potassium acetate
buffer [115 mmol/L potassium acetate (Sigma-Aldrich) and
25 mmol/L HEPES (Amresco, Solon, OH)] for 30 minutes
at 37C. SLO was activated by adding dithiothreitol to a
ﬁnal concentration of 10 mmol/L and incubating for 30
minutes at 37C. The activated SLO was immediately added
to the cells at the indicated amounts and incubated for 30
minutes at 37C. The medium was collected, and the cells
were lysed with 0.1% Triton X-100 (Sigma-Aldrich) in
potassium acetate buffer. The decrease in absorbance at 340
nm, resulting from the oxidation of NADH on addition of
pyruvate to medium and cell lysate, was measured over 1
minute. The fraction of lactate dehydrogenase (LDH)
released to the medium after membrane permeabilization
was calculated as the ratio of LDH in the medium/sum of
LDH in the medium and in the cell lysate in each sample.
Patient Samples
A Finnish nationwide population-based breast cancer series
of primary tumors, FinProg, was collected as described pre-
viously.22 In brief, women diagnosed with breast cancer in
ﬁve well-deﬁned areas of Finland from 1991 to 1992 were
identiﬁed, and individual clinicopathological data were
collected from the hospital case records and tumor tissue
samples from the archives of the pathological departments.
Those patients whose StARD3 staining was noninformative
were excluded from the study. In total, 1325 of 2930 patients
were included in the study. In another study, FinHer,23
axillary nodeepositive or high-risk nodeenegative samples
were collected from 2000 to 2003 from women who had
undergone a breast surgery with auxiliary node dissection or
sentinel node biopsy for invasive breast carcinoma. Herein,
we included a total of 895 patients of the 1010 who partici-
pated in the study (approximately 40% of the eligible women
in Finland who received a diagnosis of breast cancer within
this period). Permission to use formalin-ﬁxed, parafﬁn-
embedded tissues for research purposes from the FinProg
study was provided as per local legislation by the Ministry of
Social Affairs and Health, Finland (permission 123/08/97).
An ethics committee at the Helsinki University Central
Hospital (Helsinki, Finland) approved the FinHer study and
the current study (permission HUS 125/13/03/02/2014).
Study participants provided written informed consent before
tissue sample collection or initiation of the study treatments.
Tissue microarrays were constructed as described earlier.22
Tissue microarray sections (5 mm thick) were cut on Super-
Frostþ slides from Menzel-Gläser (Braunschweig, Germany),
deparafﬁnized in xylene, and rehydrated through a decreasing
alcohol gradient. Endogenous peroxidase activity was blocked
with 1% hydrogen peroxide. Antigen retrieval for Src-Tyr416
was performed in 10 mmol/L sodium citrate (pH 6.0) using
an autoclave at 120C for 2 minutes. Antigen retrieval for
StARD3 was performed in Tris-EDTA (10 mmol/L Tris-Base
and 1 mmol/L EDTA, pH 9.0) in a water bath at 98C for 20
Figure 3 Removal of serum and insulin from
the growth medium increases the adherence of
StAR-related lipid transfer protein 3 (StARD3)e
overexpressing cells. A: Micrographs of cells grown
in the presence or absence of serum and insulin.
Phase-contrast images of green ﬂuorescent pro-
tein (GFP) and StARD3-GFP cells deprived of serum
and insulin for 0, 5, or 24 hours and ﬁxed with
paraformaldehyde. B: Immunoblots of cell lysates.
Representative blots of GFP (StARD3-) and
StARD3-GFP (StARD3þ) cells grown in full medium
(þserum, þinsulin) or deprived of serum and in-
sulin (serum, insulin) for 24 hours. Equal
amounts of total protein were separated by SDS-
PAGE, transferred by Western blot analysis, and
detected with anti-StARD3, anti-Src, or anti-actin
antibodies (Abs). C: Quantiﬁcation of StARD3
levels by densitometry. D: Quantiﬁcation of Src
levels by densitometry. Data represent
means  SEM for six replicates per condition from
three independent experiments normalized to
control (GFP cells, þserum, þinsulin) (C) or six
replicates per condition from three independent
experiments normalized to control (GFP control
cells, þserum, þinsulin) (D). *P < 0.05 cells in
eserum, einsulin versus complete medium (Stu-
dent’s t-test); yP < 0.05 versus GFP control cell
line (Student’s t-test). Scale bar Z 40 mm.
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minutes. Binding of the primary antibody was detected with a
PowerVisionþ Poly-HRP Histostaining Kit from Immuno-
Vision Technologies (Norwell, MA), following the manufac-
turer’s recommendations. For both StARD3 and Src,
cytoplasmic staining intensity was graded as negative, low, or
high when at least 10% of the tumor cells showed protein
expression (as is standard in the ﬁeld). Nuclear staining was not
considered relevant for this study. Example images of stained
tissue were taken with a Leica DM LB microscope (Leica
Microsystems) with an N Plan 20 objective, equipped with an
Olympus DP50 color camera (Olympus Corporation).
For ErbB2 (HER-2) staining in the FinProg series, the sec-
tions were deparafﬁnized, followed by antigen retrieval (auto-
clave treatment at 121C for 2 minutes in 10 mmol/L sodium
citrate buffer, pH 6.0). The primary antibody, CB11 from
Novocastra Laboratories (Newcastle upon Tyne, UK), was
diluted 1:200 in Powervision blocking solution from Immu-
novision Inc. (Daly City, CA) and incubated overnight at 4C.
An antimouse-peroxidase polymer from Powervision (30 mi-
nutes at room temperature) and diaminobenzidine chromogen
were used for visualization. The sections were counterstained
with hematoxylin and embedded. Positive and negative control
samples (tumors with and without HER2 ampliﬁcation in
ﬂuorescence in situ hybridization) were included in every
staining batch. Evaluation of immunohistochemistry was done
using a 20 objective. ErbB2 immunoreactivity was scored as
negative, low, intermediate, or high, and only high (3þ like)
staining was considered as ErB2 positive.22 In the FinHer se-
ries, ErbB2 protein expression was analyzed centrally using the
HercepTest, as described elsewhere.24
Immunostaining for estrogen receptors was done on adjacent
tissue array sections using the monoclonal antibody 6F11
(Novocastra Laboratories; dilution, 1:500) and for progesterone
receptors using the antibody 312 (Novocastra Laboratories;
dilution, 1:500). Immunostaining was considered as positive
when >10% of cancer cells showed staining. The p53 was
immunostained with the DO7 antibody (Novocastra Labora-
tories) at a dilution of 1:500 and Ki-67 using the MM-1 anti-
body (Novocastra Laboratories; dilution, 1:1000). Ki-67 and
p53 stainingwere classiﬁed into three categories: i) negative (no
positively staining cancer cell nuclei found), ii) borderline
(20% nuclei positive), or iii) positive (>20% of cancer cell
nuclei stained). Because there was no signiﬁcant difference in
outcome between patients who had either negative or borderline
staining, these groups were combined in further analyses.
Quantitative Real-Time RT-PCR
Cells were homogenized in RLT buffer from QIAGEN Sci-
ences (Gaithersburg, MD), and total RNAwas isolated with the
RNeasy Mini Kit (74104) from QIAGEN Sciences, according
to the manufacturer’s instructions. The total RNA (1 mg) was
reverse transcribed, as previously described.25 3-Hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGR) cDNA was
quantiﬁed using LightCycler 480 Probe 85 (04689097001)
from Roche Diagnostics (Basel, Germany). TATAA binding
Figure 4 StAR-related lipid transfer protein 3 (StARD3) over-
expression causes an increase in focal adhesion size and increased
phosphorylation of focal adhesion kinase (FAK) in the absence of serum
and insulin. A: FAK staining in the absence of serum and insulin. Cells
were deprived of serum and insulin for 24 hours, ﬁxed with methanol,
immunostained with anti-FAK antibodies (Abs), and imaged with a
confocal microscope at the basal plane, which has the most prominent
FAK staining. B: Quantiﬁcation of focal adhesion size from ﬂuorescence
micrographs. The size of FAK-stained patches was analyzed from mi-
crographs (10 cells for each condition). Box plot shows focal adhesion
size in mm2. Green ﬂuorescent protein (GFP) cells: median Z 0.55, n Z
83; StARD3-GFP cells: median Z 1.10, n Z 77. C: Immunoblotting of
FAK and pFAK-Tyr397 in the presence or absence of serum and insulin.
Equal amounts of protein were separated by SDS-PAGE and analyzed by
immunoblotting with the indicated antibodies. D: Quantiﬁcation of FAK
and pFAK-Tyr397 signals from immunoblots. Blots from three indepen-
dent experiments were quantiﬁed by densitometry. Signals were
normalized to the signal from control (GFP-overexpressing) cells in full
growth medium (þserum, þinsulin). Data represent means  SEM. n Z 10
(GFP cells); nZ 8 (StARD3-GFP cells). *P < 0.05 (Student’s t-test), ****P <
0.0001 (Mann-Whitney-Wilcoxon test) versus GFP control cell line; yP < 0.05
for eserum, einsulin versus full serum conditions (Student’s t-test). Scale
bar Z 5 mm.
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box protein was used as an internal control for normalization.
Human adrenal tissue was used as a positive control for the cell
and breast cancer tissue samples, and RNA and cDNA were
generated as for cells. Each sample was run in triplicate.
Normalized gene expression values were obtained using
LightCycler 480 software version 1.5.1 from Roche Applied
Science (Mannheim, Germany), using the basic relative quan-
tiﬁcation method. The analysis of the patient samples was done
identically, but RNA was extracted by using the Versant kPCR
Molecular System (Siemens AG, Erlangen, Germany) and
normalized gene expression values were obtained using the
LightCycler advanced quantiﬁcation method, as described in
detail previously.26 Adrenal tissue RNA served as a calibrator
sample and was used to construct the standard curves for the
target and the reference genes.
Statistical Analysis
All data assumed to have a normal distribution were repre-
sented as bar charts, with the height of the bar representing
the mean and the error bar representing the SEM. Tests of the
statistical signiﬁcance of normally distributed values were
performed using a nonpaired two-tailed Student’s t-test.
Continuous distributions of nonnormally distributed values
were summarized in box-and-whiskers plots, with the bottom
and top of the box representing the ﬁrst and third quartiles,
respectively, and the band inside the box representing the
median. The ends of the whiskers represent the lowest datum
still within 1.5 times the interquartile range of the lower
quartile, and highest datum still within 1.5 times the inter-
quartile range of the upper quartile. Data points outside of
these ranges were not included in the box plots. For non-
normally distributed values, statistical signiﬁcance was
calculated using the Mann-Whitney-Wilcoxon rank sum test.
Statistical signiﬁcance for frequency tables was calculated
using the c2 test.
An analysis of breast cancerespeciﬁc survival was
available for the patients included in the FinProg series, and
was calculated from the date of breast cancer diagnosis to
death from breast cancer, censoring patients who were alive
on the date of the last follow-up and those who died from a
competing cause on the date of death. In the FinHer series,
Figure 5 Effects of StAR-related lipid transfer protein 3 (StARD3) overexpression on cholesterol balance in serum- and insulin-deprived conditions. A: Filipin
staining of cells deprived of serum and insulin for 24 hours. Cells were ﬁxed with paraformaldehyde, stained with ﬁlipin, and imaged by wide-ﬁeld ﬂuorescence
microscopy. Please note higher ﬁlipin intensity in cells with prominent StARD3egreen ﬂuorescent protein (GFP) expression. B: Fluorescence intensity quan-
tiﬁcation from cells deprived of serum and insulin. GFP and StARD3-GFP cells were deprived of serum and insulin for 5 or 24 hours, ﬁxed, stained with ﬁlipin, and
imaged as in A, using the same settings for all conditions. The total ﬁlipin ﬂuorescence intensity per cell was measured for 30 to 40 cells per condition and
normalized to control cells deprived of serum and insulin for 5 hours. C: Total cholesterol content in cells deprived of serum and insulin. GFP and StARD3-GFP cells
were deprived of serum and insulin in the presence or absence of lovastatin for 24 hours before lipid analysis. D: Sensitivity of cells to streptolysin O (SLO)
permeabilization on serum and insulin deprivation for 0, 24, or 48 hours. Resistance of the plasma membrane to SLO was measured as the fraction of total cellular
lactate dehydrogenase (LDH) released to the medium after 30 minutes of treatment at 37C. E: Sensitivity of cells to SLO permeabilization on serum and insulin
deprivation for 24 hours in the presence or absence of lovastatin.D: Values in the presence of lovastatin were normalized to the values in the absence of lovastatin
at 24 hours of serum and insulin deprivation. Data represent means  SEM (B); data represent means  SEM of cholesterol (ng) per protein (mg) (C); data
represent means  SD of triplicate measurements (D). nZ 6 to 10 from three independent experiments, cholesterol amounts normalized to GFP control within
each experiment (average of controls, 15.51 ng cholesterol/mg protein) (C). *P < 0.05 (Student’s t-test). Scale barZ 20 mm.
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overall survival was calculated from the date of randomi-
zation to the date of death, censoring patients who were
alive on the date of the last follow-up visit. Survival be-
tween groups was calculated using the log-rank test. The P
values are two sided.
Results
Stable Overexpression of StARD3 in MCF-7 Cells Alters
Cell Morphological Features
Toaddress the role ofStARD3protein in breast cancer cells and
tissues, we generated polyclonal rabbit antibodies against the
START domain of human StARD3. The afﬁnity-puriﬁed an-
tibodies were speciﬁc for StARD3 because the immunoreac-
tivity was signiﬁcantly reduced on transient StARD3 silencing
fromKPL-4 and BT-474 cells, both of which express StARD3
and ErbB2 at relatively high levels27 (Supplemental Figure S1,
AeD). Furthermore, we found that knockdown of StARD3 in
BT-474 cells decreased cell survival (Supplemental Figure S1,
E and F). As expected, ErbB2 silencing also decreased cell
survival (Supplemental FigureS1,EandF).Theseobservations
suggest that both ErbB2 and StARD3 promote the survival
of breast cancer cells, and are in agreement with earlier
ﬁndings.4
To gain insights into how StARD3 may promote cell
survival independently of HER2 ampliﬁcation, we generated
MCF-7 (HER2-negative) breast cancer cells that stably
overexpress StARD3-GFP or soluble GFP as a control.
Overexpression of StARD3-GFP and GFP proteins was
veriﬁed by Western blot analysis from cell lysates
(Figure 1A). Immunoblotting also revealed that the ErbB2
protein levels were not increased on StARD3-GFP over-
expression (Figure 1A). Thus, in this cell line, the effects of
StARD3 overexpression can be addressed in the absence of
HER2 overexpression. Confocal microscopy showed that
control GFP expression alone was cytosolic, as expected
(Figure 1B), and that the overexpressed StARD3-GFP
protein exhibited a punctate distribution, colocalizing, in
part, with the late endosomal marker, Lamp-1 (Figure 1B).
Figure 6 High StAR-related lipid transfer protein 3 (StARD3) protein levels in breast cancer correlate with increased 3-hydroxy-3-methylglutaryl-coenzyme
A reductase (HMGR) mRNA levels and decreased patient survival. A: StARD3 immunohistochemistry of primary breast cancers. Top three panels: Exemplary
micrographs of negative, low, or high StARD3 levels. Bottom panel: a close-up of the indicated area from high expression level. B: HMGR mRNA levels in
tumors with negative or high StARD3 expression. Total RNA extracted from cells was reverse transcribed, and HMGR cDNA was quantiﬁed by real-time RT-PCR.
Bars represent HMGR transcript levels and are normalized using HMGR levels in control tissue (adrenal cortex). Box plots: StARD3-negative samples (nZ 31,
medianZ 1.12) and high StARD3 samples (nZ 38, medianZ 1.42). PZ 0.048 (Mann-Whitney-Wilcoxon test). Outliers, as deﬁned in Materials and Methods,
are not shown on the plot. C: Kaplan-Meier analysis for breast cancerespeciﬁc survival of patients in FinProg cohort with negative, low, or high StARD3 protein
levels and Kaplan-Meier analysis for end point overall survival of patients with StARD3 protein levels available in FinHer cohort. Negative, low, or high StARD3
expression. P Z 0.007 (log-rank test) when all three categories are included. ****P < 0.0001 (log-rank test) when all three categories are included. Scale
bar Z 100 mm (A); 25 mm (bottom panel, A).
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In addition, some of the StARD3-GFP localized to the
plasma membrane, as suggested by the prominent surface
ﬂuorescence observed in a fraction of cells (Figure 1,
C and D). Total internal reﬂection ﬂuorescence micro-
scopy revealed a punctate pattern of StARD3-GFP ﬂuo-
rescence in the plasma membrane plane, reﬂective of plasma
membrane domains and/or small vesicles immediately un-
derneath. These results are in accordance with our previous
observations on StARD3 subcellular localization.14
Remarkably, the overall morphological features of the
StARD3-GFPeoverexpressing cells were strikingly different
from those of control GFP cells. The StARD3-GFP cells grew
in clusters of rounded-up cells that did not adhere well to the
substratum and lacked growth contact inhibition, as demon-
strated by phase-contrast and GFP-ﬂuorescence images of
living cells (Figure 1C). Such growth pattern is often charac-
teristic of malignant cells.
StARD3 Overexpression Results in Altered Cellular
Cholesterol Balance
To study whether the overexpression of StARD3-GFP af-
fects cellular cholesterol homeostasis, we stained StARD3-
GFPe and GFP-expressing cells with ﬁlipin, a ﬂuorescent
sterol-binding compound that stains cholesterol (and other
sterols with a 3-carbon OH-group) in cells.28We found that
StARD3-GFP cell clusters showed increased ﬁlipin in-
tensity, especially in the plasma membrane, as compared to
control cells (Figure 2A). This suggests the possibility that
the cholesterol content of StARD3-overexpressing cells
may be elevated. However, on the basis of biochemical
cholesterol determination, the amount of total cellular-free
cholesterol in StARD3-GFP cells was not increased, but
rather slightly decreased, as compared to control cells
(Figure 2B). Therefore, the increased ﬁlipin staining in-
tensity in StARD3-overexpressing cells more likely reﬂects
an altered cellular cholesterol distribution. This idea was
corroborated by the ﬁnding that the level of HMGR mRNA
was increased in StARD3-overexpressing cells (Figure 2C).
HMGR, the rate-limiting enzyme of cholesterol biosyn-
thesis, is located in the ER and known to be up-regulated on
ER cholesterol depletion.29 To further study if the ER
of StARD3-overexpressing cells is cholesterol poor,
we analyzed the levels and processing of the key tran-
scriptional regulator of cholesterol metabolism, sterol
regulatory element-binding protein 2. Under ER cholesterol
depletion, sterol regulatory element-binding protein 2 is
increased and its processing to the mature, transcriptionally
active form is enhanced. We found this to be the case in
StARD3-GFPeoverexpressing cells compared to control
cells (Figure 2, D and E). Thus, in StARD3-overexpressing
cells, the ER appeared to be cholesterol poor and cholesterol
synthesis elevated.
To investigate whether the plasma membrane cholesterol
content was altered on StARD3 overexpression, we
measured the resistance of the cells to SLO. This sterol-
binding bacterial toxin forms pores in cholesterol-rich plasma
membrane regions.30 The fraction of cytosolic LDH activity
released from cells is used as a measure of membrane per-
meabilization and, indirectly, as a measure for membrane
cholesterol content. As expected, in both GFP- and
StARD3-GFPeoverexpressing cells, SLO induced the
release of LDH from cells (Figure 2F). More important,
LDH release from StARD3-GFPeoverexpressing cells was
higher than that from GFP-expressing cells (1.16-fold;
average normalized to GFP control in both SLO concen-
trations, SD Z 0.076). This strongly suggests that the
plasma membrane cholesterol content of StARD3-
overexpressing cells is higher than that of control cells.
Together, these results provide evidence that StARD3
overexpression leads to alterations in cellular cholesterol
distribution and homeostatic control, with increased plasma
membrane cholesterol but decreased ER cholesterol.
The Effects of StARD3 Overexpression on Cell
Morphological Features Are Serum and Insulin
Dependent
While studying the morphological effects of StARD3-GFP
overexpression, we noticed a striking phenotypic change in
StARD3-GFP cells when serum and insulin were deprived
from the culture medium. Already within 5 hours after
the removal of these growth stimuli, more than half of the
StARD3-overexpressing cells became clearly more adherent
(Figure 3A). In 24 hours, most of the StARD3-GFP cells
had adhered tightly to the substratum and their morpho-
logical appearance was more closely reminiscent of that of
control GFP cells (Figure 3A). In contrast, serum and in-
sulin withdrawal had no apparent effects on the morpho-
logical features of the GFP cells within this time frame
(Figure 3A). This change in the morphological features of
StARD3-overexpressing cells did not result from reduced
StARD3-GFP protein levels on serum and insulin depriva-
tion, as evidenced by Western blot analysis (Figure 3B). In
fact, the StARD3-GFP protein levels increased under these
conditions (Figure 3, B and C), probably because of
increased protein stability, considering that the StARD3-
GFP expression was under a viral promoter. Because the
proto-oncogene Src is a key regulator of cell adhesion and
implicated in breast cancer development,31 we analyzed
its levels. This showed that Src levels were moderately
Table 1 Summary of StARD3 Immunoreactivity in the Analyzed
Patient Cohorts, with Number of Tumors and Distribution of
StARD3 Intensity
Study
StARD3 overexpression (%)
Negative Low High
FinProg (n Z 1325) 598 (45.1) 607 (45.8) 120 (9.1)
FinHer (n Z 895) 507 (56.6) 296 (33.1) 92 (10.3)
StARD3, StAR-related lipid transfer protein 3.
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elevated in StARD3-overexpressing cells in complete me-
dium conditions relative to control cells and stayed high in
both control and StARD3-overexpressing cells when serum
and insulin were removed (Figure 3D).
StARD3-Overexpressing Cells Exhibit Altered FAs and FA
Signaling in Serum- and Insulin-Deprived Conditions
To further investigate the molecular basis for the differences
in the adherence between GFP and StARD3-GFP cells, we
imaged cellular FAs. The StARD3-overexpressing cells
were largely rounded up and depleted of FAs in complete
medium (Figures 1C and 3A). However, these cells devel-
oped prominent, irregularly shaped adhesions under serum
and insulin deprivation, as revealed by anti-FAK antibody
staining (Figure 4A). Quantiﬁcation of the area occupied by
antibody staining showed that the mean area of FAs was
roughly doubled and the variability in FA size was increased
on StARD3 overexpression (Figure 4B). Considering that
FAK is a key substrate of Src kinase, we analyzed the levels
and phosphorylation status of FAK by immunoblotting.
This showed that in control cells, there was no substantial
difference in FAK protein levels or phosphorylation at
Tyr397 on serum and insulin withdrawal (Figure 4, C and
D). Although there was a tendency for increased FAK
signal, the level and degree of Tyr397 phosphorylation of
FAK were not signiﬁcantly different between control and
StARD3-overexpressing cells in complete medium. How-
ever, on serum and insulin removal, both the total levels of
FAK and its phosphorylation at Tyr397 were signiﬁcantly
increased in StARD3-overexpressing cells compared to
control cells (Figure 4, C and D). These results suggest that
altered signaling at FAs contributes to the improved
adherence of StARD3-overexpressing cells on removal of
the growth stimuli.
StARD3-Overexpressing Cells Maintain Increased
Cellular and Plasma Membrane Cholesterol Content in
Serum- and Insulin-Deprived Conditions
Considering that StARD3 overexpression altered the plasma
membrane cholesterol content and that this is known to affect
cell adhesion,32 we investigated how serum and insulin
deprivation affected the plasma membrane cholesterol con-
tent in control and StARD3-overexpressing cells. The cells
were incubated for 5 or 24 hours in the absence of these
growth stimuli and stained with ﬁlipin, and the ﬂuorescence
intensity of individual adherent cells was analyzed. This was
considerably easier to perform now that the StARD3 cells
were no longer in rounded-up clusters and the cell boundaries
were better visualized.
We found that cells overexpressing StARD3-GFP at high
levels showed a robust increase in ﬁlipin intensity compared
to control GFP cells or cells that overexpressed StARD3-
GFP at more moderate levels (Figure 5, A and B). This
effect was evident both at 5 and 24 hours of serum and
insulin deprivation (Figure 5B). Moreover, although the
ﬁlipin intensity of control GFP cells decreased from 5 to 24
hours, that of StARD3-GFP cells did not (Figure 5B). These
results suggest that the plasma membrane cholesterol content
of control cells decreased when they were serum deprived, in
Table 2 Association of StARD3 Immunoreactivity with
Histopathological Parameters in FinProg Material
Parameter
StARD3 overexpression (%)
Negative Low High
ErbB2 immunostaining
Negative 503 (93.5) 445 (82.7) 27 (23.1)
Positive 35 (6.5) 93 (17.3) 90 (76.9)
ERBB2-CISH
Negative 491 (92.8) 437 (82.1) 20 (17.4)
Positive 38 (7.2) 95 (17.9) 95 (82.6)
Molecular subtype
Luminal A 377 (75.6) 344 (69.4) 14 (13.7)
Luminal B 23 (4.6) 50 (10.1) 34 (33.3)
HER2þ/HR 12 (2.4) 40 (8.1) 48 (47.1)
Basal-like 60 (12.0) 35 (7.1) 1 (1.0)
Nonexpressor 27 (5.4) 27 (5.4) 5 (4.9)
pSrc
Negative 504 (90.8) 422 (76.6) 85 (73.9)
Positive 51 (9.2) 129 (23.4) 30 (26.1)
Estrogen receptor
Negative (<20%) 155 (29.1) 159 (29.7) 66 (60.0)
Positive (>20%) 377 (70.9) 376 (70.3) 44 (40.0)
p53
Negative (<20%) 420 (84.5) 383 (80.3) 63 (61.8)
Positive (>20%) 77 (15.5) 94 (19.7) 39 (38.2)
PgR
Negative (<20%) 226 (41.9) 234 (44.3) 84 (76.4)
Positive (>20%) 313 (58.1) 294 (55.7) 26 (23.6)
Ki-67
Negative (<20%) 341 (68.2) 309 (60.8) 38 (38.4)
Positive (>20%) 159 (31.8) 199 (39.2) 61 (61.6)
Tumor size distribution*
Min 1 (0.6) 3 (2.5)
Max 140 (87.0) 90 (76.3)
Median 20 (12.4) 25 (21.2)
Age distribution*
Min 23 (12.9) 27 (15.9)
Max 96 (53.9) 90 (52.9)
Median 59 (33.1) 53 (31.2)
Nodal metastases (P Z 0.014)
No 384 (65.4) 368 (62.5) 61 (51.3)
Yes 203 (34.6) 221 (37.5) 58 (48.7)
Histological features
Ductal 433 (72.4) 470 (77.4) 102 (85.0)
Lobular 121 (20.2) 69 (11.4) 8 (6.7)
Other 44 (7.4) 68 (11.2) 10 (8.3)
Grade
I 118 (27.1) 108 (23.5) 6 (6.1)
II 212 (48.7) 211 (46.0) 53 (53.5)
III 105 (24.1) 140 (30.5) 40 (40.4)
P < 0.0001, in all parameters except nodal metastases; Mann-Whitney
test for statistical signiﬁcance was used for tumor size and age
distributions.
*StARD3 columns negative and low combined.
CISH, chromogenic in situ hybridization; HR, hormone receptor; Max,
maximum; Min, minimum; PgR, progesterone receptor; StARD3, StAR-
related lipid transfer protein 3.
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accordance with the notion that serum lipoproteins are a major
source of cellular membrane cholesterol. In contrast, the
StARD3-GFP cells seemed to be capable of maintaining
elevated plasma membrane cholesterol levels in the absence of
serum and insulin.
Biochemical cholesterol determinations showed that serum-
and insulin-starved StARD3-GFP cells maintained an elevated
cholesterol content compared to control GFP cells (Figure 5C).
To test if this was due to increased cholesterol synthesis, we
treated the cells with lovastatin, an inhibitor of HMGR, during
the 24-hour serum and insulin deprivation. Statin treatment
abolished the capability of StARD3-GFP cells to elevate their
cholesterol content (Figure 5C), implying that increased
cholesterol synthesis accounted for the elevated cholesterol
levels in StARD3-GFPeexpressing cells. Moreover, the
plasma membrane cholesterol amounts of StARD3-GFP cells
were higher than those of control cells after 24 to 48 hours of
serum and insulin deprivation, as assessed by sensitivity to
SLO permeabilization (Figure 5D). This was also repressed by
statin, as expected (Figure 5E).
High StARD3 Protein Levels in Human Breast Tumor
Samples Associate with ERBB2 Ampliﬁcation,
Cholesterol Imbalance, and Src Activation
To investigate StARD3 protein expression in Finnish breast
cancer patients, we performed immunohistochemical stain-
ing of 1325 primary breast cancer samples deriving from the
FinProg cohort22 using our anti-StARD3 afﬁnity-puriﬁed
antibody. The StARD3 staining intensity was graded as
negative, low, or high (Figure 6A). Stromal cells were not
stained, and normal epithelial cells showed negative or low
staining. In cells with high staining intensity, the staining
exhibited a perinuclear, dot-like staining pattern, with nuclei
devoid of staining (Figure 6A). These observations are in
concordance with previous results.8,33 We found that 120
(9.1%) of the samples exhibited high StARD3 staining, 607
(45.8%) showed low StARD3 staining, and 598 (45.1%)
were negative (Table 1). High StARD3 immunoreactivity
was associated with ErbB2 immunoreactivity and HER2
ampliﬁcation, and several factors related to a poor disease
outcome, such as high proliferation rate, bigger tumor size,
and nodal metastases at the time of diagnosis, as well as es-
trogen and progesterone receptor negativity and p53 protein
expression (Table 2). Considering that our in vitro data
suggested high StARD3 expression to be associated with
increased Src-FAK signaling, we also analyzed the tumor
samples by anti-Src Tyr416 (pSrc) staining, which provides a
measure of Src activation. We found that in the FinProg
material, 1011 (82.8%) of the samples scored as negative and
210 (17.2%) positive for pSrc staining, and that positive Src
phosphorylation associated with high StARD3 protein
expression (Table 2).
To address StARD3 and pSrc immunoreactivity in an
independent patient cohort, we analyzed 895 primary breast
cancer tissue specimen from the FinHer study.23 We found
that 92 (10.3%) of these samples exhibited high StARD3
staining, 296 (33.1%) showed low StARD3 staining, and
507 (56.6%) were negative (Table 1). For pSrc, 485 (56.1%)
of the FinHer samples were negative, and 380 (43.9%) were
positive. In this cohort, high StARD3 immunostaining was
strongly associated with HER2 gene ampliﬁcation, ErbB2
immunoreactivity, and pSrc positivity, as well as hormone
receptor negativity and p53 expression (Table 3). From a
subset of the FinHer material, RNA was available and we
could analyze HMGR mRNA levels. The subset consisted
of 38 primary breast tumors scored as highly StARD3
positive and 31 tumors that were scored StARD3 negative
by immunostaining. The analysis showed that the highest
HMGR transcript levels were found in the highly StARD3-
positive tumors (Figure 6B). Together, these ﬁndings suggest
that elevated StARD3 protein expression was accompanied by
increased cholesterol synthesis and Src activation in human
breast cancers. Finally, our analyses showed that high StARD3
protein level was strongly associated with decreased cumula-
tive patient survival in both FinProg (P < 0.0001) and FinHer
(PZ 0.007) cohorts (Figure 6C).
Discussion
This study was conducted to address how elevated StARD3
protein expression affects breast cancer cells and to delin-
eate parameters characteristic of primary human breast
cancers that exhibit high StARD3 protein content. This is of
interest because StARD3 has been shown to be coampliﬁed
and co-overexpressed as part of the HER2/ERBB2 17q12
amplicon in a subset of breast cancers.4,17,33e35 Moreover,
anti-ErbB2 antibody therapy is widely used in the clinical
Table 3 Association of StARD3 Immunoreactivity with Histo-
pathological Parameters in FinHer Material
Parameter
StARD3 overexpression (%)
Negative Low High
HercepTest
0 or 1þ 473 (96.7) 168 (58.1) 3 (3.3)
2þ 12 (2.5) 73 (25.3) 26 (28.6)
3þ 4 (0.8) 48 (16.6) 62 (68.1)
ERBB2-CISH
Negative 483 (95.3) 199 (67.2) 9 (9.8)
Positive 24 (4.7) 97 (32.8) 83 (90.2)
pSrc
Negative 361 (64.3) 105 (47.3) 19 (23.2)
Positive 200 (35.7) 117 (52.7) 63 (76.8)
Estrogen receptor
Negative (<20%) 110 (21.7) 85 (28.7) 58 (63.0)
Positive (>20%) 397 (78.3) 211 (71.3) 34 (37.0)
p53
Negative (<20%) 379 (79.1) 209 (72.6) 46 (51.1)
Positive (>20%) 100 (20.9) 79 (27.4) 44 (48.9)
P < 0.0001 in all cases.
CISH, chromogenic in situ hybridization; StARD3, StAR-related lipid
transfer protein 3.
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setting, yet 50% or even more of ErbB2-positive patients
show no response, or become resistant to the treatment.36 It
has been proposed that some of the coampliﬁed gene
products may contribute to cancer progression.3,4,7 StARD3
is an attractive candidate for such a modulator, because as
earlier data and our current results in two Finnish patient
cohorts indicate, the gene is practically invariably coam-
pliﬁed and the protein co-overexpressed with ErbB2 in
HER2-positive breast cancers.
StARD3 is a cholesterol-binding protein with a 1:1 stoi-
chiometry10 and has been shown to affect intracellular
membrane and cholesterol transport.11,14,15 Cancers,
including breast cancer, have been associated with alterations
in cholesterol metabolism,37 with both cholesterol and its
metabolites being capable of deregulating breast cancer
cells.38 Cancer cells require a continued supply of cholesterol
for membrane biogenesis, to support cell growth and divi-
sion. In addition, cholesterol plays an important role in
organizing cholesterol-sphingolipiderich membrane do-
mains, lipid rafts, that are involved (e.g., in cell signaling and
adhesion).39 Alterations in the plasma membrane cholesterol
content affect cell signaling, adhesion, and motility.40e42
These processes are fundamental to the survival and
growth of cancer cells as well as their ability to metastasize.
To dissect the potential ErbB2-independent role of
elevated StARD3 protein content in breast cancer cells, we
generated MCF-7 cells overexpressing StARD3. On the
basis of our results, overexpressing StARD3 caused several
alterations in cellular cholesterol homeostasis that are
potentially cancer promoting. The StARD3-overexpressing
cells had increased levels of the mRNA encoding the rate-
limiting cholesterol biosynthesis enzyme HMGR. Increased
cholesterol biosynthesis allows cells to survive and to keep
dividing, especially in low nutrient conditions, where
membrane biogenesis is normally limited. In addition, the
StARD3-overexpressing cells exhibited increased plasma
membrane cholesterol levels. Moreover, the cholesterol
content of StARD3-overexpressing cells was refractory to
the withdrawal of the exogenous cholesterol source (ie,
serum lipoproteins). Compared to control cells, the
StARD3-overexpressing cells managed to maintain elevated
total and plasma membrane cholesterol levels in the absence
of serum due to the up-regulated cholesterol biosynthesis.
The sterol-binding compounds used, ﬁlipin and SLO, also
bind cholesterol precursor sterols that are up-regulated
during cholesterol biogenesis. Thus, these may contribute
to the increased sterol content.
A high plasma membrane cholesterol level supports raft-
dependent signaling via lipid-anchored proteins, such as Src
family kinases. This, in turn, alters the adhesive properties
of cells.43 Indeed, we observed that StARD3 overexpression
affected cell adherence: the cells were globular and loosely
attached to the substratum in the presence of serum and
insulin, but became adhesive on their withdrawal. Consis-
tently, the cells displayed exaggerated FAs and increased
phosphorylation of FAK, a major Src substrate. It could be
envisioned how such alterations in cell morphological fea-
tures might, on one hand, favor shedding of cancer cells to
the bloodstream and, on the other hand, allow cells to adhere
tightly to the underlying tissue and endure limited nutrient
conditions within a solid tumor.
There are several mechanisms by which StARD3 could
increase plasma membrane cholesterol. First, the newly
synthesized StARD3 protein moves to the LEs via the
plasma membrane.16 Increased StARD3 production is likely
to increase the amount of StARD3 in the plasma membrane,
where it may enhance cholesterol deposition similarly as we
have shown for LEs.14 Second, increased cholesterol in
StARD3-containing LEs may become transported to the
plasma membrane. The LEs communicate actively with the
plasma membrane, and we have recently demonstrated that
LEetoeplasma membrane cholesterol transport is an
important regulator of cell migration.42 Finally, newly
synthesized cholesterol is efﬁciently delivered from the ER
to the plasma membrane.44 Thus, increased cholesterol
biosynthetic activity observed in StARD3-overexpressing
cells probably also facilitates plasma membrane choles-
terol enrichment.
In two large nationwide cohorts, FinProg and FinHer,
with a total of >2000 breast cancer patients, we observed
that HER2 gene ampliﬁcation and ErB2 immunoreactivity
were tightly associated with high StARD3 protein expres-
sion. This subgroup of highly StARD3-positive tumors was
composed of approximately 1 of 10 patients in both cohorts.
In fact, we could not identify patients who would have high
StARD3 immunoreactivity without HER2 ampliﬁcation.
Hence, we cannot make statements about the speciﬁc role of
high StARD3 expression alone in the clinical setting.
Nevertheless, we found that high StARD3 protein levels
correlated with elevated HMGR mRNA levels in the FinHer
cohort, in accordance with the in vitro cell data. Moreover,
high StARD3 protein levels associated with high levels of
Src phosphorylation on the activating Tyr416 in both Fin-
Prog and FinHer cohorts. This, together with the cell data
that show increased Src, elevated phosphorylation of the
downstream kinase FAK, and enlarged FAs on StARD3
overexpression in the absence of HER2 ampliﬁcation; these
ﬁndings ﬁt with the idea that high StARD3 protein levels
promote Src signaling.
More important, Src activation appears as a key contrib-
utor to trastuzumab resistance in HER2-positive can-
cers,45,46 because patients with active Src were found to be
signiﬁcantly less responsive to trastuzumab than those
without Src activation. Although ErbB2 itself is linked to
Src activation, other candidates in the HER2 amplicon have
not, to our knowledge, been directly implicated in this
process. Our study provides evidence that elevated StARD3
expression is linked to increased Src activity and points to
the possibility that StARD3 may contribute to the aggres-
sive behavior of trastuzumab-resistant tumors. Therefore, it
would be warranted to investigate if repression of StARD3
activity (e.g., by using small-molecule inhibitors) might be
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useful in HER2-positive cancers and could be used to
combat trastuzumab resistance.
In conclusion, we show that overexpression of STARD3,
a gene coampliﬁed with HER2, results in increased levels of
plasma membrane cholesterol and Src, altered adhesiveness,
and FAK signaling in HER2-negative breast cancer cells
in vitro. These ﬁndings suggest that elevated StARD3
expression has a potential to contribute to breast cancer cell
aggressiveness, by increasing membrane cholesterol and
thereby enhancing oncogenic signaling. The clinical corre-
lations were consistent because approximately 10% of the
analyzed 2220 human breast cancers had high StARD3
protein levels, which associated with high ErbB2 levels,
increased Src activity, and poor patient survival. Inhibition
of StARD3 function might, therefore, be beneﬁcial in
HER2-positive cancers.
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Abstract
A modern biomedical research project can easily contain hundreds of analysis steps and
lack of reproducibility of the analyses has been recognized as a severe issue. While thor-
ough documentation enables reproducibility, the number of analysis programs used can be
so large that in reality reproducibility cannot be easily achieved. Literate programming is an
approach to present computer programs to human readers. The code is rearranged to fol-
low the logic of the program, and to explain that logic in a natural language. The code exe-
cuted by the computer is extracted from the literate source code. As such, literate
programming is an ideal formalism for systematizing analysis steps in biomedical research.
We have developed the reproducible computing tool Lir (literate, reproducible computing)
that allows a tool-agnostic approach to biomedical data analysis. We demonstrate the utility
of Lir by applying it to a case study. Our aim was to investigate the role of endosomal traf-
ficking regulators to the progression of breast cancer. In this analysis, a variety of tools
were combined to interpret the available data: a relational database, standard command-
line tools, and a statistical computing environment. The analysis revealed that the lipid
transport related genes LAPTM4B and NDRG1 are coamplified in breast cancer patients,
and identified genes potentially cooperating with LAPTM4B in breast cancer progression.
Our case study demonstrates that with Lir, an array of tools can be combined in the same
data analysis to improve efficiency, reproducibility, and ease of understanding. Lir is an
open-source software available at github.com/borisvassilev/lir.
Introduction
The results of a study can be reproduced and evaluated when all data has been disclosed [1]
and the computational methods have been shared in detail [2]. A study of 18 published data
analyses showed that the majority of the analyses could not be reproduced, often due to the
incomplete specification of the data processing and the analysis [3]. To improve reproducibility
of computational analyses several guidelines have been suggested. For example, Sandve et al.
proposed a list of ten simple rules for reproducible computational research [4]. Wilson et al.
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compiled an itemized list of best practices for scientific computing [5], and Shade et al. pre-
sented a step-by-step guide to computational analysis aimed at biologists [6]. While it would be
beneficial to a data analyst to follow stringently all provided guidelines, there is a paucity of
computer software that facilitates the implementation of all of them.
Generic software used in programming, such as version control and build utilities, cover
some of the needs for reproducible analysis. Other software is specifically aimed at computa-
tional data analysis. One such software, Sweave, allows embeddingR code into a document
typeset with LATEX [7]. The results of the automated data analysis described in the embedded
code are inserted into the generated report to guarantee reproducibility. The utility of Sweave
inspired an improvement, Knitr, that addresses most of the perceived shortcomings of its pre-
decessor [8]. Both tools offer an electronic, automated version of the “lab notebook” as
describedby Noble [9] for the R Statistical Environment [10]. IPython is a notebook solution
for the Python programming language [11]. It has evolved into Jupyter (jupyter.org), a plat-
form which supports reproducible computing notebooks in many programming languages,
and has becomewidely accepted [12]. A curated list of publications that employ such note-
books, with links to the data analyses, is available at go.nature.com/mqonbm.
Complex frameworks for the integration of heterogeneous, large-scale biological data have
also been developed [13, 14]. An interesting solution proposed by Kitchin [15] addresses the
problem of sharing the data analysis in journal publications by embedding the computer exe-
cutable code within the published PDF.
Existing solutions either assume the exclusive use of a single programming language, such
as R or Python [7, 8, 11], or require a non-trivial tool chain and a domain specific language [13,
14]. Here, we introduce Lir: a tool for reproducible computing that encourages and simplifies
the use of any combination of existing software platforms and programming languages within
the same data analysis [16].
Lir is based on the idea of literate programming as proposed by Donald Knuth [17]. Literate
programming allows the user to organize and document their work free of the restrictions on
code placement, file structure, or naming imposed by programming languages. This is achieved
by embedding all code within named paragraphs called code chunks. Code chunks may appear
in any order within the literate source file. In the original implementation by Knuth, a code
chunk would immediately follow the text that explains the rationale of the code and its impor-
tance within the logic of the whole program; Lir follows that convention. Code chunks have
descriptive names in natural language, and can contain other code chunks through name refer-
ences. Thus, all computer code can be presented as the logic of the analysis requires. Addition-
ally, Lir provides facilities for combining programs written in any programming language in
the same data analysis. For instance, a relational database can be used to organize and query
the data, a scientific computing platform to analyze it, and a statistical computing environment
to summarize and visualize it.
The complete analysis—documentation, source code, placeholders for display items, discus-
sion of results—is maintained as a text file. This file (S1 File) contains code chunks in the syn-
tax recognizedby the most widely used language-agnostic literate programming tool, noweb.
This source file is used to dynamically generate all results and the final human-readable docu-
ment (S2 File).
To demonstrate the application of Lir, we studied the effects of endosomal trafficking regu-
lators on the progression of breast cancer by using gene amplification, mRNA expression, and
patient survival data from The Cancer Genome Atlas repository [18]. Endosomal trafficking is
the process by which cells internalize, sort, and recycle nutrients and signalingmolecules with
the help of vesicles formed at the cell’s outer membrane, the plasma membrane. Defects in
endosomal uptake, sorting, recycling, and degradation of cell metabolites, external signals, and
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cell surface receptors can lead to deregulation of the cell cycle. The focus of the study was on
genes and gene products involved in endosomal lipid trafficking and in breast cancer progres-
sion. The complete analysis is available as a supplement (S1 File).
Methods
Lir
Lir defines a markup language for defining and documenting a data analysis, and presenting its
results. The data analysis is defined by the declared data objects (data files), the defined data
transformations (executable programs that consume and produce data files), and the declared
rules for applying a data transformation on data objects. Lir provides three command-line pro-
grams, lir-tangle,lir-make, and lir-weave, that generate the results of the data
analysis and compile a human-readable document (Fig 1A). For most use cases, the three steps
can be invoked in simple succession; the convenience program lir does that. The Tutorial
that accompanies the Lir implementation gives an introduction to how Lir is meant to be used,
and the User Guide provides a complete reference (available at https://github.com/
borisvassilev/lir and https://github.com/borisvassilev/lir-tutorial).
Source file. A Lir source file is a valid noweb source file. The noweb syntax splits a text
file into a sequence of documentation chunks and code chunks, and imposes no restrictions on
the content of these chunks [19]. Code chunks are named, and names can be arbitrary strings,
containing for example formatted text or mathematical symbols and formulas. Code chunks
can include other code chunks through name references. Code chunks that are not referenced
by other code chunks are root code chunks. The executable programs evaluated during the data
analysis are defined in root code chunks named after the transformation object they represent.
Documentation chunks can be formatted and structured using any markdown recognizedby
Pandoc.
Analysis definition. Lir extends the semantics of noweb by embedding in code chunks
with special names the dependencies between executable code, input data, and results. The
data objects, data transformations, and the rules describe a directed acyclic graph (DAG): the
data objects are the vertices of the graph, and the rules for applying data transformations are
the directed edges. In this DAG, the sources are the input data files; the final results and figures
are the sinks. The input data files (the sources) must be explicitly declared. If a placeholder for
a display item (for example, a table or a figure) appears in the Lir source file, the file containing
the display item is a sink. Additional sinks can be declared for results that are not displayed in
the final document but have to be generated. The rules for applying a data transformation on
data objects are declared in their own code chunks, in the language recognizedby Make. In
these rules, data objects are referred to by the names used in the declarations of sources and
sinks. Data transformations are referred to by the root code chunk names in which they are
defined.
Generating results. In a first step, lir-tangle extracts the data transformations
defined in the source file to executable programs, and uses the declared data objects and rules
to build a valid makefile. In the next step, lir-make invokes Make to generate all results,
observing the dependencies between input data, intermediate files, and final results. By keeping
this step separate it is possible to execute it on a different machine, for example a remote appli-
cation server. Only the tools used in the data analysis and Make have to be installed on the
machine running the data analysis: neither Lir, nor any of its dependencies (noweb, SWI-Pro-
log, Pandoc, Bash, and so on) are required.
Compiling the final document. In the last step, lir-weave produces an HTML docu-
ment that contains the full text of the source file, all display items, and links to all generated
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files that are not displayed (see S2 File). The code chunks containing the executable programs
are numbered and cross-linked to help browsing and reading the code. If markdown is used in
the documentation chunks, the final document is formatted accordingly and has a table of con-
tents. Figures, tables, and plain text results are displayed with their own labels (“Figure”,
“Table”, “Listing”), may have captions, and are numbered separately.
Implementation. Tangling the source file with lir-tangle is implemented as a Bash
script that makes use of the low-level tools provided by noweb, and standard Linux command
line tools like Awk, sed, and grep. Generating all results with lir-make is implemented as
an invocation of Make with a makefile generated by lir-tangle and the appropriate com-
mand-line options. The implementation of lir-weave employs two steps. First, the lir
source file is converted to an intermediate representation. This is implemented in SWI-Prolog
Fig 1. Overview of the method and tools provided by Lir. A: Documented executable code, placeholders for the display items, and discussion of
the displayed results are maintained as a text file: the Lir source. Dependencies between the input data (data objects) and the executable code (data
transformations) are an integral part of the source. The executable code and instructions for running it are extracted from the source file by
lir-tangle. The code is evaluated by lir-make to obtain results and display items. A human-readable, cross-linked document that faithfully
represents the literate source text file and integrates all display items is compiled by lir-weave. B: An overview of the work flow using this method.
All steps that are performed by a computer are automated, including resolving dependencies between data objects and data transformations. This
facilitates exploratory data analysis with short iteration cycles between formulating a question, evaluating its answer, and refining or extending the
analysis.
doi:10.1371/journal.pone.0164023.g001
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[20], as it is a convenient tool for both parsing the Lir source file and generating HTML
markup. In this step, code chunks and display items are numbered, cross-linked, and struc-
tured using HTML span and div elements modifiedwith HTML attributes. The intermediate
representation is compiled to a final document using Pandoc and formatted with a default CSS
style sheet provided by Lir. Compiling the final document with lir-weavemay be extended
to produce other output formats, for example a PDF file for printing.We chose HTML as the
first supported final document format for two reasons. First, it is a format that can be viewed
any platform with a modernweb browser. Second, the final layout and formatting can be cus-
tomized by the user by providing another CSS style sheet, without changing or extending the
implementation.
Compatibility. The tools provided by Lir and all its dependencies are open source soft-
ware that can be installed on any GNU/Linux, BSD, and OS X. It is possible to install and use
Lir on a MicrosoftWindows system, but the differences in file path naming conventions
between POSIX and MicrosoftWindows might cause incompatibilities at the level of the Lir
source file.We cannot currently guarantee, for example, that a Lir source file that contains file
paths with backslashes as component separators or file names with spaces (allowed by the
MicrosoftWindows Uniform Naming Convention) can be interpreted on a POSIX system
without normalizing the file paths.
Breast cancer data
The raw data on gene amplification and mRNA levels for breast cancer patients were obtained
from The Cancer Genome Atlas project (TCGA) [18] and pre-processed to obtain two data
matrices: the amplification status and mRNA levels for approximately 18 thousand genes for
tissue samples from over 500 patients.
We downloaded level 1 Affymetrix SNP Array data from the Cancer Genome Atlas [18].
The data was processed anonymously. All TCGA data were preprocessed using Anduril [13].
We genotyped the probes, and estimated and normalized copy-number values to 2 with
the CRLMM algorithm [21]. Copy-number data were segmented with the circular binary
segmentation (CBS) algorithm using the R package DNAcopy (parameters undo.splits=
sdundo,SD = 3, alpha = 0.01) [22]. Copy-numbers for each gene were assigned to three
states (gained, normal and deleted) similarly to TCGA [18].
Gene expression had beenmeasured with an Agilent two-channel microarray from which
only the channel containing measurements from a patient sample were used.We mapped
probes to genes, and removed probes mapping to multiple genes or no genes. Gene expression
values for genes, which are tagged by several probes, were combined using the median over
these probes. Gene expression values were normalized to a mean of 0 over the samples.
For each gene and sample, the amplification value was either 0 (no amplification) or 1 (gene
is amplified). The mRNA level was represented as a numerical value that can be compared
between patient samples for the same gene. Each gene was uniquely identified by an Ensembl
Gene ID. Each sample was uniquely identified by a TCGA “barcode” that contains meta-infor-
mation including, among others, details about the collection site, sample type, and study partic-
ipant. Clinical data for all patients, including survival data, was also obtained from TCGA.
Statistical methods and visualizations
The overall goal of the case study was to see how well the genes that regulate endosomal traffick-
ing correlate at mRNA, miRNA and copy-number levels. In the copy-number correlation analy-
ses we used the χ2 test statistic for a 2 × 2 contingency table that represents the amplification
status values for each pair of genes. The contingency table itself was visualized as a bar plot where
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each bar represents one of the table cells. The correlation of the mRNA levels was estimated using
the Pearson’s correlation coefficient.All plots were generated using R’s built-inmethods except
for survival curves,which were generated using R’s survival package [23, 24].
Results and Discussion
In order to demonstrate Lir, we analyzed breast cancer data including amplification status,
mRNA level data, and survival data from 516 patients. The analysis employed a relational data-
base, an array of standard command-line tools for text and table manipulation, and the R sta-
tistical environment for statistical analysis and visualization. The results were obtained using
the basic work flow outlined in Fig 1B.
We were initially interested in three genes. These genes code for proteins implicated both in
endosomal lipid trafficking and in breast cancer. StARD3 (StAR-related lipid transfer domain
protein 3) is a cholesterol-binding late endosomal (LE) protein that contributes to the progres-
sion of ErbB2-positive breast cancer, an established aggressive cancer sub-type [25]. NDRG1
(N-myc downstream regulated gene 1), implicated in several cancers [26], regulates endosomal
trafficking and degradation of the cell-surface receptor for low-density lipoprotein [27].
LAPTM4B (Lysosomal-associated transmembrane protein 4-beta) is a LE membrane protein
associated with chemotherapy resistance in several cancers. Recent results show that it controls
ceramide export from the LE and thereby affects sensitivity to anti-cancer drugs [28]. Altered
STARD3, NDRG1, or LAPTM4B expression has been associated with neoplasms in multiple
reports. According to experimental findings in cell culture models, all three proteins function
at different points along the endosomal trafficking route, and regulate intracellular lipid traf-
ficking. It was therefore of interest to assess if their gene amplification or mRNA expression
levels correlate with each other or with breast cancer patient survival.
Correlating genes of interest
The genes of interest, STARD3, NDRG1, and LAPTM4B are located in the following chromo-
somal regions: STARD3 in the ERBB2 amplicon in 17q12-21 [29],NDRG1 in 8q12-24, often
coamplified with MYC [30], and LAPTM4B on the same chromosome arm in 8q22 [31],
approximately 35 Mb apart from theNDRG1 locus. First, we investigated whether the gene
amplification or mRNA levels of STARD3, NDRG1, and LAPTM4B correlate with each other
in breast cancer tumor tissue. As a positive control we calculated correlation between STARD3
and ERBB2, which are known to be highly correlated on the DNA, mRNA, and protein level
[25, 29, 32]. The amplification statuses of these two genes is almost identical, and they correlate
strongly at the mRNA level (Pearson’s ρ = 0.79, Fig 2A, Panel I).
We found no correlation betweenNDRG1 and STARD3 amplification status or mRNA lev-
els (Pearson’s ρ< 0.1, Fig 2A, Panel II). Instead, a weak correlation between STARD3 and
LAPTM4Bwas observed.Although the amplification status of these two genes did not corre-
late, on the mRNA level there was a weak positive correlation (Pearson’s ρ = 0.16, Fig 2A,
Panel III). This suggests that the two genes might be co-regulated on the transcriptional or
post-transcriptional level. Interestingly, LAPTM4B and NDRG1 correlate positively both in
their gene amplification status and mRNA levels (Pearson’s ρ = 0.34, Fig 2A, Panel IV). This
may be related to their close proximity in the 8q region amplified in cancers.
An overviewof the data flow used to generate the above results is outlined in Fig 2B. A
range of tools are used: standard command line tools for examining and preparing the input
data (wc, sed, awk, tr, cut, etc.), a relational data base (SQLite) for the meta data, R for
the statistical analysis and plot generation. Code chunks are given descriptive names in free
text, allowing for a self-documenting, consistent, literate writing style independent of the
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Fig 2. Using Lir to correlate genes of interest. A: Four of the display items generated by the analysis outlined in (A). In the scatter plots, red indicates
a sample in which both genes were amplified, blue indicates a sample in which both genes are at basal levels, and green indicates a sample with
differential amplification status of the two genes. The interpretation of the results of each display item shown here is added to the source file: the
interpretation becomes an integral part of the analysis. B: Diagram demonstrating the data flow for an analysis. The input data (a large data matrix in a
text file) is sanitized and saved as a native R object. Meta-data of the genes and the samples is saved to a relational database to facilitate querying the
data. The relevant data is extracted, analyzed, and visualized, producing several display items. In this diagram, data objects are colored in green, data
transformations are colored in red, and arrows represent the dependencies declared in the source file and used by Lir to generate the intermediate data
objects and the display items.
doi:10.1371/journal.pone.0164023.g002
Language-Agnostic Reproducible Data Analysis
PLOS ONE | DOI:10.1371/journal.pone.0164023 October 6, 2016 7 / 14
programming language used (for example, see S1 File, lines 618–702). Scripting tools like R
offer little flexibility when it comes to positioning code within the file or sharing code between
files.Multiple references by name to the same code chunk can be used to avoid code repetition
and reorganize code, overcoming this practical limitation (see S1 File, line 264, used at 225,
535, 598, 894, . . .).
Analyzing the effect of genes of interest on patient survival
We next assessed whether the overexpression of a gene or a pair of correlated genes have an
effect on patient survival within five years. We have earlier reported that high StARD3 protein
levels associate with poor breast cancer specific survival in two Finnish nationwide patient
cohorts [25]. This was, however, not observedon the amplification or transcript level in the
TCGA data set (S2 File). Thus, we tested the survival effect of SERPINA1, another recently
reported predictor of survival in breast cancer [33].
A clear positive correlation of both SERPINA1 amplification status and mRNA levels with
patient survival was observed (Fig 3A, Panel I). On the other hand, both LAPTM4B and
NDRG1 levels correlated with reduced patient survival: in the case of LAPTM4B, the negative
effect was evident at the level of gene amplification (Fig 3A, Panel II), while for NDRG1, the
correlation was better at the transcript level (Fig 3A, Panel III).
To test the combined effect of LAPTM4B and NDRG1mRNA overexpression on patient
survival, the patients were split into two groups. First, one group contained those patients that
have highmRNA levels (over median within the gene) for both genes, and the other group all
other patients (Fig 3A, Panel IV). These groups had similar survival. Then, the mixedmRNA
level patients (one mRNA below, the other above median) were excluded from the data set and
only those patients with high or low mRNA levels for both transcripts were compared with
each other. This revealed a lower survival for patients with elevated transcript levels; however,
the effect was similar to that obtained by NDRG1 upregulation alone, implying that co-overex-
pression of LAPTM4B and NDRG1 did not have an additional negative effect on patient sur-
vival in this data set.
The data flow of these analyses is summarized in Fig 3B. The data flow documents how the
reuse of existing data objects avoids the need for excess code and lowers the amount of compu-
tational work. The structure of the data flow strongly resembles that of the work flow presented
in Fig 2B. The formal syntax used by Lir for declaring dependencies allows to reuse existing
data flow structures, further avoiding unnecessarywork (see S1 File, lines 798–801, reusing
lines 285–90, 293–7, and 301–5).
Assessing miRNA target genes by integrating two independent data
sets
Micro RNA (miRNA) are short non-coding RNA molecules that regulate mRNAs after tran-
scription, usually inducing gene silencing [34, 35]. Individual miRNAs may target as many
as 100 different mRNA molecules. For three of the genes of interest, we identified experi-
mentally validated miRNAs relevant in the context of breast cancer: for ERBB2, miR-155
[36], for LAPTM4B, miR-188 [37], and for NDRG1, miR-769 [38]. To find potential addi-
tional targets for each miRNA, we usedmiRWalk [39], additionally querying four more
online resources: microRNA.org [40], miRDB [41], RNA22 [42], and TargetScanHuman
[43]. There were 2553 genes in the TCGA breast cancer data set that were predicted targets
with the selected cut-off (Fig 4A, Panel I). Of all the predicted targets that correlated with
the corresponding gene on the transcript level (S2 File and Fig 4A, Panel II), two of the
LAPTM4B/miR-188 genes were especially interesting: PVR (Poliovirus receptor protein),
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Fig 3. Using Lir to determine the effects of upregulation of the genes of interest on patient survival. A: Three of the display items generated by
the analysis outlined in (A). As in Fig 2, the interpretations of the results shown below each display item appear verbatim in the literate source. B:
Diagram demonstrating the data flow for further analysis based on the results shown in Fig 2. Importantly, data objects generated in the previous analysis
are reused. In this diagram, data objects are colored in green, data transformations are colored in red, and arrows represent the dependencies declared
in the literate source file and used by Lir to generate the intermediate data objects and the display items.
doi:10.1371/journal.pone.0164023.g003
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Fig 4. Using Lir to integrate two independent data sets and visualize the results. A: The display items generated by the analysis outlined in (B).
The result of each step, represented by the corresponding display item, is taken into consideration when formulating the next question and designing
the analysis. B: Diagram demonstrating the data flow for an analysis that incorporates a new data set. The new data set associates genes with a
measure of the certainty that they are targeted by the same micro-RNA as a gene of interest. The existing relational database object was updated (not
re-generated) to include the additional data. The analysis was done in three consecutive steps: First, a reasonable cut-off for the prediction certainty of
Language-Agnostic Reproducible Data Analysis
PLOS ONE | DOI:10.1371/journal.pone.0164023 October 6, 2016 10 / 14
and SNX22 (Sorting nexin-22). The Poliovirus receptor protein might provide tumors with a
mechanism of immunoevasion, and it plays a role in mediating tumor cell invasion and
migration [44]. Sorting nexin-22 may be involved in several stages of intracellular traffick-
ing, inferred from sequence similarity, and contains binding sites for phosphatidylinositol
3-phosphate [45].
The contingency tables of the amplification status and the scatter plots of the mRNA levels
of LAPTM4B and the two genes are shown in Fig 4A, Panel III. They allow for the following
observations: the genes are clearly correlated on the mRNA level, despite the fact that they are
not co-amplified. Thus, our data suggest that the mRNA levels of these genes are regulated by
miRNA-188, together with LAPTM4BmRNA. The phenomenon of one miRNA targeting a
complex of functionally related proteins is known [46, 47]. It is therefore possible that
LAPTM4B, PVR, and SNX22 contribute to shared functions.
Fig 4B outlines the data flow of the combined analyses performed. Existing intermediate
results are not regenerated. For example, only the miRNA target data is inserted into the
existing relational database, while the already present amplification and mRNA data object is
used as it is. This minimizes the time for generating and visualizing new results, thus encour-
aging an iterative, exploratory approach to data analysis without sacrificing repeatability. In
addition, code chunks support ad hoc reuse of code (S1 File, lines 1357–78). In most common
use cases achieving code reuse with R’s package system is more complex and time-consum-
ing. The use of Lir does not prevent us from using R’s package system or the corresponding
code reuse paradigm of any other programming platform. Rather, Lir facilitates a systematic
approach to organizing computer code that is independent of any particular tool and can be
used only if deemed beneficial.
Conclusions
In this study, we have introduced a tool for reproducible computing called Lir. We used Lir to
analyze a heterogeneous data set in order to see whether there is putative coregulation between
a set of endosomal trafficking regulators. In the analysis, we combined a relational database, an
array of data manipulation tools, and a statistical analysis environment. Our results revealed a
coamplification of the cancer and lipid transport related genesNDRG1 and LAPTM4B, as well
as new genes potentially co-regulated and cooperatingwith LAPTM4B.
The major contribution of Lir within the context of reproducibility is to demonstrate that it
is possible and very advantageous to fully document and automate a work flow utilizing a com-
bination of software tools. Using the best tool for each task reduces the total amount of code,
thus reducing the opportunity for mistakes, and the amount of invested time [48, 49]. All
results and the computer code that generated them are presented as a human-readable docu-
ment. This document serves two equally important purposes during the development. First, it
organizes and presents the intermediate results: the data analysis can be conducted in an itera-
tive, exploratory fashion while faithfully documenting all steps. Second, it organizes, docu-
ments and presents all computer executable code: other scientists can inspect the analysis and
verify the results. In combination with a version control system, Lir directly facilitates the
implementation of best-practice guidelines as delineated in [4–6].
the micro-RNA targets was determined (Step 1); then the genes associated to the gene of interest were found (Step 2); then, the mRNA levels of the
most interesting of the associated genes was plotted against the mRNA levels of the gene of interest (Step 3). The visualization from Fig 2B was reused
in the last step. Data objects are colored in green, data transformations are colored in red, and arrows represent the dependencies.
doi:10.1371/journal.pone.0164023.g004
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Supporting Information
S1 File. The complete data analysis.This is a plain text file that uses extendedmarkdown as
understood by Pandoc. The file is a valid noweb source file. It is available at github.com/
borisvassilev/endobrca.
(LIR)
S2 File. The generated human-readabledocument.The final document is an HTML web
page that can be viewedwith a web browser. It is a faithful representation of the literate source
file, which has additionally been cross-linked and prettified. It is available at github.com/
borisvassilev/endobrca.
(HTML)
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